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Abstract 
Specific language impairment (SLI) is a neurodevelopmental disorder defined as an unexpected 
failure to develop normal language abilities despite normal intelligence and adequate educational 
opportunities. This condition has an estimated frequency of 5-8% in English-preschool children and 
it has been shown to be highly heritable. Like many behavioural traits, SLI is assumed to be a 
heterogeneous multifactorial disorder with a complex genetic basis. Over the years, linkage and 
association studies have attempted to uncover the genetic bases underlying language impairment 
and have identified some candidate genes possibly contributing to SLI susceptibility, such as 
ATP2C2, CMIP and CNTNAP2. However, a large portion of the genetic risk remains to be 
unravelled.  
Since CNVs have been demonstrated to be an important source of variation in the susceptibility to 
other neuropsychiatric disorders, such as autism spectrum disorders (ASD) and schizophrenia, we 
carried out a genome-wide CNV screen on 540 individuals of the SLIC cohort in order to 
investigate the role of structural variants in the genetic architecture of SLI. An exploratory analysis 
did not find significant differences in CNV burden between 174 affected children and 40 unaffected 
siblings of this SLI cohort. However, these are preliminary results and further investigations are 
currently being performed using a larger group of independent controls.  
Individual CNVs might be of interest and might reveal new candidate genes implicated in the 
disease susceptibility. Among the CNVs affecting genes, we focused on two particular examples of 
potentially contributing variants: recurrent CNVs on chromosome 15q11-q13 and a homozygous 
exonic microdeletion in ZNF277.  
The locus 15q11-q13 has been implicated in a range of distinct but co-morbid neurological 
conditions, such as ASD, schizophrenia, epilepsy and language delay. In the SLIC cohort, we 
identified BP1-BP2 microdeletions at 15q11.2 (involving the genes TUBGCP5, CYFIP1, NIPA1 
and NIPA2) in two families, and BP4-BP5 microduplications at 15q13.2-q13.3, including the gene 
CHRNA7, in three families. Both CNVs showed an incomplete segregation with the phenotype, 
supporting the hypothesis that these variants are unlikely to be causative for neuropathological 
conditions, showing variable expressivity and incomplete penetrance. However, since these CNVs 
are recurrently observed in neuropsychiatric conditions, it has been proposed that they might act as 
modifiers and that their outcomes could depend on the interaction with other genetic and non-
genetic factors. Therefore, it is plausible that microduplications at 15q11-q13 might play a role also 
in SLI. 
We identified a microdeletion of 21,379 bp in the ZNF277 gene, encompassing exon 5, in a single 
child with severe expressive and receptive language impairment. The microdeletion was inherited 
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from both parents, each of whom carries a heterozygous microdeletion and has a history of 
language problems, and was not found in the proband's affected sister or her brother who had mild 
language impairment. The microdeletion falls within the AUTS1 locus, a region linked to ASD. 
Moreover, ZNF277 is adjacent to the DOCK4 and IMMP2L genes, which have been implicated in 
ASD. We screened for the presence of ZNF277 microdeletions in cohorts of children with SLI or 
ASD and panels of control subjects. ZNF277 microdeletions were at an increased allelic frequency 
in SLI probands (1.1%) compared to both ASD family members (0.3%) and independent controls 
(0.4%). We performed quantitative RT-PCR analyses of the expression of IMMP2L, DOCK4 and 
ZNF277 in individuals carrying either a IMMP2L-DOCK4 microdeletion or a ZNF277 
microdeletion. While ZNF277 microdeletions reduce the expression of ZNF277, they do not alter 
the levels of DOCK4 or IMMP2L transcripts. Conversely, IMMP2L-DOCK4 microdeletions do not 
affect the expression levels of ZNF277. We postulate that ZNF277 microdeletions may contribute to 
the risk of language impairments in a complex manner, that is independent of the autism risk loci 
previously described in this region.  
The SLI family in which the homozygous ZNF277 microdeletion was discovered, represents an 
interesting example of genetic heterogeneity of the disorder within pedigrees. The affected sister, 
who did not carry the ZNF277 microdeletion, had a complete dihydropyrimidine dehydrogenase 
(DPD) deficiency, absent in the proband with the homozygous ZNF277 microdeletion. DPD, 
encoded by the gene DPYD, is the first rate-limiting enzyme of the pyrimidine catabolism pathway. 
The complete loss of the DPD activity in that child was caused by a compound heterozygosity of 
two deleterious variants in the gene DPYD: the splicing variant rs3918290, paternally inherited, and 
the missense change p.S201R, maternally inherited. The DPD deficiency leads to the accumulation 
of uracil and thymine and, like other disorders affecting the nucleotides metabolism, its clinical 
manifestations can include neurological problems, such as ASD features and language impairments. 
Therefore, we hypothesized that in this family, two risk factors (the complete loss of ZNF277 in the 
proband and the complete loss of DPD activity in the affected sister) could have independently 
contributed to the language deficits of the two affected children. 
Moreover, since DPYD represents a good candidate for both SLI and ASD, we investigated its 
involvement in the susceptibility to these two neurodevelopmental disorders. Many mutations have 
been reported in DPYD, but the splicing variant rs3918290, that causes the skipping of exon 14 in 
the mRNA leading to a non-functional protein, is the most commonly implicated mutation in the 
DPD deficiency. Therefore, we decided to analyse the frequency of the splicing variant rs3918290 
in a group of 166 SLI cases and three groups of ASD cases (231 Italian probands, 224 IMGSAC 
probands and 2681 AGP probands). We observed a higher frequency of rs3918290 in the SLI group 
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(1.2%) and the Italian probands (1.08%), while no difference was observed for the IMGSAC group 
(0.45%) and the AGP cohort (0.47%), compared to controls (~0.5% -0.6%). In the AGP collection, 
an association analysis of the region encompassing DPYD did not yield significant evidence of 
association. In addition, from the analysis of IQ performances and verbal abilities in the AGP cases 
carrying the splicing variant, we did not observe an influence of the variant on the severity of the 
phenotype. However, since we focused on a rare variant, it should be noted that these phenotypic 
analyses were based on a small number of individuals carrying rs3918290.  
The mutation screening of the gene DPYD performed on the individuals with the splicing variant (4 
SLI families including the discovery pedigree, 5 Italian families and 2 IMGSAC families) led to the 
identification of six known missense changes (p.C29R, p.M166V, p.S201R, p.S534N, p.I543V, 
p.V732I) and a novel non-coding variant in the promoter region. Several individuals were found to 
be compound heterozygotes for DPYD variants. Although the consequences of these changes are 
widely debated in literature, as contrasting results are frequently reported, we hypothesized that the 
combined effect of the mutations identified in affected individuals leads to an altered DPD activity. 
These hypotheses should be confirmed by enzymatic assay, however this small group of SLI and 
ASD cases suggests that the partial or complete loss of DPD activity might be a risk factor for 
language impairment or autism spectrum disorders.  
In summary, these results do not support a major role of the DPYD gene in SLI and ASD, but 
suggest that rare variants in DPYD might contribute to a minority of cases in a complex manner, in 
addition to other genetic or non-genetic factors. Further investigations will be required to clarify the 
role of DPYD in SLI and ASD. 
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Chapter 1 
Copy Number Variants 
1.1 Copy Number Variants. 
Analysis of the human genome has revealed an extended sequence similarity among individuals: 
any two humans are estimated to be approximately 99.9% identical in their DNA sequence. 
The most numerous variants in the genome are individual base changes called Single-Nucleotide 
Polymorphisms (SNPs). Another important source of genomic variation is represented by 
submicroscopic variants in DNA copy number (Copy Number Variants, CNVs), which usually 
involve many bases. Deletions, duplications, insertions and translocations can all results in CNVs.  
Two landmark studies carried out in 2004 (Iafrate et al., 2004; Sebat et al., 2004) showed that 
CNVs, ranging in size from kilobases (kb) to Megabases (Mb), are widespread in normal human 
genomes. More recently, two studies (Conrad et al., 2010; Mills et al., 2011) have estimated that 
CNVs account for ~4 million base pairs of genomic difference (~13%). Therefore, although the 
number of SNPs in the genome exceed the number of CNVs, their relative contribution to genetic 
heterogeneity is similar if we consider the variation in terms of nucleotides implicated.  
Copy number changes of genomic segments can be tolerated, advantageous or deleterious. Certain 
advantageous CNVs have played a significant role in primate evolution (Bailey and Eichler, 2006; 
Dumas et al., 2007). CNVs can include a variable number of genes and their phenotypic effects 
usually depend on whether dosage-sensitive genes or regulatory regions are affected (Lupski and 
Stankiewicz, 2005). Disruption of regulatory regions, promoter elements or coding sequences can 
lead to altered gene function. Genes can be inactivated by a premature truncation or an internal 
deletion. CNVs can also result in fusion or abnormal gene products with a new function (Holt et al., 
2012). Moreover, in some cases, deletions can have the effect of “unmasking” a recessive 
pathogenic allele in the heterozygous state. 
1.2 Mutational mechanisms. 
CNVs can be inherited or de novo. These structural variants can arise in both meiotic and somatic 
cells: in the first case, they represent constitutional genomic rearrangements, in the second case 
there will be mosaic populations of somatic cells carrying the CNV.  
In the next paragraphs, the four major mechanisms that can lead to the formation of CNVs will be 
described. Speculations on the causative molecular mechanism are usually based on detailed 
junction analyses at base level, as the “molecular fingerprint” of the breakpoints may help to 
understand how the structural change has arisen.  
Copy Number Variants 
 
8 
 
1.2.1 Non-Allelic Homologous Recombination (NAHR). 
Low copy number repeats (LCRs) or segmental duplications are DNA fragments >1 kb in size and 
of more than 90% of DNA sequence identity. LCRs can cause genomic instability and either 
mediate or stimulate CNV formation: genomic regions harbouring tandemly arranged LCRs are 
more prone to recurrent or non-recurrent rearrangements. 
Due to their high degree of sequence identity, a misalignment between non-allelic LCRs can occur 
and mediate non-allelic homologous recombination (NAHR), which results in unequal crossing-
over and a change in copy number (Stankiewicz and Lupski, 2002).  
NAHR has been shown to require fragments of minimal length (300-500 bp) which share extremely 
high similarity or identity between LCRs, called minimal efficient processing segments (MEPS) 
(Rubnitz and Subramani, 1984; Waldman and Liskay, 1988). The majority of NAHR events occur 
between LCRs which have a sequence identity greater than ~97%, a size that ranges from about 10 
to ~400 kb and are located at a distance less than ~10 Mb from each other. 
The outcomes of the NAHR between LCRs depend on their orientation and their location (Figure 
1.1). Misalignment can occur between LCRs located on homologous chromosomes 
(interchromosomal), on sister chromatids (intrachromosomal) or on the same chromatid 
(intrachromatid). 
Interchromosomal and intrachromosomal NAHR between directly oriented LCRs results in two 
reciprocal products: a deletion and a reciprocal duplication of the genomic segment between them 
(Figure 1.1 a and 1.1 d). Intrachromatid NAHR between directly oriented LCRs can result in a 
deletion and a loop excision (Figure 1.1 g). 
Interchromosomal and intrachromatid NAHR between LCRs in opposite orientation causes an 
inversion of the genomic segment flanked by them (Figure 1.1 b and 1.1 h). Intrachromosomal 
NAHR between LCRs in opposite orientation generates duplicated modules in an inverse 
orientation (Figure 1.1 e). 
If the LCRs have a complex structure consisting of both direct and inverted subunits, they can 
predispose the region to NAHR, leading to both deletions/duplications and inversions (Figure 1.1 c, 
1.1 f, 1.1 i). 
Copy Number Variants 
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Figure 1.1 (Stankiewicz and Lupski, 2002). Schematic representation of LCRs-NAHR based mechanisms for genomic 
rearrangements. LCRs are depicted as yellow arrows and their orientation is indicated. The chromosome 
rearrangements and predicted products of recombination are listed vertically by mechanisms (interchromosomal; 
intrachromosomal; and intrachromatid). Interchromosomal misalignment leads to deletion/duplication (directly oriented 
LCRs) (a) and inversion (inverted repeats) (b). Intrachromatid loop of inverted repeats results in inversion (h). 
Interchromatid mispairing of direct repeats results in deletion/duplication (d). Intrachromatid misalignment of directed 
repeats (g) can result in deletion and an acentric fragment. Inv dup(15) and inv dup(22) chromosomes can result from 
interchromosomal (c) or intrachromosomal (e) unequal exchange between inverted LCRs. Also complex LCRs can be 
responsible for deletion/duplication (f) or inversion (i). 
The distribution of the endpoints of CNVs arisen by NAHR along the LCRs seems to be not 
random: they have been observed to cluster in narrow “hotspots” (Lupski, 2004), where there is 
sufficient homology for homologous recombination.  
The molecular mechanism of NAHR has been shown to account for the vast majority of the 
“recurrent” rearrangements, defined as those that recur in multiple individuals, share a common size 
and present breakpoints clustering within the same regions (Figure 1.2 a).  
NAHR can also be mediated by highly homologous repetitive sequences, such as Alu sequences, L1 
elements (that will be described in the paragraph 1.2.4), minisatellites and subtelomeric repeated 
sequences. These NAHR events explain some of the “non-recurrent” rearrangements, defined as 
those CNVs with different sizes and distinct breakpoints in each event (Figure 1.2 b). Interestingly, 
some non-recurrent rearrangements can map to the same genomic location, but with endpoints in 
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many different positions: these CNVs might share a common region, indicated as the smallest 
region of overlap (SRO), whose change in copy number may be responsible for the common 
clinical features among different individuals carrying these rearrangements (Gu et al., 2008). 
 
Figure 1.2 (from Gu et al., 2008). Recurrent and non-recurrent rearrangements. The black line indicates the genomic 
region hit by CNVs, blue and red bars indicate the rearrangements observed in different individuals. a. Recurrent CNVs 
have both breakpoints mapping within the same LCRs (hatching rectangles). b. The non-recurrent CNVs have different 
length and different breakpoints, but might share a common region of overlap (SRO). In this example, the SRO 
encompasses one gene, indicated by the black rectangle. c. Some non-recurrent rearrangements show one of their 
breakpoints within a limited genomic region: the grouping of one breakpoint may occur in proximity of an architectural 
element important to the rearrangements mechanism. 
NAHR can occur in both meiotic and mitotic cells and certain LCRs might be involved in both 
types of NAHR events. Moreover, the usage of certain LCRs for mitotic NAHR events might be 
different among different tissues. This mechanism might play a significant role in tumorigenesis 
(Darai-Ramqvist et al., 2008; Fridlyand et al., 2006). Age seems to be an important risk factor for 
somatic structural abnormalities. Generally the rate of mutations, including CNVs, increases with 
age (Jacobs et al., 2012) and this accumulation, that varies with tissue type (Kennedy et al., 2012), 
could be due to an increased burden of somatic mutation and/or a reduced capacity of genomic 
maintenance.  
Furthermore, post-zygotic events can explain the finding of different genomic rearrangements 
between monozygotic twins (Bruder et al., 2008; Forsberg et al., 2012). 
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1.2.2 Non-Homologous End Joining (NHEJ) and Microhomologous-Mediated End Joining 
(MMEJ). 
Another mechanism that can lead to CNV formation is non-homologous end joining (NHEJ), one of 
the main pathways for repairing double-stranded DNA breaks (DSBs). When double-strand breaks 
are detected, NHEJ ensures that both broken DNA ends are bridged, modified, and finally ligated 
(Weterings and van Gent, 2004) (Figure 1.3). NHEJ is a homology-independent process efficient at 
restoring structural DNA integrity, however it can be imprecise at local sequence level and tolerates 
nucleotide loss or addition at the rejoining site, often leaving a “molecular scar” (Lieber, 2008). 
In contrast to NAHR, NHEJ does not require LCRs, MEPS or sequence homology to mediate the 
recombination. However, NHEJ can frequently occur within repetitive elements, such as long 
terminal repeats (LTRs), short interspersed repeat elements and mammalian interspersed repeats, 
suggesting that it may also be stimulated and regulated by certain genome architecture.  
 
Figure 1.3 (from Gu et al., 2008). The NHEJ in vertebrates proceed in four steps. The two thick lines represents the 
double stranded DNA. When double strand breaks occur, they are detected (1) and the molecular machinery of NHEJ 
(Lieber et al., 2003) mediates the molecular bridging of the broken DNA ends (2). The DNA ends are modified to be 
compatible (3) and, finally, they are ligated (4) to restore the structural integrity. 
An alternative end-joining mechanism is represented by microhomology-mediated end joining 
repair (MMEJ). MMEJ requires short microhomologies (5-25 bp) to anneal the ends of DSBs and 
leads to the deletion of the region between annealed microhomologies. 
1.2.3 Fork Stalling and Template Switching and MMBIR. 
Fork Stalling and Template Switching (FoSteS) is a replication-based genomic rearrangement 
mechanism induced by errors during DNA replication process (Lee et al., 2007). When a replication 
fork stalls at one position, the 3’ primer end of a DNA strand can disengage from the original 
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template and invade another replication fork nearby (Figure 1.4). The invasion and annealing to the 
new template strand are mediated by a microhomology sequence at the 3’ end (4-15 bp) of the 
invading strand, which subsequently primes the DNA synthesis. Initially, the replication is 
characterized by low processivity, but after multiple rounds of disengaging, invasion and extension, 
it becomes more processive. 
 
 
Figure 1.4 (from Gu et al., 2008). A schematic representation of the Fork Stalling and Template Switching (FoSteS) 
mechanism. Solid lines indicate the template DNA, dotted lines instead the newly synthesised strands. The original 
replication fork is represented by the red and blue lines. After the stalling, the lagging strand (red, dotted line) invades a 
second fork (indicated in purple and green) via microhomology (1). The 3’end of the lagging strand allows the DNA 
extension in the second fork (green dotted line) (2). Serial replication fork disengaging and invasion could occur several 
times (3) before resumption of replication on the original template (4). 
Hastings and colleagues (Hastings et al., 2009) proposed a generalization of the FoSteS mechanism, 
known as the microhomology-mediated break-induced replication model (MMBIR), based on the 
mechanism of repair single double-stranded ends. The MMBIR model postulates that the 3’end of a 
collapsed fork could anneal to any single-stranded DNA stretch, available in physical proximity, 
with which it shares microhomology, such as a lagging strand of a replication fork or ssDNA 
exposed at excision repair tracts, at sites of transcription and at secondary DNA structures, such as 
cruciforms or hairpins loops caused by complex genomic architecture.  
The chromosomal structural consequences of MMBIR could be summarized in this way (Hastings 
et al., 2009): 
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 template switch to sister or homologous chromosome behind the position where the fork 
collapsed (backward invasion), with respect to the direction of movement of the fork, 
generates a duplication; in the opposite case, a template switch to sister or homologous 
chromosome ahead the position where the fork collapsed (forward invasion) generates a 
deletion; 
 template switch to nonhomologous sequence in another chromosome causes a translocation; 
 template switch to a sequence already duplicated causes a triplication; 
 template switch to the same molecule behind the position of the fork collapse could initiate a 
rolling-circle replication and amplification.  
 whether the switch occurs in direct or opposite orientation determines if the erroneously 
incorporated fragment will be in direct or inverted orientation with respect to its original 
position. 
FoSteS/MMBIR frequently generates complex non-recurrent rearrangements, e.g., 
deleted/duplicated regions are interrupted by normal copy regions or triplicated segments. The 
complexity at the joining sites is a feature of this mechanism and can help to discriminate among 
the different potentially causing mechanisms (NHEJ, MMEJ and MMBIR) when very small regions 
of microhomology are present at the boundaries: the junctions of MMBIR events are characterized 
by the presence of segments of DNA of variable length derived from elsewhere. 
1.2.4 Retrotransposition. 
Retrotransposons are mainly represented by endogenous retroviruses, Long interspersed nuclear 
elements 1 (LINE1 or L1) and Short interspersed nuclear elements (SINEs). L1s are the only 
currently active class of autonomous retrotransposons in humans. 
Although ~500,000 copies can be found in the human genome (occupying ~18% of the whole 
genome), only 80–100 are predicted to be active full-length elements (6 Kb) and are able to 
transpose their own sequences or non-autonomous elements (e.g. the Alu sequences, the 
predominant SINE elements in the genome) to new genomic locations by a target primed reverse 
transcription (TPRT) mechanism (Goodier and Kazazian, 2008). Consistent with this model, at the 
L1 insertion site short “target site duplications” (TSDs), but occasionally deletions, can be 
generated. The insertion of retrotransposons can have variable consequences on the expression of 
the genes nearby, such as causing the premature termination of transcription (Figure 1.5.6), 
producing new transcription start sites (Figure 1.5.7) or determining the formation of new 
transcription modules (Figure 1.5.8). Sometimes, these insertions can also alter the chromatin state 
of the target region: structural chromatin changes mediated by methylation can initiate within 
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transposable elements and spread to the proximal regions, causing the repression of the adjacent 
genes (Figure 1.5.9).  
In addition to retrotransposition, recombination between retrotransposons can occur and lead to 
deletions, duplications (Figure 1.5.5) and rearrangements of gene sequence and this is particularly 
true for Alu elements. 
Both germline and somatic L1 activity contribute significantly to structural variation in human 
genomes (Lupski, 2010). 
 
Figure 1.5 (Goodier and Kazazian, 2008). Examples of genomic changes caused by retrotransposons. (1) Insertion of 
the L1 element to a new location. In the example a, the insertion causes the formation of TSDs. (2) The insertion of the 
L1 determines a deletion at the insertion site. (3 and 4) Regions flanking the retrotransposon in the original location (at 
5’ or 3’) may be carried along with the L1 element during the retrotransposition. (5) Mispairing and crossing over 
between LINE or SINE elements via NAHR, leading to deletions and duplications. (6) The retrotransposon sequence 
can cause a pausing in the transcriptional elongation, and poly(A) signals within an L1 can lead to premature 
termination of transcription. (7) The antisense promoter in the L1 5’ UTR can produce new transcription start sites for 
genes upstream of the L1 on the opposite strand. (8) Splice sites within L1s residing in introns can lead to new exons 
within genes, in a process called “exonization”. (9) L1s can alter the chromatin state, thereby altering gene expression. 
(10) L1 reverse transcriptase can mobilize Alu, SVA, mRNA, and small noncoding RNAs, leading to further genome 
expansion. (11) Template switching of L1 reverse transcriptase from L1 RNA to other sequences, such as U6 RNA or 
Alu RNA, can produce chimeric insertions in the genome. (12) Editing of inverted Alus can suppress gene expression 
by nuclear retention of the mRNA. (13) Alu elements can promote formation and expansion of microsatellites. 
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1.3 CNV Detection Methods.  
Traditional chromosome-banding techniques are able to detect microscopic structural variants (>3 
Mb), such as reciprocal translocations, inversion, deletions and duplication, and fluorescence in situ 
hybridization (FISH) allows a more refined characterization of these aberrations. However, the 
resolution of this approach is low (in the range of tens of thousands kb-Mb) and these methods miss 
the majority of structural variants. 
The development of new technologies has provided the ability to detect submicroscopic structural 
rearrangements and their breakpoints with a higher resolution (ranging from kb to base pair 
resolution) and the number of identified CNVs has dramatically increased.  
Numerous genome-wide surveys of CNVs have used array-based approaches: array comparative 
genomic hybridization arrays (array-CGH) and SNP arrays. Moreover, the advent of Next 
Generation Sequencing (NGS) technologies has allowed sequence-based approaches for mapping 
CNVs at fine scale. 
1.3.1 Array-CGH. 
The array-CGH method is based on the competitive hybridization between two DNA samples, a 
reference DNA and a DNA of interest (test DNA) (Pinkel et al., 1998). The two genomes are 
labelled with different fluorescent dyes (e.g. Cy5 and Cy3), and they compete to hybridize to arrays 
that are spotted with DNA fragments (for example BACs, PCR fragments or oligonucleotides) to 
cover the whole genome. The fluorescence ratio between the two dyes is then determined. In array-
CGH, there are no allele-specific probes, therefore the output data consists of a series of intensity 
measurements that reveal the copy number differences between the two DNA samples (Figure 1.6). 
Typically, array-CGH is carried out using a 'dye-swap' method which consists of two experiments 
(indicated by the left and right sides of the Figure 1.6): after a first hybridization experiment, a 
second hybridization is performed reversing the labelling of the reference and test DNA samples. 
This allows the detection of spurious signals, which are not common to both hybridizations. 
The use of BAC clones in array-CGH gives the advantage of extensive coverage of the genome, 
reliable mapping data and ready access to clones. The use of long oligonucleotides instead (60-100 
bp) can improve the detection resolution (theoretically from 50 kb to a few kb), compared to BACs.  
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Figure 1.6 (Feuk et al., 2006a). Array-based comparative genome hybridization (array-CGH). Reference and test DNA 
samples are differentially labeled with fluorescent tags (Cy5 and Cy3, respectively), and are then hybridized to genomic 
arrays after repetitive-element binding is blocked using COT-1 DNA (which is mainly composed of repetitive 
sequences). After hybridization, the fluorescence ratio (Cy3:Cy5) is determined, which reveals copy-number differences 
between the two DNA samples. An example output for a dye-swap experiment is shown at the bottom: the red line 
represents the original hybridization, whereas the blue line represents the reciprocal, or dye-swapped, hybridization. 
1.3.2 SNP arrays. 
Whole-genome genotyping SNP arrays offer an alternative method for the identification of copy 
number changes. Commercial SNP-array platforms can now genotype more than two million SNPs 
with >99% accuracy and the genomic density of the SNPs represented in these platforms has greatly 
improved the resolution of CNV detection, compared to array-CGH techniques, which are limited 
to the detection of structural variants of ~ten to hundreds kb.  
SNP arrays were originally designed to genotype simultaneously thousands of SNPs across the 
genome. The Affymetrix and Illumina companies developed SNP arrays based on a different 
chemistry (Figure 1.7), however, these two strategies share several aspects. Both protocols are 
based on a fragmentation of the genomic DNA of interest and the hybridization of ssDNA 
fragments to arrays containing hundreds of thousands of oligonucleotidic sequences (probes). Every 
SNP is interrogated by a set of probes, which are designed to be complementary to a portion of the 
genomic sequence containing the SNP site. Each probe is represented multiple times within an 
array. The number of SNPs represented on the array through these probes is proportional to the 
resolution of the array.  
After the hybridization, a detection system measures the fluorescent signal associated with each 
probe. In SNP arrays, in contrast with array-CGH, the signal intensities are not compared with those 
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of a reference genome, but with average values derived from a set of controls. A computational 
analysis of the raw signal data converts the intensity measures into genotype inference. 
 
Figure 1.7 (LaFramboise, 2009). Overview of SNP array technologies. In the example, a genomic region containing the 
SNP A/C is shown at the top. A. Affymetrix assay: each probe (25-nt long) targets either allele A or allele B of each 
SNP interrogated. The DNA of interest binds to the complementary probes on the array, regardless of the allele it 
carries (A or C in the example). However, the efficiency is lower when there is a mismatch (indicated by a less bright 
yellow signal). B. Illumina BeadArray: there are 50-mer probes consisting of a sequence complementary to sequence 
adjacent to the SNPs interrogated. A single-base extension with labelled nucleotides results in a appropriated-colour 
signal. 
Several algorithms have been developed for CNV discovery, such as Birdsuite (Korn et al., 2008), 
QuantiSNP (Colella et al., 2007) and PennCNV (Wang et al., 2007). QuantiSNP and PennCNV 
were originally developed for data generated by Illumina arrays. These algorithms incorporate two 
measures, the Log R Ratio (LRR) and the B Allele Frequency (BAF) (Figure 1.8), in a Hidden 
Markov model, that will be described in more detail in Materials and Methods. 
 LRR is a normalized measure of the total signal intensity at each SNP. In autosomic regions 
without CNVs (copy number = 2), LRR is ~0. LRR lower than zero may indicate a deletion, 
LRR>0 a duplication. 
 BAF represents the relative ratio of the fluorescent signals between two probes/alleles (B/A) 
at each SNP. BAF values range from 0 to 1: BAF close to 1 indicates that the marker is 
homozygous for allele B, viceversa BAF close to 0 indicates that the marker is homozygous 
for allele A. Values close to 0.5 indicate a heterozygous genotype AB. Duplicated regions 
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are characterized by intermediate BAF values (between 0.5 and 1 and between 0.5 and 0), 
correspondent to the genotypes ABB and AAB. 
 
Figure 1.8. The figure shows examples of LRR and BAF plots for a deleted region (1 copy, genotype B/- or A/-), for a 
region with 2 normal copies (three possible genotypes for each SNP: AA, AB, BB) and a duplicated region (3 copies, 
four possible genotypes for each SNP: AAA, AAB, ABB, BBB). 
Therefore, unlike array-CGH, SNP arrays offer the advantage of providing genotypic information, 
that can give support to copy number information. For example, the genotypes can reveal regions 
with loss of heterozygosity (LOH), that cannot be detected with array-CGH. Stretches of 
homozygous SNP genotypes can be a supporting evidence for the presence of a hemizygous 
deletion, which consists in the loss of a genomic segment on one chromosome (copy number =1). 
Alternatively, LOH can indicate that a genomic portion of a pair of homologous chromosomes 
derives from a single parent (segmental uniparental disomy, UPD). In this case LOH is defined as 
“copy neutral”, since there is no change in copy number (copy number =2), and can be inferred only 
from both copy number and genotypic information. UPD can also occur in a portion of somatic 
cells during mitosis (referred to as acquired UPD): loss of one allele followed by reduplication 
determines copy neutral LOH, which is common in tumour genomes (Tuna et al., 2009). Several 
mechanisms have been proposed to contribute to UPD, such as mitotic non-disjunction and double-
strand break repair errors. 
Moreover, genotype analyses are also useful to determine the parent of origin of a de novo CNV 
and SNP data allows the ascertainment of parental consanguinity: regions of homozygosity deriving 
from a shared ancestry are extremely useful to discover autosomal recessive genetic causes, also in 
complex disorders. 
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1.3.3 Next Generation Sequencing-based approaches. 
The characterization of human variation has been revolutionized by the recent introduction of Next 
Generation Sequencing technologies (NGS).  
Massively parallel sequencing platforms, such as the HiSeq and MiSeq (Illumina), Ion Torrent (Life 
Technologies) and 454 Life Sciences (Roche), are able to perform sequencing of millions of small 
DNA fragments in parallel. Although these platforms use different sequencing technologies, these 
protocols are all based on a fragmentation of the DNA into small pieces, each of them is then 
sequenced and computationally aligned to the reference human genome. The sequences of each 
fragment (“reads”) are substantially shorter than the ones that can be obtained by capillary-based 
sequencing technology. However, the total number of base pairs sequenced in a run is orders of 
magnitude higher and this has provided an extraordinary increase in DNA sequencing throughput.  
New computational approaches have enabled using NGS data also to detect and map structural 
variants at nucleotide resolution. The main methods, represented in Figure 1.9, are briefly 
described. 
a) Read-pair analysis (RD) or paired-end mapping (PEM). Sequences of pair of clone ends 
(Kidd et al., 2008; Korbel et al., 2007; Tuzun et al., 2005) or high-throughput sequencing 
fragments are computationally mapped to the human reference genome: abnormal mapping 
can reveal the presence of a CNV. For example, when the region spanned by the paired-ends 
in the sample genome is shorter than the correspondent region in the reference genome, this 
can indicate a deletion; when it is longer instead, this might indicate a simple insertion. 
b) Read depth analysis (RD) is a method that detects structural variants by analysing read 
depth-of-coverage, which is measure by counting the number of reads mapping to a certain 
genomic window. Assuming that this number follows a Poisson distribution, the observation 
of an increase or a decrease of the normalized read count in a certain region may indicate a 
gain or a loss, respectively. A comparison between the PEM method and the Read Depth 
method (Yoon et al., 2009) has shown only a minority of CNVs overlap between the two call 
sets, indicating that these approaches have unique advantages in detecting different classes of 
CNVs.  
c) Split-read analysis (SR) evaluates gapped sequence alignment for structural variants 
detection (Ye et al., 2009). For example, when a read spans across the breakpoint of a deletion, 
this sequence does not map to a single position on the reference genome, but it will be split 
into two fragments that map separately, indicating the position of the breakpoints.  
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d) Sequence assembly (AS) enables the fine-scale discovery of CNVs, including novel sequence 
insertions, which are sequences absent in the reference assembly (Hajirasouliha et al., 2010; 
Simpson et al., 2009). The human reference genome is itself a hybrid that contains sequences 
derived from different sources and individuals. Some physical gaps remain and some 
sequences might have been missed. Algorithms, such as EULER (Chaisson and Pevzner, 
2008) and ABySS (Simpson et al., 2009), have been developed to assemble together the reads 
that do not map to any region of the genome (“orphan reads”): a contig formed by unmapped 
sequences might predict a novel inserted region. 
 
Figure 1.9 (Mills et al., 2011). Schematic representation of the sequence-based methods to detect CNVs. The arrows 
indicate the reads. Different sequence-based CNV-detection approaches are represented by different coloured reads. 
One of the limitations of NGS technologies is represented by regions rich in GC content or with 
repeated architecture, that can be poorly represented in the read set or can determine erroneous 
mapping. 
One of the main advantages of the sequence-based approaches is the base-pair resolution of the 
CNVs detected, which also enables the identification of the breakpoint position. Analysis of DNA 
region motifs surrounding the breakpoints allows to hypothesize the formation mechanism. 
The Structural Variation Analysis Group of the 1000 Genomes Project 
(http://www.1000genomes.org), a project created with the goal of providing a deep characterization 
on human genetic variation in different populations, has recently applied these sequence-based 
approaches in order to discover CNVs larger than 50 base pairs in 185 human genomes (Mills et al., 
2011). In this study, the breakpoint analysis has provided an estimation of the relative contribution 
of the different formation mechanisms. Nonhomology-based mechanisms (i.e., NHEJ) or MMBIR 
were estimated to be responsible of approximately 70.8% of the deletions, whereas 89.6% of small 
insertions were likely to be mediated by retrotransposition activity (Alu and L1 elements). Most 
tandem duplications showed a microhomology of 2–17 bp at the junctions and they likely arose by 
FoSTeS/MMBIR. Large deletions or duplications displayed extensive regions of sequence identity 
(>95%) at breakpoints, suggesting that they were generated by NAHR. 
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1.3.4 Validation of structural variants. 
Genome-wide CNV screenings use computational methods to identify CNVs across the genome. 
These algorithms assign a measure of likelihood to each regions harbouring a copy number variant: 
higher scores correspond to more confident CNV calls. Generally, a cut-off for this confidence 
score is established to reduce the rate of false positives. Another important parameter for the 
selection of confident CNVs is the minimum length or the number of probes: a higher number of 
SNPs or longer probes (array-CGH) are stronger supporting evidence for the existence of a CNV in 
that region. The algorithms can also have specific parameters that can be set to reduce the number 
of false positives. An additional possible strategy consists in the analysis of the same data set with 
more than one detection algorithm: CNVs that reciprocal overlap between the call sets generated by 
different algorithms have higher probability to be real (Pinto et al., 2011).  
However, the array-specific intensity signal variability and the DNA quality can influence the 
reliability of the raw data used for the CNV calling. Therefore, any structural variant detected with a 
prediction algorithm should be experimentally validated and several PCR-based methods are 
available for this purpose.  
A traditional sensitive method adopted to confirm the presence of a predicted deletion or 
duplication is Real-Time quantitative PCR (qPCR). In a qPCR assay, fluorescent molecules (such 
as SYBR Green) that interact with DNA are used to monitor changes in DNA concentration. At 
each PCR cycle, the emitted fluorescence is measured and, during the exponential phase, it is 
proportional to the amount of DNA produced in the reaction. The comparison between a target 
region and a region with known copy number determines whether there is a gain or loss. 
Multiplex PCR based-methods, alternative to qPCR, have been developed, such as Multiplex 
Ligation-Dependent Probe Amplification (MLPA) (Schouten et al., 2002) and Quantitative 
Multiplex PCR of Short Fluorescent Fragments (QMPSF) (Charbonnier et al., 2000). 
If the CNV boundaries are predicted at high resolution instead, a long-range PCR could be directly 
performed, in order to accurately characterize the breakpoints. Long-range PCR can be an easy 
validation method for deletions: primers spanning the CNV breakpoints generate a PCR product 
shorter than the expected for the reference genomic sequence and, if resolution is sufficient, this 
allows the fine mapping of the boundaries. For copy number gains instead, this approach can be 
complicated, for example, by the two possible orientations of the duplicated region.  
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1.4 CNVs in Neuropsychiatric disorders. 
Complex psychiatric and neurodevelopmental disorders, such as Autism Spectrum Disorders 
(ASD), schizophrenia (SCZ), Tourette Syndrome (TS) and bipolar disorder (BD), show a high 
heritability, but they have been proven to have a complex genetic architecture, in which multiple 
loci contribute to the overall risk.  
In the past two decades, the mapping of genes underlying these diseases has been focused on two 
alternative hypotheses: the “common disease-common variants” model (Risch and Merikangas, 
1996) and the “common disease-rare variants” model. Studies attempting to test the first hypothesis 
have found that common variants confer only a small or moderate level of risk (McClellan and 
King, 2010). These findings have suggested that the aetiology of these common diseases might be 
explained instead with the “common disease-rare variants” model, in which a number of different 
causes (SNPs or CNVs), each of them with low frequency in the population and typically highly 
penetrant, could collectively account for a large proportion of attributable risk (McClellan and 
King, 2010). These two hypotheses have been subsequently integrated in a new multifactorial 
model, in which common disorders could be result of a heterogeneous set of numerous rare and 
common variants, with different impact on the phenotype and collectively implicating a large 
number of different genes (Gibson, 2011). 
Detection of CNVs has become an important field of genetic studies of complex disorders, as CNVs 
can make a substantial contribution to the genetic mechanisms underlying disease susceptibility 
and, in particular, rarer CNVs have been indicated as a potential source of missing heritability 
(Manolio et al., 2009).  
Within CNV research, three study designs have been widely used. 
a) Family-based approach: this approach, which examines CNVs at individuals level, enables the 
identification of de novo CNVs and allows the determination of their frequency and the 
association of these mutations with the disorder; 
b) Case-control analysis of CNV burden: this approach analyses CNVs at population levels and 
examines whether the cases show a greater CNV genome-wide burden (i.e. the number of 
CNVs carried by an individual) compared to controls. Burden analyses can be carried out for 
specific categories of CNVs (such as deletions, duplications, CNVs overlapping genes or 
exons, etc..) and, in particular, the comparison of the collective frequency of rare variants 
(with frequency less than 1% in the general population) between cases and controls allows to 
investigate the contribution of rare CNVs to the disease.  
c) Association of Target regions or Genes: this approach analyses the association of specific 
CNV loci with the disease phenotype. 
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Several interesting themes have begun to emerge from CNV studies in psychiatric and 
neurodevelopmental complex diseases. 
Family-based studies have revealed a higher rate of de novo CNVs in cases compared to controls, 
indicating that they represent a contributing factor in 5-10% of ASD patients (Levy et al., 2011; 
Pinto et al., 2010; Sanders et al., 2011), 5-10% of schizophrenia cases (Kirov et al., 2012; Malhotra 
et al., 2011) and 4.3% of individuals affected by bipolar disorder (Malhotra et al., 2011).  
De novo CNVs seem to have a stronger and more robust effect size compared to inherited CNVs. 
Therefore, it has been hypothesized that de novo mutations might be important risk factors in 
sporadic forms of these disorders. In autism and schizophrenia, a higher incidence of de novo CNVs 
in children from simplex families (i.e. families with one affected individual) compared to children 
from multiplex families (i.e. families with multiple affected individuals) was observed in some 
initial studies (Marshall et al., 2008; Sebat et al., 2007; Xu et al., 2008); however this difference did 
not emerge from more recent studies (Malhotra et al., 2011; Pinto et al., 2010). 
In autism and schizophrenia, burden analyses have shown a general enrichment of potentially 
pathogenic duplications in a larger size range (>500 kb), and of deletions in smaller size range (30-
500 kb) (International_Schizophrenia_Consortium, 2008; Pinto et al., 2010). CNVs larger than 500 
kb usually contain multiple genes and can be found in a small proportion of the general population 
(~8%), suggesting that these large rearrangements are under purifying selection and they are likely 
to be potentially pathogenic. Small CNVs instead are more frequent in the general population and 
this complicates the identification of pathogenic CNVs; however small CNVs can also represent 
important risk factors and the investigation of their role needs future studies with sufficient power 
in sample size and resolution. 
Studies including large cohorts of cases of autism (Levy et al., 2011; Sanders et al., 2011) and 
schizophrenia (International_Schizophrenia_Consortium, 2008; Stefansson et al., 2008) have found 
a significant increase in large rare/de novo CNV burden in cases compared to both controls and 
unaffected siblings. In other two studies, the burden enrichment of rare CNVs appeared more 
pronounced when considering only rare CNVs overlapping genes (“genic” CNVs) (Pinto et al., 
2010; Walsh et al., 2008). 
Regarding Tourette Syndrome, a case-control study, carried out in Caucasian individuals, did not 
report an increased burden of rare CNVs in cases compared to controls (Fernandez et al., 2012). 
Another study, carried out in two Latin-American populations, found a significant increase of large 
CNVs in cases (Nag et al., 2013). 
Conflicting results have been reported for bipolar disorder: two studies found an enrichment of rare 
CNV in patients compared to controls (Priebe et al., 2012; Zhang et al., 2009), but this finding was 
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not replicated in another two studies (Grozeva et al., 2010; McQuillin et al., 2011). However, a 
study focused on rare de novo structural variants, found a significant increase in the de novo rate in 
patients affected by BD compared to controls (Malhotra et al., 2011).  
No evidence for CNV burden enrichment was observed for dyslexia (Girirajan et al., 2011).  
Another interesting observation that emerged from these burden analyses is the fact that the size and 
the rate of rare/de novo CNVs seem to correlate with the severity of the phenotype. The highest 
burden of large rare/de novo CNVs has been observed in cases with intellectual disability (ID) and 
dysmorphic features (Girirajan et al., 2011), the lowest burden in bipolar cases, in between the 
extremities are schizophrenia and autism. This trend seems to support a model where 
neurodevelopmental disorders, based on their severity and co-morbidities of ID, are considered part 
of a continuum (Figure 1.10). 
 
Figure 1.10 (Coe et al., 2012). An oligogenic model for neurodevelopmental disorders. In this model, a higher number 
of large, rare, de novo CNVs and, more in general, disruptive genetic mutations correlates with an increase in the 
severity of the clinical phenotype. 
Another interesting theme emerged from CNV studies is the fact that a CNV locus can be 
recurrently identified in association with a variety of multiple neurological phenotypes (pleiotropic 
effect). In some cases, a CNV is necessary and sufficient to result in a specific phenotype: these 
CNVs are often associated with known syndromes (“syndromic CNVs”). By contrast, there are 
CNVs which are much more variable in their outcome. These loci exhibit a variable expressivity, 
which means that individuals carrying the same CNV show either a qualitative or quantitative 
phenotypic variation, and a reduced penetrance, as these CNVs can be identified also in 
asymptomatic carriers (the penetrance is the probability of expressing a trait given a certain genetic 
change). Therefore, in contrast with syndromic CNVs, these recurrent CNVs often show an 
incomplete segregation within multiplex families and are likely to be inherited from a parent, who 
may present any of the phenotypic manifestations associated with the CNV or have normal 
phenotype. Some of these CNV hotpots are 16p11.2, 15q13.3, 1q21.2, 3q29, 17q21.31 and 7q11.23 
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loci (Coe et al., 2012). A well-characterized example is represented by microdeletions and 
microduplications at 15q13.2-15q13.3, that are presented in the next paragraph.  
The variable expressivity observed among the cases carrying the same CNV might be determined 
by secondary insults (“hits”), including additional pathogenic CNVs or damaging sequence 
mutations, by differences in the genetic background and epigenetic regulation and could be 
modulated by sex-related or age-related factors and environmental factors. Whether the CNV is 
maternally or paternally inherited can also have consequences on the phenotype, if the locus 
affected by the CNV is includes imprinted genes (Hehir-Kwa et al., 2013).  
Moreover, these recurrent CNVs show that losses and gains occurring at the same locus can lead to 
drastically different phenotypes or, instead, to surprisingly overlapping phenotypes. An example of 
different outcomes associated with CNVs at the same locus is given by the 7q11.23 region. The 
deletions, which cause hemizygous loss of about 20 genes, are associated with the William-Beuren 
Syndrome, characterized by mental retardation, visuo-spatial impairments, but precocious verbal 
ability and highly sociable disposition. By contrast, duplications at this locus have been found in 
association with autism (Sanders et al., 2011), which is characterized instead by deficits in social 
interactions and communication, and with schizophrenia (Mulle et al., 2013). 
Differences and similarities between clinical phenotypes caused by reciprocal CNVs 
(duplication/deletion) can be attributed in part to the variable dosage sensitivity of the genes 
encompassed by the CNV: for some genes, an increased or a reduced dosage can determine 
opposite consequences (“mirror” phenotype); for other genes, the dosage imbalance alters certain 
cellular functions, irrespectively of the type of copy-number change. It is worth noting that this 
variability is not limited to hotspot loci, but might be true also for other genomic regions. 
Genic CNVs can be an important source for the discovery of the genes contributing to complex 
disorders and of pathways implicated in complex disorders. Rare structural variants overlapping 
genes or exons may be pathogenic, but, if these variants are considered individually, it might be 
difficult to establish their contribution to the disorder. When the rare variants in a gene or in a set of 
genes acting in the same pathway are taken into account collectively instead, they may highlight the 
processes relevant to the disorder. A number of algorithms have been developed to determine 
whether sets of genes hit by CNVs are significantly overrepresented, compared with all known 
genes. 
o In autism, three studies have highlighted a CNV enrichment within or surrounding genes 
involved in the ubiquitination pathways (Glessner et al., 2009), gene sets related to 
processes such as cellular proliferation, development and maturation of synapse contacts, 
neuron motility, axon targeting, cell-cell adhesion and GTPase/Ras signaling (Gilman et al., 
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2011; Pinto et al., 2010), supporting the main role of synaptogenesis and neuronal 
connectivity in the disease. 
o Also in schizophrenia, rare CNVs tend to target functional classes of genes related to 
neurodevelopment pathways and synaptic activity, including synaptic long term 
potentiation, glutamate receptor signaling, axon guidance signaling and ERK/MAPK 
signaling (Malhotra et al., 2011; Walsh et al., 2008).  
o In Tourette syndrome, pathway analysis of rare genic CNVs pointed to the involvement of 
genes within histamine receptor signaling pathways, sphingolipid metabolism, axon 
guidance, cell adhesion, ubiquitination pathway, nervous system development, and synaptic 
structure and function processes (Fernandez et al., 2012). 
o In bipolar disorder, a study (Zhang et al., 2009) reported an overrepresentation of genes 
involved in pathways important for learning behaviours and psychological disorders,  
whereas a second study that focused on de novo CNVs (Malhotra et al., 2011), did not 
identify an enrichment of genes involved in neuronal function or development, but instead 
genes related to cell proliferation and shape and phospholipid metabolism.  
Interestingly, single case reports and network analyses indicate that the pathways implicated in 
different diseases may converge on common genes, such as CNTNAP2 (contactin associated 
protein-like 2) and NRXN1 (Neurexin 1), suggesting that there are some key genes important for 
several aspects of brain development and, if mutated, they can contribute to a range of disorders, 
depending on the genetic background. This supports the hypothesis of shared biological pathways 
among different neuropsychiatric conditions (Guilmatre et al., 2009). 
At least for ASD, network analyses have estimated that hundreds of genes will be involved in the 
disorder, confirming the locus heterogeneity underlying complex neurodevelopmental diseases. So 
far, the rarity of the contributing variants and their heterogeneity have represented a challenge for 
the identification of the genes implicated in these disorders. However, in the next years, the gene 
discovery effort is expected to be facilitated by the increasing availability of high-throughput CNV 
and sequencing data. The integration of structural and sequence information will allow the capture 
of a larger fraction of the rare disease-causing variants and to explain a larger proportion of the risk. 
1.5 Recurrent CNVs on chromosome 15q11-q13. 
The proximal region of the long arm of chromosome 15 (15q11-q14) is a well-known hotspot for 
CNVs. The presence of complex patterns of highly homologous LCRs makes this locus one of the 
most unstable regions in the human genome and this can also be appreciated observing the large 
number of CNVs reported for this region in the DGV. The structural and sequence features of the 
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15q11-qq14 region can lead to a number of different rearrangements, e.g. deletions, duplications, 
translocations, inversions and, also, supernumerary inv-dup(15) chromosomes. Deletions and 
duplications are likely to be caused by NAHR between the LCRs. The breakpoints of these CNVs 
usually coincide with clusters of LCRs, that have been designated BP1-BP6 (Figure 1.11). 
 
Figure 1.11 (Sanders et al., 2011). The genomic architecture of the BP1-BP5 region on chromosome 15q. The position 
of each BP is indicated. Class 1 indicates BP1-BP3 deletions, class 2 instead indicates  the BP2-BP3 deletions. 
 
1.5.1 Recurrent CNVs at 15q11.2 locus (BP1-BP2 region). 
The BP2-BP3 region includes imprinted genes, therefore the effects of mutations in this region 
depend on the origin (maternal or paternal) of the chromosome in which they occur. BP1-BP3 
deletions (Type I) or BP2-BP3 deletions (Type II) (Figure 1.12) can result in Prader-Willi 
Syndrome, if the deletion is inherited from the father, or Angelman Syndrome, if the deletion is 
inherited from the mother. Duplications instead can be associated with learning disabilities, seizures 
and autism (maternal duplications are present in 1-3% of individuals with ASD (Veenstra-
VanderWeele and Cook, 2004)).  
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Figure 1.12 (Burnside et al., 2011). The figure shows the BP1-BP3 region on chromosome 15q: the genes are 
differentially coloured, depending on their imprinting.  
BP1-BP2 microdeletions and microduplications have been proposed as risk factors for a range of 
neurological problems, in particular, language delay and developmental delay (Burnside et al., 
2011; Doornbos et al., 2009), ID (Cooper et al., 2011), ASD (Doornbos et al., 2009; Sanders et al., 
2011; van der Zwaag et al., 2010), schizophrenia (Kirov et al., 2009; Stefansson et al., 2008) and 
epilepsy (de Kovel et al., 2010), but they have been observed also in controls. A screening for large 
CNVs performed on 15,767 children with ID and various congenital deficits and 8,329 healthy adult 
controls (Cooper et al., 2011), found that BP1-BP2 microdeletions were significantly associated 
with neurodevelopmental disorders (p-value= 4.73 x 10
-6
), epilepsy (p-value= 1.48 x 10
-3
) and 
autism (p-value= 1.99 x 10
-2
). Moreover, another paper (Burnside et al., 2011), describing a 
retrospective analysis of cases with BP1-BP2 rearrangements, showed that a high percentage of 
these subjects had speech delay (50% of duplications carries, 90% of deletions carriers), but also 
developmental delay (39% of duplications carries, 59% of deletions carriers) and ASD features 
(41% of duplications carries, 29% of deletions carriers). The interval between BP1 and BP2 
(~500kb) contains four non-imprinted genes: TUBGCP5, CYFIP1, NIPA1 and NIPA2. These genes 
are evolutionary conserved and they code for proteins that could be potentially implicated in 
neurological dysfunctions:  
 TUBGCP5 (OMIM 608147) encodes the gamma-tubulin complex component GCP5, a 
member of cytoskeleton tubulin complex;  
 CYFIP1 (OMIM 606322) codes for a cytoplasmic protein that interacts with FMRP, the 
protein implicated in fragile X syndrome;  
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 NIPA1 (non imprinted in Prader-Willi/Angelman syndrome 1, OMIM 608145) and NIPA2 
(non imprinted in Prader-Willi/Angelman syndrome 2, OMIM 608146) code for magnesium 
transporters that can be found in a variety of neuronal and epithelial cells, suggesting that 
these proteins may have a role in nervous system development and maintenance. 
1.5.2 Recurrent CNVs at 15q13.2-15q13.3 locus (BP4-BP5 region). 
The segmental duplications BP4 and BP5 (15q13.2-15q13.3) can mediate a range of different 
recombination events. The typical rearrangements occurring between BP4 and BP5 are CNVs with 
a size of ~1.6 Mb and encompass six RefSeq genes (MTMR15, MTMR10, TRPM1, KLF13, 
OTUD7A and CHRNA7) and the microRNA gene hsa-mir211. These recurrent large BP4-BP5 
deletions and duplications (Figure 1.11) have been found across multiple conditions and also in 
asymptomatic carriers. In particular, the deletion has been reported in cases of mental retardation 
with seizures (Sharp et al., 2008), autism (Miller et al., 2009; Pagnamenta et al., 2009), 
schizophrenia (International_Schizophrenia_Consortium, 2008; Stefansson et al., 2008), bipolar 
disorder (Ben-Shachar et al., 2009) and epilepsy (Helbig et al., 2009; Masurel-Paulet et al., 2010) 
and language delay (Ben-Shachar et al., 2009).  
However, BP4 and BP5 have a complex organization and can lead also to smaller deletions and 
duplications (Figure 1.11). Recurrent atypical smaller microdeletions and microduplications (350-
680 kb) have also been found in a similar range of neuropsychiatric phenotypes (Leblond et al., 
2012; Szafranski et al., 2010).  
All these CNVs include the gene CHRNA7 (OMIM 118511), encoding the α7 subunit of the 
neuronal nicotinic acetylcholine receptor, and the first exon of one isoforms of OTUD7A (OMIM 
612024), encoding a putative deubiquitinating enzyme. Between these two genes, CHRNA7 seems 
to be the most likely candidate gene for cognitive and neurobehavioral deficits, as it is highly 
expressed in the brain and, given its functions, relates to seizures and epilepsy (Shinawi et al., 2009; 
Szafranski et al., 2010), therefore it has been hypothesized that abnormal dosage of CHRNA7 could 
alter the neuronal homeostasis (Shinawi et al., 2009; Szafranski et al., 2010). 
A recent study (Moreno-De-Luca et al., 2013) has analysed the frequency of rare CNVs recurrently 
found in association with neuropathological phenotypes, combining published data available for 
large cohorts of clinical cases and control data sets. The analysis was performed on a group of 
31,516 cases (including patients with developmental delay, ID, ASD or multiple congenital 
abnormalities) (Cooper et al., 2011; Kaminsky et al., 2011) and 13,696 controls (Cooper et al., 
2011; International_Schizophrenia_Consortium, 2008; Magri et al., 2010; Shaikh et al., 2009). As 
shown by Table 1.1 and Table 1.2, statistical support for a pathological role was found for several 
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CNV loci, including the BP4-BP5 region on chromosome 15q13.2-q13.3. The BP4-BP5 deletion 
was detected in 88 cases, whereas the BP4-BP5 duplication was identified in 34 cases and 5 
controls. Both CNV types were reported to have a statistical significant increase in cases compared 
to controls. However, while the deletion appears to have a complete penetrance, the reciprocal 
microduplication shows incomplete penetrance. 
 
Table 1.1 (Moreno-De-Luca et al., 2013). Deleterious recurrent deletions in clinical cohorts. 
 
Table 1.2 (Moreno-De-Luca et al., 2013). Deleterious recurrent duplications in clinical cohorts. 
The analysis was then restricted to 3,955 cases belonging to three of the largest ASD cohorts and 
included 1124 cases from the SSC, 996 from AGP and 1835 from Autism Genetic Resource 
Exchange (AGRE) (Geschwind et al., 2001; Itsara et al., 2010; Pinto et al., 2010; Sanders et al., 
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2011). In this subset, only BP4-BP5 deletions yielded a statistical significant difference between 
cases and controls (p-value =1.26 x 10
-4
), while the BP4-BP5 duplications did not showed a 
significant enrichment in cases (p-value =0.66) (Moreno-De-Luca et al., 2013).  
In conclusion, BP1-BP2 and BP4-BP5 CNVs can be observed in a wide spectrum of clinical 
phenotypes of variable severity and some of them, such as BP1-BP2 microdeletions and BP4-BP5 
microduplications, are present also in healthy individuals, suggesting that they have variable 
expressivity and incomplete penetrance and are probably not sufficient to cause pathological 
phenotypes (Leblond et al., 2012; van Bon et al., 2009). However, since they involve interesting 
candidate genes and have a higher frequency in clinical cohorts, they might contribute to the 
susceptibility to certain neuropsychiatric disorders in specific genetic backgrounds, where 
secondary alterations could have an additive or epistatic effect.  
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Chapter 2 
Specific Language Impairment 
2.1 What is Specific Language Impairment? 
Language is a peculiar faculty of human beings that plays a central role in social interactions. 
Verbal forms of communication can be found also in other organisms, but the structural complexity 
of human language is a unique property.  
Specific Language Impairment (SLI) is a common neurodevelopmental disorder defined as an 
inability to develop appropriate language skills despite normal intelligence and access to adequate 
educational opportunities. SLI is diagnosed when expressive and receptive language abilities are 
severely affected, whereas non-verbal cognitive abilities are within age expectation, in the absence 
of any medical conditions that might underlie the language problems (e.g. hearing loss, mental 
retardation, autism). SLI is a heterogeneous condition that can vary in both severity and language 
impairment profiles. This disorder affects up to 8% of preschool children (Law et al., 2000), with a 
higher prevalence in males and, in some cases, it persists into adulthood (Conti-Ramsden et al., 
2001).  
2.2 Measurement of SLI symptoms.  
The acquisition of language is one of the key milestones of childhood. Children affected by specific 
language impairment (SLI) struggle to acquire basic competence in one or more aspects of spoken 
language. Adequate language development requires the acquisition of the ability to comprehend 
what others say (receptive language) and to produce utterances that other people can understand 
(expressive language). Language abilities can be further subdivided into several domains, including 
the knowledge and appropriate use of: 
- words and their meaning (lexicography, semantics, or vocabulary);  
- the way that sequences of words combine in sentences (grammar or syntax);  
- linguistic forms involved in social interactions (pragmatic language);  
- the system of speech sounds that make up the language (phonology). 
Children with SLI display difficulties of variable degree in one or more of these language domains 
(Table 2.1). 
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Characteristics of Specific Language Impairments (SLI)  
Diagnostic criteria  
 Language is significantly below level expected from age and IQ, usually interpreted as 
scoring in the lowest 10% on a standardized test of expressive and/or receptive language 
 Nonverbal IQ and nonlinguistic aspects of development (self-help skills, social skills) fall 
within broadly normal limits 
 Language difficulties cannot be accounted for by hearing loss, physical abnormalities of the 
speech apparatus or environmental deprivation 
 Language difficulties are not caused by brain damage 
Common presenting features* 
 Delay in starting to talk; first word may not appear until 2 years of age or later 
 Immature or deviant production of speech sounds, especially in preschool children 
 Use of simplified grammatical structures, such as omission of past tense endings or the 
auxiliary “is” well beyond the age when this is usually mastered 
 Restricted vocabulary, in both production and comprehension 
 Weak verbal short term memory, as evidenced in tasks requiring repetition of word or 
sentences 
 Difficulties in understanding complex language, especially when the speaker talks rapidly 
*SLI shows considerable heterogeneity, as well as age-related changes 
Table 2.1 (Bishop, 2006). Phenotypic characteristic of SLI. 
There are many tests that analyse lots of different aspects of language. These tests provide 
quantitative measures of different language endophenotypes, that can be also used for genetic 
investigations. However, an exhaustive description of them is beyond the scope of this section. 
Several tests have been developed for English-speaking children, such as TOLD (Test Of Language 
Development) and Clinical Evaluation of Language Fundamentals Revised test (CELF-R).  
TOLD (Hammil et al., 1987; Hammil and Newcomer, 1988; Newcomer and Hammil, 1988) is a 
comprehensive test of language functioning that evaluates specific subtypes of language domains, 
such as comprehension, expression, grammar, syntax and phonology. 
CELF-R (Semel et al., 2004; Semel et al., 1992) is widely used to identify, diagnose and follow-up 
language impairments in school-age children (5–17 years). CELF-R examines expressive and 
receptive language domains separately and then combines the results in a composite language score. 
Different batteries of test are available, depending on the age of the subject.  
Another important language-related domain that can be evaluated is the Phonological Short Term 
Memory (PSTM), a working memory critical for a temporary storage and processing of incoming 
words or sounds. PSTM allows a representation of speech sounds (phonemes) in the brain. Based 
on this theory, Gathercole et al. (Gathercole et al., 1994) developed a test, known as “NonWord 
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Repetition” (NWR), to assess the capacity that phonological working memory has to store and 
process unfamiliar words or words with no meaning (nonsense words). In this task, the child cannot 
recall his stored knowledge, but he is forced to rely upon the temporary representation of the non-
word in the short-term phonological store. Children with SLI poorly perform on this repetition task 
(Bishop et al., 1996; Gathercole et al., 1994), suggesting that the amount of memory necessary to 
hold novel phonological forms in their PSTM is insufficient to allow in-depth processing and 
transfer of this information to the long-term memory. Interestingly, this test is able to reveal deficits 
also in individuals reported to have language difficulties during early childhood, later resolved, 
indicating that this measure is a good marker for language impairments. 
The Past Tense (PT) test (Marchman et al., 1999) evaluates grammatical competencies, that are not 
assessed by CELF and NWR tests, such as the ability to add appropriate inflectional endings to 
verbs, which is frequently impaired in English-speaking children affected by SLI.  
Reading tests can also be informative about aspects of language, because the comprehension of a 
written text requires both reading abilities and language comprehension skills. Indeed, although 
reading impairment is distinct from specific language impairment, these deficits co-occur in 50% 
of the affected individuals (Flax et al., 2003). 
2.3 The genetic bases of SLI.  
The evidence for an influence of genetic factors in spoken language disorders has emerged from 
twin and familial studies.  
A review of eighteen studies relative to spoken language impairment (Stromswold, 1998) indicated 
that the incidence of language deficits was significantly greater in families with a SLI “proband” 
(the individual through whom the family was identified) than in families with an unaffected 
proband with normal speech and language (controls). 
Studies based on the concordance rate of the disorder between co-twins allows to distinguish 
genetic from environmental influences, and therefore they can prove if a disorder is heritable. 
Monozygotic twins (MZ) can be considered 100% genetically identical, whereas dizygotic twins 
(DZ) are assumed to be 50% genetically similar. Three twin studies have shown an increased MZ 
concordance compared with DZ concordance rates (Bishop, 2002; Bishop et al., 1995; DeThorne et 
al., 2006; Tomblin and Buckwalter, 1998). Considering that both twin types usually share the same 
environment, a higher MZ concordance indicated that SLI has a strong genetic component. 
However, family studies have failed to detect a simple dominant or recessive pattern of inheritance, 
suggesting a complex genetic architecture underlying the disorder. 
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2.4 Molecular genetic studies for SLI susceptibility. 
In order to identify the genetic risk factors conferring susceptibility to SLI, linkage and association 
studies have been performed. Both approaches are based on the genotyping and analysis of genetic 
markers, which are polymorphic variants with a known position in the genome (e.g. SNPs or 
microsatellites).  
2.4.1 Linkage studies. 
Linkage studies are based on the principle that polymorphic genetic markers located in proximity of 
disease-causing variants cosegregate with the affection status, across generations: the linkage 
between these markers and the disease-causing variants is detected when they are transmitted 
together to the offspring more often than expected under independent inheritance. Their probability 
of being separated by a crossing over during meiosis is proportional to their distance on the 
chromosome. These studies involve related individuals and can include large pedigrees (with 
extended families and/or multiple generations) or a large number of small nuclear families 
(consisting of a father, a mother, and their children).  
Linkage methods can be divided into two main approaches:  
 “model-based” or parametric linkage analyses, which rely on the specification of a genetic 
model of the disease, in particular the inheritance pattern (dominant or recessive), the 
penetrance levels, the expected frequencies of the disease allele in the population; 
 “model-free” or non-parametric linkage analyses (NPL), suitable for disorders with an 
unknown genetic model, which is often the case of complex and heterogeneous diseases. A 
non-parametric linkage approach consists of the analysis of the number of identical-by-
descendent (IBD) alleles shared by pairs of affected siblings (ASP). For any genetic locus, 
siblings can share both alleles (IBD=2), half their alleles (IBD=1) or none of their alleles 
(IBD=0), depending on the segregation pattern of parental alleles, with probabilities of 25%, 
50% and 25%, respectively. This linkage sib-pair method is based on the hypothesis that 
chromosomal region harbouring the disease-causing genes (and thus the alleles of 
polymorphic markers close to these genes) are likely to be shared by ASPs. Therefore, 
genomic regions where the IBD alleles are shared by sib-pairs more often than expected by 
chance allow the identification of loci linked to the disease. These analyses can be 
qualitative or quantitative, depending on whether they test the correlation between genetic 
similarity (estimated by the IBD sharing) and binary (presence or absence) traits or trait on a 
continuous scale. 
Specific Language Impairment 
 
36 
 
Results of linkage analyses are reported as Logarithm Of Odds (LOD) scores, that are a function of 
the recombination fraction (θ), which indicates the probability of a recombination event between 
two loci at meiosis. LOD scores indicate the likelihood that a marker and the disease-gene are 
physically linked. When the LOD scores are calculated taking into account the fact that several 
different genes can contribute to the susceptibility of a disorder (locus heterogeneity), they are 
reported as Heterogeneity LOD scores (HLOD).  
Traditionally, the threshold for significant linkage is indicated as a LOD score of 3. More stringent 
criteria may be required, depending on the number of genotyped markers and the type of analysis 
used. Sometimes, lower LOD scores (~2) are reported as suggestive linkage. Linkage studies 
usually identify large regions of susceptibility (in the order of Mb), encompassing a large number of 
genes, and their success is affected by genetic and phenotypic heterogeneity of the disorder. 
2.4.2 Association studies. 
Association studies aim to find an allelic association between specific genetic variants and the 
disease phenotype in a population, assuming that the marker itself or a variant close to it confers 
susceptibility to the disease. When an allelic variant is associated with a trait, this result can be 
interpreted as: 
a) a direct association, if the variant has a causal role in the phenotype susceptibility; 
b) an indirect association, if the variant is in Linkage Disequilibrium with the causal variant 
(LD is a phenomenon arising from alleles at linked loci, that tend to cosegregate more often 
than expected by chance and forming “haplotypes blocks”);  
c) a false positive, that may be due to chance or to problems such as population stratification or 
inappropriate statistical methods. 
These studies are usually performed with one of two main different approaches (McCarthy et al., 
2008). 
 Case-control association studies involve large numbers of unrelated cases and controls (the 
sample size should be in the order of thousands of individuals) to examine if the prevalence 
of specific variants is significantly higher in cases than in controls. Cases and controls are 
required to be well-matched, in particular for ethnic background, to avoid spurious 
association signals that can be due to population substructures (stratification). The control 
group should be formed by individuals classified as “unaffected” after specific assessment 
for the absence of the disease (also referred to as “supernormal” controls), but often is 
formed by large numbers of individuals randomly collected from the population 
(“unscreened” controls). For common diseases, when screening for the investigated 
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phenotype is possible, “supernormal” controls represent a better alternative as they increase 
the power to detect associations (Lewis and Knight, 2012). 
 Transmission disequilibrium test (TDT) is a robust family-based strategy based on parental 
heterozygous markers: if an allele is associated with the disease, it will be transmitted to the 
affected children more often than expected by chance (50%) (Spielman et al., 1993). 
Although the TDT has a reduced statistical power compared to the case-control studies, it 
avoids issues related to the optimal selection of control samples, because the parental alleles 
not transmitted to the affected offspring are considered “internal controls”. TDT also allows 
to differentiate effects of alleles, testing whether there is a preferential paternal or maternal 
transmission of susceptibility alleles (parent-of-origin). 
Results of association studies are usually expressed as P values or –log10(P): very low P values 
provide strong evidence for association. The significance threshold depends on the number of 
markers: as the number of markers increases, the required number of tests increases and the 
significance threshold becomes more stringent. The traditionally accepted significance threshold for 
genome-wide association studies (GWAs) is 5×10
-8
, which was estimated to give a probability 
higher than 95% of having no false positives for 1,000,000 independent tests (Risch and 
Merikangas, 1996). This threshold is appropriate, for example, for arrays with 1 million SNPs on 
them. Generally, association studies require a higher density of markers than linkage studies, but 
they identify candidate chromosome regions with a better resolution. 
2.4.3 Nuclear families studies: evidence for linkage to chromosome 16 and 19.  
A quantitative trait locus (QTL) genome-wide linkage analysis for SLI was undertaken by the SLI 
Consortium (SLIC) (SLIC, 2002). This study included 98 nuclear families, each with at least one 
child affected by SLI. The children’s language-related abilities were assessed using CELF-R and 
NWR tests, and their cognitive abilities using the Wechsler Scales of Intelligence (WISC) (as 
described in Materials and Methods). All probands had Expressive and Receptive Language Scores 
(ELS and RLS, obtained from CELF-R) >1.5 standard deviations (SD) below the normative mean 
for their chronological age and a Performance IQ (PIQ) >80.  
The quantitative analyses were performed using two non-parametric sibling pair methods: the 
Haseman-Elston (HE) (Haseman and Elston, 1972) and Variance-Components (VC) methods (Pratt 
et al., 2000). HE is a linear regression-based method that assumes an inverse relation between the 
squared differences in the sib-pair trait scores and the proportion of IBD alleles shared at the loci 
close to genes influencing the trait (QTL). The VC linkage method separates the trait variance into 
three components: a major gene variance, a background polygenic variance, and a variance due to 
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random environmental effects. This approach is different from the methods described above and 
estimates the relative contribution of these components and the likelihood of linkage between the 
phenotypic variability and shared IBD alleles at particular marker loci, under the hypothesis of a 
major gene (QTL) effect. 
In this first SLIC study, two significant linkage regions were found: one on chromosome 16q 
(designated SLI1, OMIM 606711), linked to NWR trait (maximum LOD score of 3.55, HE 
analysis), and another on chromosome 19q (designated SLI2, OMIM 606712), linked to the ELS 
trait (maximum LOD score of 3.55, HE) (Figure 2.1). 
 
Figure 2.1 (SLIC, 2002). Genome-wide plot of HE linkage to three language-related measures (ELS, ELS; NWR) 
under multipoint analysis. 
In 2004, after collecting 86 additional families, the SLIC performed another linkage analysis to 
further investigate the two regions previously identified (SLIC, 2004). In this cohort, that included 
also the previously collected families (n=98), giving a total number of 184 families, the linkage 
between chromosome 16 and NWR performance was confirmed, with a combined maximum LOD 
score of 7.46. The linkage on chromosome 19 also replicated, but the region was linked to different 
language-related measures: in first wave (the 2002 cohort) the linkage was found for ELS, in the 
second wave (the 2004 sample) for NWR. Taking into account both samples, the maximum LOD 
score on chromosome 19 with NWR was 1.4 (HE). 
A study of an independent cohort of 93 nuclear families, collected through the Manchester 
Language Study, tried to replicate the SLIC linkage findings (Falcaro et al., 2008). The selected 
children had PIQ ≥80 and were mainly assessed for NWR and Past Tense marking trait (PT) task, 
but also ELS (CELF-R) data were available.  
Linkage analyses were performed using two methods: the HE method and another method (Fulker 
et al., 1991), hereafter referred to as the “DF-linkage” method, which represents an extension of the 
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classic DeFries–Fulker approach. The classical method, originally developed to estimate the 
heritability of traits from MZ and DZ twins and based on a regression model, was implemented to 
detect linkage regions in sib-pairs, using quantitative phenotypic measures and shared IBD as a 
measure of the genetic similarity between siblings. The DF-linkage method assumes that if a IBD 
value for a marker has a significant effect on the extent of regression toward the population mean, 
then there is evidence for linkage between the marker and a trait locus. 
A weak linkage with NWR was found on chromosome 16q (maximum LOD score of 1.69, DF-
linkage) while a significant linkage with ELS was identified on chromosome 19q (maximum LOD 
score of 5.8, DF-linkage).  
Linkage to these regions was seen also to past tense phenotype. It has been suggested that, by a 
certain age, PT competence is either acquired or not acquired and it therefore should be analyzed as 
a qualitative trait (Bishop, 2005, 2014). In this study, two alternative hypotheses were tested: PT 
abilities were examined either on a continuous scale or as a binary trait (affected or unaffected). 
When PT was measured as a continuous trait, some linkage was found on both chromosome 16 
(maximum LOD score of 1.8, DF-linkage) and chromosome 19 (maximum LOD score of 2.2, DF-
linkage); considering PT as a binary trait instead, a linkage signal was detected only on 
chromosome 19 (maximum LOD score of 1.66, HE).  
2.4.4 Extended pedigree studies: evidence for linkage to chromosome 13. 
Linkage studies are based on the segregation of marker alleles with the disease phenotype, therefore 
extended pedigrees with multiple affected individuals are generally more informative than nuclear 
families, and have an increased power of identifying chromosomal regions linked with a disease. A 
linkage screen for SLI was carried out in five large Canadian families, two nuclear and three 
extended (Bartlett et al., 2002). Some of the individuals enrolled in this study were originally 
identified during a linkage study of schizophrenia, as they were reported to have a history of 
language or reading deficits (Brzustowicz et al., 2000). Although a diagnosis of SLI excludes the 
presence of other neurological disorders, the authors asserted that the low number of schizophrenic 
individuals included in the analysis (n=7) would not influence the identification of SLI 
susceptibility loci, considering that the largest pedigree (34 individuals) was connected to a 
schizophrenia family only by marriage. 
From a total of 86 individuals from whom DNA was available, language phenotypes could be 
assessed for 73 subjects. Several tests were used, including an age-appropriate version of the 
language development test TOLD and reading subtests from the Woodcock Reading Mastery Test 
(single word and single non-word reading tests).  
Each family included at least two SLI probands, defined as those with Spoken Language Quotient 
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Standard Score (SLQ, taken from the TOLD) of >1SD below that expected by age, PIQ of ≥80 and 
PIQ≥ SLQ. Three categorical diagnoses (not mutually exclusive) were derived for all family 
members: a) language impairment (SLQ ≤85); b) reading impairment (single non-word reading 
score of >1SD below PIQ); c) clinical impairment (history of language or reading difficulties).  
A total of six parametric linkage analyses were performed: for each diagnostic category, two 
distinct models were tested, assuming either dominant or recessive inheritance. The highest LOD 
scores were also characterized with a Bayesian statistical approach, called Posterior Probability of 
Linkage (PPL) (Vieland, 1998; Vieland et al., 2001). PPL calculates a posterior probability of 
linkage between a marker and a trait gene, incorporating prior genomic information and prior 
probabilities (i.e. recombination fraction probability and linkage probability), that can be adjusted 
for the structure of the dataset in hand. This flexible method is particularly suited to the study of 
complex disorders, as it takes into account also the fact that the same susceptibility locus can show 
different modes of transmission among families. Moreover, it allows the accumulation of linkage 
evidence across many datasets. PPL values range from 0 to 1, but are commonly converted into 
percentages: values converging to 1 (or 100%) provide strong support to linkage peaks. 
Significant evidence of linkage was found on chromosome 13q (max LOD=3.92) with a reading-
based phenotype, under the recessive model of inheritance (Figure 2.2). The maximum PPL for this 
locus was 0.53, indicating a probability of 53% that a risk factor for SLI falls in this region. No 
linkage was detected in the two loci found by the SLIC, on chromosomes 16q (SLI1) or 19q (SLI2). 
 
Figure 2.2 (Bartlett et al., 2002) Genome-wide plot of maximum two point heterogeneity LOD scores for all six models 
(R= reading discrepancy, C=clinical diagnosis, L= language impaired, Dom=dominant, Rec=recessive). The three 
highest peaks are labelled by marker and model tested. 
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In 2004, Bartlett et al. further investigated the region on chromosome 13q using a larger cohort, 
which included 22 additional nuclear and extended families (279 individuals from the United 
States), ascertained through a single proband (Bartlett et al., 2004). Assessment and proband 
designation were the same as described in Bartlett et al., 2002. In this second study, they also 
investigated a potential genetic overlap with autism, looking at two loci linked to autism, on 
chromosomes 2q and 7q, that will be discussed later (paragraph 2.6.3). The assessment tools, 
criteria for diagnosis and model parameters were the same used in their first study. The two sample 
sets (Canadian and US) were combined using alternative methods: the PPL method and the 
heterogeneity LOD score method (HLOD). Two HLOD variants were used: HLOD-P, which pools 
datasets to calculate one HLOD score, and HLOD-S, which calculates HLOD scores for each 
sample separately and then sums them across datasets. 
The loci on chromosomes 2q and 7q did not provide conclusive evidence for linkage. Linkage was 
obtained for chromosome 13q, instead, in each separate sample set (US sample HLOD=2.616, 
PPL=16.8%; Canadian sample HLOD=3.565, PPL=54.2%) and when the sample were combined 
(HLOD-P=6.031; HLOD-S=6.181, PPL=92.3%), under the recessive reading impairment model. 
These analyses replicated and strengthened the findings previously reported for chromosome 13. 
Therefore, this region has been designated as SLI3 (OMIM 607134). 
2.4.5 Extended pedigrees from an isolated population: Robinson Crusoe island. 
A linkage study involving extended pedigrees was carried out on an isolated Chilean population 
with an increased prevalence of SLI (known as TEL in Spanish-speaking countries) (Villanueva et 
al., 2011). This population inhabits the Robinson Crusoe Island, located 677 km west of Chile and 
belonging to the Juan Fernández archipelago. In the late 19
th
 century, eight families repopulated the 
island and, as a result of its geographical isolation, the current population (633 residents, based on 
the 2002 Chilean census) shows a high degree of consanguinity (Villanueva et al., 2008). Given the 
relatively recent ancestors, a genealogical reconstruction was carried out and, interestingly, found 
that the vast majority of known affected individuals (84% of the individuals from whom DNA was 
available) descended from a single pair of founder brothers (Villanueva et al., 2011) (Figure 2.3). 
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Figure 2.3 (Villanueva et al., 2011). Pedigree structure of the descendants of a single pair of founder brothers. 
Island “colonising” children (i.e. related to one of the founder families) show a very high incidence 
of SLI (35%), compared to the frequency of SLI among the non-colonising children (3.8%), which 
is almost the same as that reported in mainland Chile (4%) (Villanueva et al., 2008).  
Therefore, due to its derivation from small group of relatively recent founders, to its decreased 
genetic heterogeneity and the common environment, this Chilean founder population represents a 
powerful resource for the identification of genetic factors contributing to susceptibility to SLI. In 
particular, for complex disorders like SLI, these founder populations may be extremely useful for 
the identification of rare monogenic forms of the disease.  
Non-parametric and parametric (assuming dominant or recessive mode of inheritance, a frequency 
of 35% and full penetrance) linkage analyses were performed on “colonizing” families. Five regions 
(on chromosomes 6, 7, 12, 13 and 17) yielded genome-wide significant linkage in non-parametric 
analyses. In this study, linkage was not observed for the previously implicated loci on chromosomes 
16 (SLI1) or 19 (SLI2), but the region identified on chromosome 13 was close to SLI3. Across the 
different analyses, the most consistently linked locus (max NPL=6.73, P=4x10
-11
) was a 48 Mb 
region on chromosome 7q, which overlaps with a region that has been linked to autism (AUTS1 
locus, OMIM 209850) and encompasses several interesting candidate genes, including FOXP2 and 
CNTNAP2, both implicated in language development and discussed in more detail below.  
Further studies will be required for a fine mapping of the relevant regions, in order to identify the 
genes contributing to the increased frequency of language impairment on the island. 
2.4.6 A comparison between the different linkage studies for SLI. 
None of the regions of linkage described above was replicated across all these studies. In addition to 
locus heterogeneity, which is an important component of complex disorders, several factors may 
have influenced the lack of overlap of the results across the three cohorts. The most striking 
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differences regard the design strategy and the phenotype definition. 
SLIC used non-parametric analyses and a cohort of nuclear families, the Bartlett group applied a 
parametric approach to a small number of large families, and the Robinson Crusoe study used both 
parametric and non-parametric methods with an extremely large pedigree deriving from an isolated 
population. Each linkage approach presents advantages and disadvantages. Non-parametric methods 
offer the advantage of not requiring the specification of a model and for this reason are more 
suitable to complex diseases with unknown mode of inheritance. Parametric analyses instead need 
the specification of a model, but if the parameters are correct, they provide increased power. They 
can be seriously affected by locus heterogeneity and mis-specification of parameters can lead to 
false positives. However, previous studies (Abreu et al., 1999; Greenberg et al., 1998) have shown 
that, if both mode of inheritance (dominant and recessive) are tested, parametric analyses can have 
sufficient power to detect genomic regions linked to complex disorders. Moreover, they used 
families with multiple affected members, that are more informative compared to small nuclear 
families with one affected member and are expected to have a reduced genetic heterogeneity. This 
is particularly true for large and multigenerational pedigrees. 
Second, there are differences in the way the SLI phenotypes were measured and analysed. The 
absence of a standard definition for a diagnosis of SLI leads to differences in the classification of 
affected and unaffected individuals. The studies of extended pedigrees used binary categories of 
language impairment by setting an arbitrary threshold for affection. When the threshold is 
appropriate, this approach can increase the power and reduce the heterogeneity. SLIC instead 
considered language abilities along a continuous scale, using standard scores calibrated against the 
general population, and this allowed a quantitative analysis of three highly heritable traits (ELS, 
RLS and NWR).  
The loci found by the three groups were linked to different phenotypes or sub-phenotypes: 
 the region on chromosomes 16 was linked to NWR (Falcaro et al., 2008; SLIC, 2002); 
 the region on chromosome 19 was linked to ELS (Falcaro et al., 2008; SLIC, 2002), to 
NWR (SLIC, 2004) and to PT (Falcaro et al., 2008); 
 the region on chromosome 7 was linked to language impairment (Villanueva et al., 2011); 
 the locus on chromosome 13 was linked to reading impairment in a language impaired 
sample (Bartlett et al., 2002). Reading impairment was not interpreted as a dyslexia 
phenotype, but as a language-related trait, considering that impaired language development 
can also lead to difficulties in reading skills (Flax et al., 2003).  
Co-morbidity between reading and language abilities has been examined also by two recent GWA 
studies (Eicher et al., 2013; Luciano et al., 2013): association signals with both language and 
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reading skills have been found for variants in the genes ZNF385D (chromosome 3p24.3), DAZAP1 
(chromosome 19p13.3), CDC2L1, CDC2L2 and RCAN3 (located on chromosome 1), while 
association with specific language traits has been found for variants in the genes ABCC13 
(chromosome 21q11) and NDST4 (chromosome 4q26).  
The investigation of alternative traits (“endophenotypes”) can be useful in dissecting the genetic 
bases underpinning a disorder like SLI, however the results of these kind of studies frequently 
present lack of overlap. This might indicate that the quantitative/qualitative traits chosen to evaluate 
language skills might be individually too restrictive to capture the complex scenario of the 
molecular mechanisms underlying language impairment. Complex disorders like SLI, characterized 
by genetic heterogeneity, are estimated to involve numerous genes and each of them might 
influence multiple phenotypic aspects. 
2.4.7 Targeted association studies of chromosome 16. 
In order to investigate the linkage of NWR trait to the SLI1 locus, a high density association screen 
of SLI across this region of linkage on chromosome 16q (~10 Mb) was carried out by the SLIC 
Consortium (Newbury et al., 2009). In this study, including 211 SLIC families, a family-based 
quantitative association analysis (known as QTDT) and a categorical case-control analysis were 
performed. The QTDT is a linkage disequilibrium test able to detect association with quantitative 
traits in nuclear families through a regression-based approach, which tests the correlation between a 
continuous trait measure and the number of alleles of a given marker carried by a child. This model 
takes into account variance within- and between-families. The case-control analysis instead, was 
carried out using the NWR trait as a binary measure: individuals with low NWR (>2 SD below the 
SLIC cohort mean, n=79) were defined as cases, whereas family members with above-average 
NWR performance (>0.5 SD above population mean, n=71) were selected as controls. To obtain a 
group of unrelated cases and controls, only one case or one control was selected from each family. 
Strong association signals were found for two clusters of SNPs, 3Mb apart: one falling in the CMIP 
gene (c-Maf inducing protein, minP=5×10
-7
), between exon 2 and exon 5, and the other one in the 
ATP2C2 gene (ATPase, Ca
2+
 transporting, type 2C, member 2, minP=2×10
-5
), between exon 7 and 
12. Both genes are expressed in the brain and they are described later in more detail. The 
associations with CMIP and ATP2C2 were reported to be independent, suggesting that both these 
genes could separately contribute to SLI susceptibility.  
Both associations were followed up in a replication sample, selected from the population-based 
cohort “Avon Longitudinal Study of Parents and Children” (ALSPAC) (Jones et al., 2000). The 
children enrolled in this long-term project have been periodically checked from the age of 7 years, 
and a series of physical, behavioural and neuropsychological traits has been assessed, including 
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language and reading development. From that larger group, only children with low language 
measures were selected (490 cases). In this second stage, the same association methods were 
applied, but, given the differences observed in the distributions of NWR between SLIC and 
ALSPAC, different case/control cut-offs were used in the case-control analyses. Significant 
associations were found for two markers in ATP2C2 (minP=0.0058), that replicated the trend 
observed by SLIC. Regarding CMIP, two SNPs showed a significant association with NWR 
(minP=0.0182), but the genotype trends were in the opposite direction from SLIC (the genotypes 
associated with high NWR scores in SLIC were associated with low NWR scores in the replication 
cohort). Although this contrasting result may indicate a false positive, another possible explanation 
could be the differences in the relationship between the markers and the causal variant in the two 
samples (Lin et al., 2007).  
The relationship between ATP2C2 and CMIP markers and NWR performance was also investigated 
at a population level, using the entire ALSPAC cohort (n=3612), but no evidence for association 
emerged from this analysis, leading to the hypothesis that variants in these two genes might affect 
NWR only in language-impaired individuals. 
CMIP and ATP2C2 were also included among the language candidate genes in a targeted 
association study investigating the potential genetic overlap between SLI and dyslexia (Newbury et 
al., 2011). These two neurodevelopmental disorders show an extensive co-morbidity, therefore it is 
plausible that they might share some aetiological factors. The study focused on a set of known 
candidate genes for SLI and dyslexia and was performed on the SLIC cohort and two dyslexia 
samples. Quantitative analyses were carried out for several language and reading scores. Although 
the dyslexia samples did not yield significant association for any of the SLI loci, multiple SNPs in 
CMIP showed significant association with both language and reading impairments in the SLIC 
cohort. By contrast, the association of ATP2C2 instead appeared to be specific to language 
measures (ELS, RLS, NWR).  
Moreover, another study performed on the ALSPAC cohort (Scerri et al., 2011), found association 
between SNPs in CMIP and general reading skills, in particular for single word reading and single 
word spelling performance. The data showed that the association was not driven by reading-
impaired individuals, in accord with the results obtained for dyslexia (Newbury et al., 2011). The 
allelic trend of the associated SNPs was consistent with the one reported for the ALSPAC language-
impaired subgroup (Newbury et al., 2009). Again, association with reading abilities was not 
reported for ATP2C2. 
These findings suggest that CMIP could contribute to normal reading variation and represent a 
modifier locus for language, whose effects on the phenotype might be determined by the presence 
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of other variants, and thus it might affect both language- and reading-related processes in certain 
genetic backgrounds.  
2.5 SLI candidate genes ATP2C2 and CMIP.  
CMIP (OMIM 610112) encodes a C-MAF inducing protein and it is expressed in several neuronal 
cells (Nagase et al., 2000). It is an adapter protein known to interact with filamin A (Grimbert et al., 
2004), an actin-binding protein involved in the reorganization of the cytoskeleton during cell shape 
changes and migration, with RelA subunit, an anti-apoptotic factor belonging to the NF-κB family 
(Kamal et al., 2009), a family of transcriptional factors important for the regulation of processes 
associated with synaptic activity and plasticity and neurodegeneration, and with the PI3 kinase 
complex (Kamal et al., 2010), playing a role in the ERK signalling cascade. This evidence indicates 
that CMIP may be involved in multiple biological pathways. 
ATP2C2 (OMIM 613082) encodes an ATPase (type 2C, member 2), also known as SPCA2 
(secretory pathway calcium ATPase), that transports Ca
2+
 and Mn
2+
 into the Golgi, but is also able 
to interact with Ca
2+
 channels on the cell surface, eliciting entry of Ca
2+
 (Feng and Rao, 2013). 
Many signalling pathways use calcium as a messenger, and its homeostasis is crucial to various 
neuronal functions and processes, including working memory. The activity of several kinases and 
phosphatases required for working memory is dependent on calcium levels (Dash et al., 2007). The 
homeostasis of manganese ions is also tightly regulated (Tuschl et al., 2013) and a number of 
proteins (such as SPCA1 and SPCA2, divalent metal transporter 1, the ZIP family metal 
transporters and others) are suggested to be involved, however the degree of their specific 
contribution has still to be determined. 
Although little is known about the function of the candidate genes CMIP and ATP2C2 in the brain, 
their functions and several findings are in favour of a potential role of these genes in SLI and 
neurodevelopmental disorders presenting co-morbidity with SLI, such as dyslexia (as discussed 
before), ASD, and Attention Deficit-Hyperactivity Disorder (ADHD), as presented below. 
A de novo deletion on chromosome 16, involving the two genes GAN and CMIP, was identified in 
an autistic child with severe receptive and expressive language deficits. Since mutations disrupting 
GAN cause giant axonal neuropathy, the authors hypothesized that haploinsufficiency of CMIP was 
more likely to be responsible for the ASD phenotype (Van der Aa et al., 2012). 
An interesting finding regarding ATP2C2 comes from a study of ADHD. The most recent GWA 
studies for ADHD (Mick et al., 2010; Neale et al., 2010a; Neale et al., 2010b; Stergiakouli et al., 
2012) have failed to detect association signals reaching genome-wide significance, however signals 
with P values close to the threshold might indicate potentially contributing loci. In one of these 
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studies (Lesch et al., 2008), the list of the top 30 markers located in genic regions revealed a sub-
threshold signal of association within ATP2C2 (P=8 x 10
-7
). Interestingly, children with ADHD 
showing co-morbidity with SLI display reduced performance in working memory tasks, that have 
been shown to correlate more closely with language deficits rather than ADHD (Cohen et al., 2000; 
Jonsdottir et al., 2005). Considering that the SLIC studies did not exclude individuals predicted to 
have also reading problems, ADHD or developmental coordination disorder (representing ~1/3 of 
their samples) and considering that, in SLI, ATP2C2 was found in association with NWR (Newbury 
et al., 2009), which is a measure of working memory, this domain has been proposed to be an 
”overlapping zone” between ADHD and SLI.  
Molecular mechanisms through which variants in ATP2C2 might affect the storage and processing 
of verbal information are still unknown, however these findings support the idea that ATP2C2 may 
be involved in neurological processes important for phonological short-term memory and may be 
relevant to developmental disorders characterized by working memory impairments, such as SLI 
and ADHD. 
2.6 Co-morbidity of SLI with Autism Spectrum Disorders (ASD). 
2.6.1 Autism Spectrum Disorders. 
According to the fifth edition of the Diagnostic and Statistical Manual of Mental disorders (DSM-
V) (APA, 2013), Autism Spectrum Disorders (ASD), also known as Pervasive Developmental 
Disorders (PDD), indicate an umbrella of childhood disorders that are characterized by impairments 
in two core domains:  
1) social communication and social interaction;  
2) restricted and repetitive behaviours and interests.  
This diagnostic category includes:  
 Autism, which presents deficits in communication, social interactions and repetitive 
behaviours; 
 Asperger’s disorder, which is characterized by the absence of clinically significant delay in 
language and cognitive development; 
 Childhood Disintegrative Disorder (CDD), which typically occurs later than autism and 
involves a more dramatic loss of skills (regression);  
 Pervasive Development Disorder-not otherwise specified (PDD-NOS), which presents sub-
threshold symptoms and/or later onset.  
These neurodevelopmental conditions differ in the severity and the pattern of the core symptoms, 
developmental course, and cognitive and language abilities. The ASD have an estimated prevalence 
Specific Language Impairment 
 
48 
 
of ~60/10,000 individuals (Elsabbagh et al., 2012; Levy et al., 2009) and a male to female gender 
bias, with a ratio of ~4:1 for classical autism and higher ratios for ASD (Williams et al., 2008).  
The importance of genetic factors in these disorders emerged from family and twin studies. Several 
studies have shown that ASD recur in families and siblings of affected probands have a higher 
prevalence of ASD compared to the general population (~25 times higher, according to the 
estimates of the most recent studies) (Constantino et al., 2010; Ozonoff et al., 2011). Twin studies 
have indicated that ASD have a high heritability (generally >80%) (Ronald and Hoekstra, 2011), 
except for one recent study, which reported only a modest effect for genetics (37%) (Hallmayer et 
al., 2011). However, concordance rates between MZ twins do not take into account the genetic 
factors that may differ in co-twins, such as epigenetic factors, X-inactivation and mutations de novo 
arisen after the separation of the embryos.  
In support of the hypothesis of a strong genetic background, family studies have shown that siblings 
of autistic probands display a higher recurrence of features typical of ASD phenotypes compared 
with the general population. These mild forms of impairments, usually affecting only one of the 
core domains, are classified as “broader phenotypes”. 
2.6.2 Phenotypic overlap between SLI and ASD. 
In autism, which is the most severe form of ASD, verbal communication is usually abnormal, but 
the language profiles can be extremely varied. About 50% of autistic children do not develop any 
verbal language or show a marked delay in the development of spoken language (Hus et al., 2007). 
Autism presents also a high variation in cognitive skills, therefore low IQ scores may influence the 
most severe forms of language impairments. 
The most frequent linguistic deficit in autistic individuals is an inappropriate use of language in 
social contexts (pragmatic domain). However, structural aspects (phonology, vocabulary and 
syntax) can also be affected, in a way that resembles SLI. Subgroups of high level functioning 
autistic children showed profiles similar to children with SLI on tests of phonological processing, 
vocabulary and higher order grammatical skills (Kjelgaard and Tager-Flusberg, 2001). 
In contrast, individuals affected by SLI are mainly characterized by structural language difficulties. 
However, a subgroup of children with SLI have been reported to display significant difficulties also 
in social and communication domains (Leyfer et al., 2008). These children show more problems in 
socializing with their peers and processing social-affective information compared to controls. 
Moreover, studies of adolescents with a documented history of SLI indicated that a minority of 
them meet standard diagnostic criteria for autism or present with behaviours reminiscent of autism 
(Conti-Ramsden et al., 2006; Howlin et al., 2000; Mawhood et al., 2000). 
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Converging evidence of potentially shared mechanisms emerged also from family members of 
children affected by these disorders: first and second-degree relatives of autistic patients display a 
higher prevalence of language impairment than the general population, vice versa siblings of 
children with SLI present a higher risk of a diagnosis of autism compared to the general population 
estimates (Tomblin et al., 2003).  
However, further investigations on the areas of potential phenotypic overlap between SLI and 
autism have provided contrasting results. Studies comparing nonword and sentence repetition tasks 
in children with SLI and autistic children with structural language difficulties have reported poor 
performances in both groups, but with different patterns of errors, that may indicate distinct 
underlying cognitive deficits (Riches et al., 2010; Whitehouse et al., 2008).  
Therefore, the similarities and the differences in socialization and language domains have stirred a 
debate regarding the potential overlap between SLI and autism, leading to two alternative 
hypotheses: one argues that some genetic susceptibility factors might be shared by the two 
disorders, the other one instead argues that the similarities are superficial and different patterns of 
language deficits reflect alternative distinct causes. 
2.6.3 Genetic overlaps between autism and SLI. 
Several whole-genome linkage studies have been performed for autism and, although many loci 
have been implicated, replicated regions between samples are rare, reflecting the extensive 
heterogeneity underlying the disorder and the likely small effect size attributable to single genes. 
The first regions linked to autism were identified by the International Molecular Genetic Study of 
Autism Consortium (IMGSAC, 1998, 2001; Maestrini et al., 2010) on chromosomes 7q (designated 
AUTS1, 7q21-q32, OMIM 209850) and 2q (designated AUTS5, 2q24-q33, OMIM 606053) and 
these have been also the most consistently replicated loci (Badner and Gershon, 2002; Buxbaum et 
al., 2001; Schellenberg et al., 2006; Shao et al., 2002; Trikalinos et al., 2006).  
A possible strategy to increase the chances of identifying contributory risk genes in a context of 
high heterogeneity is the study of single “endophenotypes”. The observation of broader phenotypes 
in family members of autistic individuals led to the hypothesis that autism could be dissected into 
three heritable, potentially distinct, core components (social interaction, language, and repetitive 
behaviour), or “endophenotypes”. Some linkage studies for autism have focused on language-
related endophenotypes.  
One of these linkage screens (Bradford et al., 2001) found linkage to chromosomes 7q and 13q, the 
latter overlapping with that identified in SLI families (Bartlett et al., 2002). Both signals appeared to 
be attributable to the families with ASD probands with Phrase Speech Delay (PSD) beyond 36 
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months of age, and parents with a history of language difficulties. In another ASD linkage study 
(Alarcón et al., 2002), the samples were stratified according to three endophenotypes obtained from 
the Autism Diagnostic Interview-Revised (ADI-R): "age at first word", "age at first phrase" and 
"repetitive and stereotyped behaviour". The strongest evidence of linkage was obtained for "age at 
first word", on a region on chromosome 7q, close to the susceptibility locus reported by IMGSAC 
(IMGSAC, 1998). 
The other main investigated linkage locus (IMGSAC, 2001), on chromosome 2q, has also been 
studied in relation to language delay. Two studies (Buxbaum et al., 2001; Shao et al., 2002) found 
that linkage in this region was strongest when the analysis was restricted to families which included 
autistic children with PSD. Although the region on chromosome 2q has not been implicated in SLI 
studies (Bartlett et al., 2004), the evidence obtained from the ASD studies, however, seem to 
suggest that this locus may harbour risk factors for language development. 
The SLI2 locus on chromosome 19q (SLIC, 2002) overlaps with a region of suggestive linkage with 
autism (Liu et al., 2001). In that study, the analyses were performed using two phenotypic 
categories: a strictly-defined group of autistic families, in which the probands had to meet 
diagnostic criteria for autism in all three core domains and an age at onset of <3 years (narrow 
category), and a broader category, including also individuals affected by Asperger’s disorder or 
other PDD. The linkage on chromosome 19q was found to be driven by the group of strict autism. 
One would expect that the greatest overlap with SLI would be found in the less severely affected 
individuals. However, in the broader group there were also patients with Asperger’s disorder, which 
is characterized by relatively high linguistic capabilities. Thus, it remains possible that variants that 
contribute to susceptibility to SLI and autism may be found on chromosome 19.  
More recently, linkage studies with higher resolution and larger cohorts of ASD families (Szatmari 
et al., 2007; Weiss et al., 2009) have shown that the linkage regions described above failed to reach 
genome-wide significance. In the study realized by the Autism Genome Project (Szatmari et al., 
2007), that included 1,168 families with at least two affected individuals, suggestive linkage was 
obtained only for a region on chromosome 11p12-p13. The samples were also stratified in 
categories, but, even in these subsets, the loci on 7q and 2q reached only suggestive evidence of 
linkage in the individuals of European ancestry, confirming the genetic heterogeneity underlying 
the ASD and hindering the identification of genetic cause. 
A novel design strategy was used in a recent linkage study in order to specifically investigate the 
overlap between autism and SLI (Bartlett et al., 2013). A genome-wide analysis was performed in 
70 families with at least one person with ASD and at least one person with SLI, described in a 
previous study (Bartlett et al., 2012). Such pedigrees were recruited in order to increase the chance 
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of identifying loci relevant to both disorders. Moreover, the disorders were in distinct individuals 
and not co-morbid, allowing the examination of whether linkage signals are driven specifically by 
language, ASD or both. The language phenotypes, assessed in all family members, were classified 
in two categories: LI, which included individuals with oral language impairment or ASD, and RI, 
which included individuals with written language impairment (reading) or ASD. LI yielded 
evidence of linkage to a region of 24.2 Mb on chromosome 15q13-16.2 (maximum PPL= 0.57), 
whereas RI was found to be linked to a region which spans 8.9 Mb on chromosome 16p12.1-12.3 
(maximum PPL= 0.36). Both loci were not linked to nonverbal IQ, suggesting these signals were 
not influenced by cognitive impairment. Moreover, the exclusion of the autistic or the language-
impaired individuals reduced the PPL scores for both regions, indicating that both groups 
contributed to these linkage peaks. The genome-wide association analysis instead did not detect any 
strong signal, but this may be due to the regions of linkage were not adequately tagged or to the 
insufficient power to detect variants of small effect because of the small sample size. 
Genome-wide association studies in large cohorts of autistic individuals (Anney et al., 2012; Anney 
et al., 2010; Wang et al., 2009; Weiss et al., 2009) have been carried out, but the common variants 
identified explain only a small fraction of the genetic risk. On the other hand, recent findings 
suggest that de novo and rare inherited variants of intermediate-high penetrance could collectively 
account for a large proportion of risk (Devlin and Scherer, 2012), according to the “common 
disease-rare variant” hypothesis (see paragraph 1.4). Recent high-throughput CNV screenings and 
exome-sequencing studies, that apply NGS technologies to sequence the coding regions of the 
genome, have begun to uncover a large number of individually rare sequence mutations and 
structural rearrangements potentially contributing to the ASD susceptibility (Devlin and Scherer, 
2012). Based on these findings, hundreds of risk genes in autism are estimated to be implicated in 
these disorders. The next challenge will be to determine which of the potentially deleterious 
variants actually play a role in the disease: investigating whether they affect genes involved in 
interconnected pathways could narrow down the list of candidate genes and clarify the molecular 
mechanisms impaired in ASD. 
Exome-sequencing or CNV studies for SLI have not been published yet, but these kind of studies 
will help to elucidate the genetic architecture of SLI, establishing the contribution of rare sequence 
variants and structural rearrangements and determining the genes involved in the disorder. Network 
analyses might provide new evidence of potential genetic overlaps between SLI and other 
neurodevelopmental conditions, like ASD.  
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2.7 The gene CNTNAP2: an example of a functional link between 
neurodevelopmental disorders. 
Dysfunctions of genes involved in processes that are crucial for several aspects of brain 
development can have an effect on a range of neurological functions. These genes may explain 
shared or related genetic mechanisms present in related neurodevelopmental disorders, such as SLI, 
autism and others. Evidence for this hypothesis is provided by studies of biological pathways 
mediated by FOXP2 (Fisher and Scharff, 2009).  
The identification of FOXP2 derives from a three generation pedigree, known as the KE family, 
with a rare monogenic form of a severe speech and language disorder. A point mutation that alters 
an invariant amino-acid residue (p.R553H, NM_014491.3) in the forkhead domain was detected in 
all affected members of the KE family (Lai et al., 2001). Subsequently, other cases carrying 
damaging mutations in FOXP2 have been reported (Feuk et al., 2006b; Lennon et al., 2007; 
MacDermot et al., 2005; Shriberg et al., 2006; Zeesman et al., 2006), suggesting an important role 
in language development. This highly conserved gene maps on chromosome 7q31 and encodes a 
transcription factor protein that contains a polyglutamine tract and a forkhead DNA-binding 
domain. Chromatin-Immunoprecipitation (ChIP) experiments and expression analyses have found 
hundreds of potential FOXP2-target genes in neuronal cells, mouse models and human developing 
brain (Spiteri et al., 2007; Vernes et al., 2011; Vernes et al., 2007) and it seems that, in most cases, 
the protein acts as a repressor. 
A well characterized FOXP2-target is the CNTNAP2 gene (OMIM 604569), which is one of the 
largest genes in the human genome (~2.3 Mb) and is located at chromosome 7q35-36.1 (Figure 2.4 
a). FOXP2 binds a sequence within intron 1 of CNTNAP2 and negatively regulates this gene. 
Levels of CNTNAP2 are indeed lowest at high FOXP2 levels and vice versa (Figure 2.4 b) (Vernes 
et al., 2008). CNTNAP2 codes for the contactin-associated protein-like 2, also known as CASPR2, 
a transmembrane adhesion protein that belongs to the neurexin family. The classical members of 
this family are on the pre-synaptic side and interact with neuroligins, on the post-synaptic side, to 
establish synaptic connections (Craig and Kang, 2007). The proteins of the CNTNAP family are 
non-classical neurexins involved in neuron-glia interactions and clustering of K
+
 channels in 
myelinated axons (Poliak et al., 1999; Poliak et al., 2003). For the correct localization of these 
channels, CNTNAP2 interacts with contactin 2 (CNTN2) (Poliak et al., 2003). Interestingly, in the 
human fetal brain, an unusual enrichment of CNTNAP2 levels was observed in regions important 
for language e.g., the perisylvian cortex (Abrahams et al., 2007), indicating that CNTNAP2 could 
also represent a good candidate gene for language-related phenotypes. 
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Figure 2.4 (Fisher and Scharff, 2009). Functional genetic bridges between distinct language disorders. (a) Locations of 
FOXP2 on 7q31 and CNTNAP2 on 7q35-36.1 are indicated. The genomic organization of CNTNAP2 is given below. 
The red arrow indicates direction of transcription, diamonds represent exons and the square shows the FOXP2-bound 
region, mapping in intron 1. (b) mRNA expression in human neuron-like cells stably transfected with FOXP2. Levels of 
CNTNAP2 mRNA (primers A-C) were inversely proportional to that of FOXP2 (****=p<0.0001, ***=p<0.001). (c) 
The most common multimarker haplotype (ht1) for the nine SNPs (between exons 13–15) associated with deficits in 
NWR, negatively influenced NWR performance. When children were divided into three groups based on the numbers 
of carried copies of ht1, it was found that mean NWR dropped by ∼6 points (∼0.4SDs) as a consequence of carrying >0 
risk alleles. Error bars represent standard errors. 
Investigations of the potential implication of variants in FOXP2 in complex forms of language 
impairment have shown that this gene is unlikely to have a direct contribution to SLI susceptibility 
(Meaburn et al., 2002; Newbury et al., 2002; O'Brien et al., 2003).  
Common variants in CNTNAP2 instead have shown association with language impairment. A 
QTDT analysis, performed on 184 SLIC families, tested the association of 38 SNPs across 
CNTNAP2 with ELS, RLS and NWR measures (Vernes et al., 2008). Several markers yielded 
significant evidence of association, primarily to NWR (minP=5×10
-5
, rs17236239) and, to a lesser 
extent, to RLS (minP=0.003, rs4431523) and ELS (minP=0.008, rs17236239). Interestingly, all 
nine SNPs associated with NWR fall in the region between exons 13 and 15. The same region 
(exons 13-15) has been found in association with the trait "age at first word" in an autism cohort of 
multiplex families (minP=0.002, rs2710102) (Alarcón et al., 2008) and the endophenotype of “early 
language development” (minP=0.0239, rs2710102) in a population-based cohort (the Raine sample) 
(Whitehouse et al., 2011). Moreover, the SNP rs2710102 was associated with NWR (p=0.0174) in a 
dyslexia family cohort, although the signal was driven by the opposite allele (Peter et al., 2011). In 
a study discussed earlier (paragraph 2.4.7) (Newbury et al., 2011), CNTNAP2 did not show 
significant association in the dyslexia cohorts, whereas in the SLIC families showed a strengthened 
signal for NWR (minP=8 x 10
-5
, rs17236239) and yielded association also with reading-related 
Specific Language Impairment 
 
54 
 
traits. Thus, these common variants, likely to be in linkage disequilibrium with the causal variants, 
suggest that CNTNAP2 may modulate language abilities, but also may influence reading skills.  
Further support for a role in language and cognitive development is provided by rare variants. A 
homozygous recessive frameshift mutation (3709delG) in CNTNAP2 was identified in individuals 
from an isolated population (Old Order Amish), affected by a rare syndrome associated with ASD 
and characterized by language regression and abnormalities of neuronal migration, called Cortical 
Dysplasia-Focal Epilepsy syndrome (CDFE) (Strauss et al., 2006). A mutational screening for 
CNTNAP2 detected 13 rare non-synonymous changes among 635 non-syndromic ASD patients 
(Bakkaloglu et al., 2008). Eight of them were predicted to be deleterious or altered highly conserved 
residues. However, these variants were inherited from an apparently unaffected parent, indicating 
incomplete penetrance. This suggests that some alterations of CNTNAP2 may be required to occur 
in conjunction with mutations in other genes to result in neurological disorders (“multiple hit” 
model (Leblond et al., 2012)). Under this hypothesis, the specific outcome is determined by the 
nature of the mutation, the molecular pathways affected and the genetic and environmental 
background of subjects.  
An example supporting this hypothesis is provided by a recent exome-sequencing study, in which a 
rare mutation (p.H275A) in CNTNAP2 was identified in an autistic proband (O'Roak et al., 2011). 
This missense mutation, predicted to be deleterious, was present in the proband and an unaffected 
sister, inherited from the mother. In addition to the CNTNAP2 change, the proband, who presented 
severe ASD, language delay and moderate intellectual disability, carried a de novo frameshift 
mutation in FOXP1 (p.A339SfsX4), which leads to a truncated protein. The role of FOXP1 (OMIM 
605515) in neurodevelopmental disorders, including ID, ASD, language disorders and motor 
development delay, has recently begun to be elucidated (Bacon and Rappold, 2012). The gene is 
known to be closely related to FOXP2 and the phenotypic spectra of their mutations indicate that 
they can operate in both different and shared pathways. Like FOXP2, FOXP1 downregulates 
CNTNAP2: in the presence of the truncated form of FOXP1, levels of CNTNAP2 were shown to be 
increased (O'Roak et al., 2011). 
In addition to sequence variants, complex rearrangements and CNVs involving CNTNAP2, in 
particular deletions, have also been reported across several neurodevelopmental conditions, 
including autism (Bakkaloglu et al., 2008; Poot et al., 2010), stuttering (Petrin et al., 2010), ADHD 
(Elia et al., 2010), Tourette’s syndrome (Verkerk et al., 2003), schizophrenia and epilepsy 
(Friedman et al., 2008) and mental retardation (Zweier et al., 2009). 
In conclusion, a wide set of heterogeneous mutations in CNTNAP2 can be found in numerous and 
variable conditions, that present a certain degree of co-morbidity, and indicate a widespread effect 
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of CNTNAP2. As demonstrated also by brain imaging studies and animal models (such as songbirds 
and mice) (Peñagarikano and Geschwind, 2012), this gene has a pivotal role in neurodevelopment, 
in particular in frontal-striatal brain circuits, and alterations of its function may affect a variety of 
processes, leading to distinct but overlapping phenotypes. Therefore, these findings support  the 
idea of shared and/or intersected neurogenetic pathways converging on common genes, like 
CNTNAP2.  
The falling cost of high-throughput sequencing technologies is expected to facilitate the 
identification of similar candidate genes.  
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Chapter 3 
DPYD: a candidate gene for neurodevelopmental disorders 
3.1. The enzyme dihydropyrimidine dehydrogenase (DPD). 
The human DPYD gene (OMIM 612779) maps to chromosome 1p21.3 (GRCh37/hg19) and codes 
for the enzyme dihydropyrimidine dehydrogenase (DPD), the initial and rate-limiting factor in 
uracil and thymine catabolism. The pyrimidine degradation pathway consists of three consecutive 
steps (Figure 3.1):  
1) Step 1: DPD catalyses the NADPH-dependent reduction of uracil to 5,6-dihydrouracil and 
of thymine to 5,6-dihydrothymine; 
2) Step 2: dihydropyrimidinase (DHP, encoded by the gene DPYS) catalyses the hydrolysis of 
5,6-dihydrouracil to N-carbamyl-β-alanine and of 5,6-dihydrothymine to N-carbamyl-β-
aminoisobutyric acid; 
3) Step 3: the third reaction is catalysed by the β-ureidopropionase (BUP-1, encoded by the 
gene UPB1), that converts N-carbamyl-β-alanine (also known as β-ureidopropionate) into β-
alanine and N-carbamyl-β-aminoisobutyric acid (also known as β-ureidoisobutyrrate) into β-
aminoisobutyric acid (β-AIB), producing also ammonia and CO2. 
 
Figure 3.1 (Van Kuilenburg et al., 2004). Catabolic pathway of the pyrimidines uracil and thymine. 
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3.2 Dihydropyrimidine dehydrogenase deficiency. 
The deficiency of dihydropyrimidine dehydrogenase (OMIM#274270) causes an autosomic 
recessive disease caused by homozygous or heterozygous-compound mutations in the DPYD gene. 
A total absence of DPD activity causes a large accumulation of uracil and thymine (thymine-
uraciluria) in blood, urine and cerebrospinal liquid. The phenotypic outcomes of the disorder are 
extremely variable, ranging from asymptomatic conditions to neurological abnormalities (van 
Kuilenburg et al., 2002; Van Kuilenburg et al., 1999).  
The first case of deficiency of dihydropyrimidine dehydrogenase was described in a 4 year old boy 
with transient seizures, speech retardation and behavioural problems (van Gennip et al., 1981). 
Since then, several cases of thymine-uraciluria associated with similar neurological problems have 
been reported (Berger et al., 1984; Brockstedt et al., 1990). An example showing how the clinical 
presentation of the disorder can be heterogeneous, also within the same family, is provided by two 
male siblings, born from two first-cousin Asian parents, both with a diagnosis of thymine-uraciluria 
(Henderson et al., 1995). Interestingly, although levels of pyrimidines in urine and of enzymatic 
activity indicated a total absence of DPD in the two children, they had different phenotypes: the 
proband presented facial dysmorphism, absent in the older brother, who was reported to have 
instead problems in phonology, for which he received speech therapy.  
Further evidences for the high variability associated with the disorder were provided by a study of 
22 children with complete deficiency of DPD and onset of the clinical phenotype during childhood 
(Van Kuilenburg et al., 1999). Convulsive disorders, motor retardation and mental retardation were 
observed in the majority of cases, whereas growth retardation, microcephaly, autism and 
dysmorphism were less frequently observed. A minority of cases did not present any of the 
previously mentioned abnormalities, but they had other neurological problems, such as lethargy, 
dizziness, monoplegia and, interestingly, minor difficulties in learning speech and language. A 
mutation screening of DPYD in this group of patients identified 7 mutations: 2 microdeletions 
causing a frameshift with the introduction of a premature stop codon (DPYD*7 [295-298delTCAT] 
e DPYD*3 [1897delC]), 4 missense changes (p.C29R, p.R235W, p.R886H, p.V995F) and a splice-
site mutation [IVS14 +1 G>A, also known as allele DPYD*2A], that resulted to be the most 
common variant (observed in 52% of analysed cases). Individuals carrying the same mutation were 
reported to have different clinical features, making the establishment of a correlation of genotype-
phenotype difficult and complex.  
However, an important point of this and subsequent studies is the frequent observation of 
neurological abnormalities, although of different entities, in patients with complete deficiency of 
DPD, suggesting that this gene might be implicated in neurodevelopment. 
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3.3 DPD: a key player in 5-FU metabolism. 
Besides its crucial role in the catabolic pathway of pyrimidines, DPD is involved also in the 
catabolism of the widely used anti-neoplastic agents 5-Fluorouracil (5-FU) and its orally active 
prodrug capecitabine (Thorn et al., 2011).  
The activation mechanism is based on the conversion of 5-FU to 5-fluoro-2’-deoxyuridine 
monophosphate (FdUMP), which competes with the natural substrates of thymidylate synthase 
(TS), preventing the pyrimidine synthesis (Figure 3.2). However, more than 85% of the 
administered 5-FU is rapidly degraded by DPD (catabolic pathway).  
 
Figure 3.2 (Loganayagam et al., 2013). Anabolic and catabolic pathways of the 5-FU. In the degradation pathway, 5-
FU is converted to dihydrofluorouracil (DHFU) by DPD (indicated with DPYD). DHFU is subsequently converted to 
fluoro-β-ureidopropionate (β-FUPA) by dihydropyrimidinase (indicated with DPYS). 
The efficacy of the 5-FU anti-tumoral treatment depends on a narrow therapeutic window: as for 
other anti-neoplastic agents, there is a delicate equilibrium between toxic and therapeutic effects. 
Therefore, the breakdown of 5-FU is an important step of its metabolic regulation. Mutations in the 
DPYD gene causing partial or complete deficiency of DPD activity are associated with mild and 
severe toxicity in cancer patients receiving 5-fluorouracil chemotherapy, which can be lethal in the 
most extreme cases (Ezzeldin et al., 2003; van Kuilenburg et al., 2001). The typical toxic reactions 
to 5-FU when DPD is partially/completely deficient are diarrhoea, fever, neutropenia and mucositis. 
Given the availability of quantitative measures of these symptoms, toxicity reactions are classified 
in different categories: grades 0-2 indicate a mild-moderate toxicity, grades 3-4 a severe toxicity. In 
some cases, myelosuppression and CNS alterations, such as acute cerebellar ataxia, mental 
deterioration and myelopathy can occur (van Kuilenburg et al., 2003). Investigation on 5-FU-
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dependent neuronal alteration and neurological abnormalities reported in children with complete 
DPD deficiency might contribute to the understanding of the role of endogenous pyrimidines in 
neuronal activity. 
Since the late 1980s, numerous cases with severe toxic reactions to 5-FU have been reported and 
have contributed to the identification of several variants in the DPYD gene. In addition to patients 
with homozygous mutations (Van Kuilenburg et al., 1999; Vreken et al., 1996), patients with 
multiple heterozygous mutations have been described (Gross et al., 2003), suggesting that the DPD 
deficiency might be determined by complex patterns of variants. Moreover, in accordance with the 
studies of thymine-uraciluria, individuals with the same genotypic profiles can display variable 
responses to 5-FU administration. 
Considering the wide use of 5-FU in cancer chemotherapy and the absence of a clear genotype-
phenotype correlation, it would be important to assay the DPD activity before the 5-FU treatment, 
in order to exclude an adverse reaction in the patient. Levels of DPD activity can be determined 
with a radio-enzymatic assay (Johnson et al., 1997). This method measures DPD activity using 
radio-labelled substrates, such as uracil, thymine or 5-FU, and its sensitivity allows the 
discrimination between partial and complete deficiency. Various tissues can be examined: 
peripheral blood mononuclear cells are particularly suitable to the measurement of the DPD 
activity, because the subsequent enzymes of the pyrimidine catabolic pathway (DHP and UP) are 
absent. Valid alternative methods have been also introduced, such as the determination of plasmatic 
uracil/dihydrouracil ratios (Ciccolini et al., 2006; Zhou et al., 2007) and the uracil breath test 
(UraBT) (Mattison et al., 2004), in which 2-
13
C-uracil is orally administered to the patient: as CO2 is 
one of the final products of the pyrimidine catabolism, estimates of 
13
C levels in exhaled CO2 allow 
to rapidly identify partial and profound DPD deficiencies. 
3.4 Hypotheses for a role of DPYD in the central nervous system. 
The frequent observation of neurological abnormalities, often with a childhood onset, in patients 
with DPD deficiency led researchers to hypothesize a role for DPYD in neurodevelopment.  
It has been suggested that an altered homeostasis of β-alanine, a structural analog of gamma-
aminobutyric acid (GABA) and glycine (Figure 3.3), which are major inhibitory neurotransmitters 
in the central nervous system, may account for some of the clinical abnormalities described in 
patients with DPD deficiency (Van Kuilenburg et al., 1999). 
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Figure 3.3 (Tiedje et al., 2010). Glycine, β-alanine, gamma-aminobutyric acid (GABA). 
β-alanine biosynthesis can occur via three main ways: 
1) Deamination and carboxylation of uracil (pyrimidine catabolism), mainly occurring in liver; 
2) Interchangeable conversion of L-alanine and pyruvate; 
3) L-aspartate decarboxylation by gut microbes. 
Molecules of β-alanine can reach the central nervous system (CNS) crossing the blood brain barrier. 
Moreover, this aminoacid can be converted to malonate semialdehyde and, within the brain, the 
reverse reaction (transamination of malonate semialdehyde, catalysed by the enzyme GABA-T) can 
represent an additional source of β-alanine. β-alanine is present throughout the CNS and high-
affinity uptake systems in glial and neuronal cells contribute to the regulation of its concentration, 
supporting a role in the modulation of the neuronal response (Tiedje et al., 2010). β-alanine can be 
recognized by multiple receptors, such as GABAA and glycine receptors, indicating that it can 
behave as an agonist of these inhibitory neurotransmitters. It is also a potent blocker of GABA re-
uptake in glial cells. 
Alterations of the balance between inhibitory and excitatory neurotransmissions can generate 
seizures. To contrast this hyperexcitability, GABAergic inhibition can be potentiated and the 
reuptake of GABA temporarily blocked (Pfeiffer et al., 1996), with an anticonvulsive effect. Since 
β-alanine is an agonist of GABA, it is possible that this neurotransmitter could be also involved in 
response to convulsions, a frequently observed symptom in DPD-deficient patients. 
Although reduced levels of β-alanine would be expected in patients with DPD deficiency, they were 
reported to be only slightly lower in urine and plasma, and normal in cerebrospinal liquid, 
compared with controls (Van Kuilenburg et al., 2004). This finding suggested that alternative 
pathways for the production of β-alanine might compensate the effect of the decreased production 
of β-alanine from the pyrimidine pathway. 
On the other side, DPD has a crucial role in the catabolism of pyrimidines. Pyrimidines are essential 
precursors for DNA and RNA synthesis, but they have also many more roles and are important for 
the activity of the central nervous system. The availability of pyrimidines in the cell is determined 
by the correct balance between synthesis (de novo and salvage pathways) and degradation. 
Therefore, alterations of the homeostasis of pyrimidines in brain, in particular in early 
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developmental stages, may lead to neurological abnormalities. In addition to the DPD deficiency, 
there are other disorders caused by inborn errors in the nucleotide metabolism, such as 
dihydropyrimidinase (DHP) deficiency and β-ureidopropionase (BUP-1) deficiency (DHP and 
BUP-1 are the second and the third enzymes of the pyrimidine catabolic pathway, see paragraph 
3.1) and they also present neurological dysfunctions, such as myelination delay, epileptic attacks, 
speech and developmental delay (Micheli et al., 2011). Therefore, it is possible to hypothesize that 
metabolic changes influencing pyrimidine homeostasis, and their downstream products, may 
account for some of the clinical manifestations observed in patients with DPD deficiency. However, 
the actual molecular link of purines and pyrimidines altered metabolism with the development and 
functionality of the central nervous system remains to be unravelled.  
3.5 The structural organization of DPYD and genetic variation. 
Two transcript variants encoding different isoforms have been found for the gene DPYD (Figure 
3.4):  
-isoform 1 (NM_000110.3, chr1:97543300-98386615, hg19, strand -), which consists of 23 coding 
exons and codes for a protein of 1025 aminoacids (NP_000101) with a molecular weight of 111 
kDa; 
-isoform 2 (NM_001160301.1, chr1:98185314-98386615, hg19, strand -), which includes only 6 
coding exons and codes for a protein of 173 aminoacids (NP_001153773), of which the first 161 aa 
are common to isoform 1 protein. 
Recently, two antisense non-coding genes, DPYD-AS1 (NR_046590, chr1:97561479-97788511, 
strand +) and DPYD-AS2 (NR_046591.1, chr1:98262477-98263607, strand +), have been mapped 
at the 3’ end and the 5’ end of the isoform 1, respectively, but their function is still unknown. 
 
Figure 3.4. Schematic representation of the isoforms of DPYD, DPYD-AS1 and DPYD-AS2 from the Genome Browser 
UCSC (Feb. 2009, GRCh37/hg19). 
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The promoter for DPYD has also been characterized, with the identification of two essential 
regulatory elements in the region flanking the 5’ of the DPYD gene: the regulatory element I 
(between -23 and -42), and the regulatory element II (between -72 and -51) (Shestopal et al., 2000) 
(Figure 3.5). A subsequent study (Zhang et al., 2006b) showed that the Sp1 and Sp3 transcription 
factors bind to DPYD promoter. Three Sp-target sites were identified: SpA (from -148 to -140), 
SpB (from -68 to -60) and SpC (from -37 to -19). The major promoter activity was detected for 
SpB, suggesting that it may function as an upstream enhancer, while SpC may represent an element 
of the basal promoter. 
 
 
Figure 3.5 (Shestopal et al., 2000). Localization of the two regulatory regions described in the DPYD promoter. Base 
positions are indicated respective to the transcription start site (+1). Exon 1 is underlined and the aminoacids are 
indicated under the correspondent triplettes. Putative binding sites for transcription factors AP-2, Sp, Egr, NF-κB are 
also indicated. 
A large number of polymorphisms have been found in the coding, intronic and untraslated regions 
of the gene DPYD, and these findings have been mainly driven by studies regarding 5-FU toxicity. 
Among the missense amino-acid changes known to have a deleterious effect on the DPD activity, 
the most common variant in DPD-deficient individuals is the point mutation in the donor splice site 
of intron 14 (IVS14 +1 G> A, DPYD*2A, rs3918290). The change of the first base of the donor 
splice site (GT) prevents the recognition of the site by the splicing machinery, resulting in a mRNA 
lacking exon 14, which is translated into a non-functional protein missing the correspondent 55 
amino-acids (Vreken et al., 1996). 
There are two other mutations reported to be consistently associated with a decreased DPD activity: 
 rs55886062 (c.1679T> G, DPYD*13), which determines the substitution of isoleucine with 
a serine (p.I560S), 
 rs67376798 (c.2846A>T), which substitutes aspartic acid 949 with valine (p.D949V). 
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Several other variants have been identified in DPD deficient patients or individuals with adverse 
responses to 5-FU treatment, however their role in DPD deficiency has not been completely 
elucidated, because different studies often report contrasting results. A highly variable effect on 
DPD activity has been observed for heterozygous variants in DPYD (Amstutz et al., 2011).  
Two main explanations have been hypothesized for the lack of correlation between mutations and 
DPD activity and/or 5-FU toxicity. One suggestion is that there could be an allelic regulation 
mechanism, leading to increased expression of the wild-type allele in the presence of a mutated 
allele on the other chromosome (Amstutz et al., 2011). The alternative hypothesis suggests that 
some sequence variants might represent “protective” alleles, which lead to an above-average 
enzymatic activity. The effect of a damaging mutation on one allele could be then compensated by a 
protective variant on the other copy of the gene. This hypothesis is supported by the observation of 
a broad range of DPD activity levels in the general population and by the recent findings of an in 
vitro assay (Offer et al., 2013), described in the next paragraph, where the variants C29R and 
S534N were shown to determine an increased DPD activity. 
Moreover, even though the vast majority of the intronic variants are expected to be non-functional 
and, for this reason, are usually not investigated in mutational screenings, part of this genetic 
variation may contribute to the large variability in DPD activity, also in the general population. 
Intronic regions can harbour variants with a great functional impact, such as the mutations affecting 
the splicing. A cryptic splice donor site has been identified in intron 10 (c.1129-5923, rs75017182, 
chr1:98045449): the change C>G creates a splice donor site, causing a frameshift and a premature 
stop codon (van Kuilenburg et al., 2010). Interestingly, this variant is in linkage with a haplotype 
hapB3, previously found to be associated with severe adverse reactions to 5-FU (Amstutz et al., 
2008).  
Epigenetic factors could also influence the regulation of DPD activity. The promoter methylation 
has been investigated as a potential contributing factor. In a study including only five cancer 
patients (Ezzeldin et al., 2005), a partial methylation of the DPYD promoter was reported to be 
correlated to the reduced activity of the enzyme. However, these findings have not been 
subsequently replicated in larger independent samples of cancer patients (Amstutz et al., 2008; 
Savva-Bordalo et al., 2010; Schwab et al., 2008), indicating that the hypermethylation of the 
promoter is unlikely to be an important contributing mechanism. 
3.6 The DPD protein. 
A deep knowledge of the protein sequence and structure offers the possibility to predict and test the 
effect of point variants. The human DPD protein (Q12882-1, 1025 aa) has been purified from liver, 
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one of the tissues where DPYD expression is higher, and that allowed the characterization of its 
enzymatic activity and the localization of functional domains. This cytosolic enzyme works as a 
homodimer and several important regions have been identified in the protein, including the uracil-
binding site, the FMN-interaction site, the NADPH-binding region, iron/sulphur domains and the 
FAD-binding site. Moreover, these domains are conserved across evolution and present a high 
amino-acid identity between mammalians and Drosophila melanogaster (>85% identity between 
human and Drosophila for the first four domains, 54% for FAD-binding site) (Mattison et al., 
2002).  
Rat, pig and bovine DPD proteins have also been purified. Studies of the 3-dimensional structure of 
the pig protein (Dobritzsch et al., 2002; Dobritzsch et al., 2001) have been carried out: these models 
allow the prediction of potential conformational changes and altered interactions caused by 
mutations of amino-acids (Figure 3.6).  
In the past, bacterial expression systems have been used to characterize the most interesting variants 
found in DPD-deficient patients. Recently, a new cellular system has been set up to test the effect of 
DPYD variants in vitro (Offer et al., 2013). In the human cell line HEK293T, endogenous DPD 
activity is not detectable, therefore, transfecting these cells with DPYD expression constructs 
containing a certain variant allows the determination of its effect on the activity of the protein. 
Moreover, the authors suggest that this system is suitable to test the effect of variants in the 
heterozygous state, by co-expression of the DPYD allele carrying the mutation with the wild-type 
DPYD allele. 
All these approaches (comparative sequence analysis, expression systems and protein studies) are 
expected to provide new insights into the structural basis of DPD deficiencies caused by naturally 
occurring point mutations in the human DPYD gene. 
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Figure 3.6 (Ezzeldin and Diasio, 2004). Stereo view of the DPD structure, obtained from the pig liver protein. 
Functional domains are indicated in green. The position of known sequence variants frequently reported in literature is 
also indicated. 
3.7 Involvement of DPYD in neurodevelopmental disorders. 
The identification of rare sequence and structural variants in DPYD in neurological disorders has 
provided new evidence for the hypothesis of a potential involvement of this gene in processes 
important for brain development. 
In a recent study (Carter et al., 2011), hemizygous deletions involving the gene DPYD have been 
described in four individuals with ASD and severe speech delay, belonging to three unrelated 
families (Figure 3.7 b). 
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Figure 3.7 (Carter et al., 2011). A. The figure shows the position of the three deletions (black bars) detected in the 
study of Carter et al. B. Pedigrees of the three families described in this study. The four affected individuals, each 
carrying a DPYD deletion, are indicated in grey. In family 1, I173V indicates the missense mutation in PTCHD1 and T 
indicates a translocation t(19;21)(p13.3;q22.1). 
 Patient 1 carried a de novo deletion of ~1Mb on chromosome 1p21.3, involving DPYD and 
the adjacent gene MIR137 (Figure 3.7a). In addition, he had a missense mutation (p.I173V) 
in PTCHD1 and translocation t(19;21)(p13.3;q22.1), both inherited from the mother (Noor 
et al., 2010). These two variants were also present, separately, in unaffected sisters (Figure 
3.7 b). 
 Patients 2 and 3 presented a translocation of a 1.5 Mb region on chromosome 1, including 
DPYD and the adjacent gene PTBP2 (Figure 3.7 a), to the short arm of chromosome 10, a 
rearrangement inherited from the mother. 
 Patient 4 was shown to have a 10Kb intragenic deletion, involving only exon 6 of DPYD 
(Figure 3.7 a), inherited from the mother. This CNV is predicted to cause a frameshift, with 
a premature truncation of the protein. 
In order to check whether the non-deleted copy of DPYD carried a damaging sequence mutation, 
leading to a complete loss of the functional protein DPD in compound heterozygosity, a mutational 
screening of the coding regions of the gene was performed in the four probands. However, no 
coding variants were reported in these individuals. From the screening of 300 unrelated autism 
probands instead, four missense mutations (p.P3C, p.C622Y, p.T793I, p.P1023T) and the splicing 
variant IVS14+1 G>A (rs3918290) were identified, each of them present in 1/300 probands. All 
these variants were inherited from an unaffected parent, but absent in 48 controls. The changes 
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p.P3C and p.T793I are not reported in dbSNP nor in the ESP database 
(http://evs.gs.washington.edu/EVS/), that collects data from exome sequences of a large number of 
European American (EA) and AfricanAmerican (AA) individuals. p.C622Y (rs201433243) is also 
rare (minor allelic frequency=0.023% in EA, not reported in AA subjects), and p.P1023T 
(rs114096998) has not been identified in EA individuals, but it is reported in African American 
individuals with a minor allelic frequency of 3.8%.  
Then, this study suggested that de novo and inherited variants in DPYD could contribute to the ASD 
susceptibility, probably in conjunction with mutations in other genes. An example is given by the 
family 1, in which the proband, in addition to the de novo deletion in DPYD, had also inherited a 
missense change in PTCHD1, which is a X-linked autism susceptibility gene. This family was 
originally included in a study (Noor et al., 2010) that reported mutations in PTCHD1 in 1% of 
males with ASD and with ID. Therefore, in some individuals, the presence of mutations in 
PTCHD1 could modulate the phenotype associated with the partial loss of DPD. 
A CNV screening carried out in ~700 ASD unrelated cases (Prasad et al., 2012) also detected two 
rare inherited deletions in DPYD and an inherited exonic copy number loss in UPB1, the gene 
coding for the enzyme β-ureidopropionase. 
Deletions encompassing DPYD have been identified also in individuals with Intellectual Disability 
(ID) (Willemsen et al., 2011). This study described five individuals, belonging to three different 
families, with moderate ID and language deficits. The deletions reported in this study are 
represented in Figure 3.8. 
 
Figure 3.8 (Willemsen et al., 2011). Schematic representation of the deletions on chromosome 1p21.3 identified by 
Willemsen et al. The shortest overlapping region among the deletions is shown in grey. The overlap with the deletions 
reported in Carter et al. is also shown. 
Patients 1, 2, and 3 were siblings and presented a 1.75 Mb deletion on chromosome 1p21.3, 
involving the genes DPYD, SNX7 and LPPR5 and the microRNA MIR137. The parents were not 
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available, therefore the heritability could not be checked. Patient 4 had a 1.41 Mb de novo deletion 
that included the two adjacent genes DPYD and MIR137. Patient 5 carried a larger de novo deletion 
(2.45 Mb), encompassing the three genes PTBP2, DPYD and MIR137. The shortest overlapping 
region (SRO) across the different CNVs was a region of 1.22 Mb that includes only DPYD and 
MIR137. Metabolic tests in individuals 1, 2 and 4 did not show the typical thymine-uraciluria 
profile that would be expected from the partial loss of DPD. Expression analyses in lymphoblastoid 
cell lines showed instead decreased levels of the precursor and mature MIR137 and, in addition, a 
significant increase of the expression of three genes (MITF, EZH2 e KLF4), negatively regulated by 
MIR137. Since also the microRNA is a good candidate gene for neurological abnormalities, as it is 
expressed in neuronal tissues, particularly in the hippocampus, the authors suggested that the ID 
phenotype was more likely to be associated with the haploinsufficiency of MIR137, although they 
did not exclude a possible involvement of DPYD in neurological disorders. 
Another study has reported an individual with mild developmental delay/ID and dysmorphic 
features carrying a de novo copy number loss (570 kb) involving both DPYD and MIR137 
(Battaglia et al., 2013). 
De novo mutations in DPYD have been detected also in individuals with schizophrenia (Xu et al., 
2012). The analysis of 795 exomes, deriving from 231 simplex families (146 Afrikaner and 85 US 
trios), highlighted four genes affected by more than one de novo event and, thus, indicated as 
potential susceptibility genes: DPYD, LAMA2, TRRAP and VPS39. In particular, the variants 
identified in DPYD were a nonsense mutation (c.1863G>A, p.W621*) and a missense change 
(c.1615G>A, p.G539R). The patient carrying the p.G539R variant had increased levels of thymine 
and uracil in urines, suggesting a deleterious effect of the variant.  
A previous GWA study for schizophrenia (Schizophrenia_Psychiatric_GWAS_Consortium, 2011) 
had identified a strong association signal for the SNP rs1625579 (P= 1.6 x 10
-11
), mapping to the 
intron 3 of the miR137-Host Gene MIR137HG. The association of this region has been 
subsequently replicated (P= 1.72 x 10
-12
, rs1198588, falling within an intergenic region ~38 kb 
upstream the gene MIR137HG) in a larger cohort of over 21,000 cases and 38,000 controls (Ripke 
et al., 2013). The SNP rs1625579 falls in a linkage disequilibrium block (D >0.9) extending to the 
5’ of DPYD (Figure 3.9) and rs1198588 represents an expression QTL for DPYD. 
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Figure 3.9. Linkage Disequilibrium block including DPYD, MIR137HG and MIR137. At the top, the position of the 
SNP rs1625579, found in association with schizophrenia, is indicated. The miR-137 Host Gene (MIR137HG) contains 5 
exons: mature microRNA-137 is encoded in exon 3 of MIR137HG. 
In Xu et al., sequence variants in MIR137 have not been detected, therefore, taking into account the 
linkage disequilibrium between MIR137 and DPYD, the association signal might reflect also the 
involvement of DPYD in schizophrenia susceptibility.  
In addition, a putative miR-137-target site has been identified within DPYD (Ripke et al., 2013), 
indicating that this gene might be regulated by miR-137 and supporting the hypothesis that both 
genes could be implicated in a range of neuropsychiatric disorders. The phenotypic outcomes may 
depend on the nature of the mutations occurring in these genes and whether they affect one of them 
(this would be the case of point mutations) or both (like in the case of large deletions).  
Moreover, a recent screening has found that miR-137 is one of the direct FOXP2-targets in 
embryonic mouse brain (Vernes et al., 2011). These findings establish intriguing connections 
between these three candidate genes FOXP2, MIR137 and DPYD, suggesting that they might be all 
involved in networks important for brain development. 
 
Materials and Methods 
 
70 
 
Chapter 4 
Materials and Methods 
4.1 Samples: SLIC cohort. 
4.1.1 Subjects. 
The individuals belonging to the SLIC cohort have been recruited from 4 centres in the United 
Kingdom: the Cambridge Language and Speech Project (CLASP), the Newcomen Centre at Guy’s 
Hospital (London), the Child Life and Health Department at the University of Edinburgh and the 
University of Manchester (Falcaro et al., 2008; Newbury et al., 2011; SLIC, 2002, 2004).  
 CLASP consists of an epidemiological investigation of speech and language problems (Burden 
et al., 1996). The recruitment of children into the study has followed a multi-stage 
ascertainment procedure. First, at age 36 months, the population was defined by means of a 
questionnaire; then, at age 39 months, language abilities were assessed in more detail and, 
finally, at age 45 months, screen–positive cases were examined in depth. At 8 years of age, the 
children and their siblings were tested by the CELF-R and Wechsler Scales of Intelligence–
Third UK Edition (WISC-III) (Wechsler, 1992).  
 The cases recruited at Guy’s Hospital were selected through three special schools for language 
disorders and through “Afasic”, a support organization for people with developmental and 
language impairments (http://www.afasic.org.uk/). Therefore, these individuals were 
considered a self-referred sample as they attended special schools because of their persistent 
language problems. 
 The cases referred by the University of Edinburgh were selected originally to participate in a 
study of children from eastern and central Scotland with severe receptive-language 
impairments (Clark et al., 2007). All probands needed specialist educational support and were 
selected to have a historical language comprehension score >2 SD below that expected for their 
age, although the majority were confirmed to also have expressive problems. A detailed family 
history was taken from the families that decided to take part in the study. 
 The Manchester Language Study (http://www.manchesterlanguagestudy.co.uk) has been 
running nationwide since 1995 (Conti-Ramsden and Botting, 1999; Falcaro et al., 2008), 
following the progress of 242 children who were attending language units at 7 years of age. 
The children have been assessed at several stages, including at the age of 17 years. The study 
involved their families and schools. A group of age-matched peers were also recruited into the 
study at the age of 16 years for comparison purposes. 
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Whole-blood (Guy’s and Edinburgh) or buccal swab (Cambridge and Manchester) samples were 
collected from all available family members, regardless of their language ability. DNA was 
extracted using standard protocols, and all buccal swab DNAs were pre-amplified using a rolling 
circle whole-genome amplification protocol (HY-Genomiphi, GE Healthcare). Only genomic 
samples were included in the CNV analyses. 
4.1.2 SLIC Cohort: phenotypic tests. 
Language skills of all available children belonging to the SLIC collection were assessed by one of 
the four centres across the UK using two baseline tests: Clinical Evaluation of Language 
Fundamentals Revised test (CELF-R) and NonWord Repetition (NWR), as described in the first 
paper of the SLI Consortium (SLIC, 2002). 
CELF-R evaluates expressive and receptive language domains independently and then combines the 
results in a composite language score. It consists of different batteries of tests, depending on the age 
of the subject. Raw scores were transformed to obtain an age-normalised standardized receptive 
language score (RLS) and an expressive language score (ELS), each with mean 100 and Standard 
Deviation of 15 in the general-population calibration sample (Semel et al., 1992). 
NWR was used as a marker of phonological short-term memory (Gathercole et al., 1994). In this 
test, children are required to hear and repeat a sequence of tape-recorded single nonsense words of 
increasing length and complexity (such as “woogalammic” or “perplisteronk”) and each repetition 
is scored as correct or incorrect. All available children of age 7.5–18 years were assessed with the 
28-item NWR test. Standard scores for a British population were then obtained by use of norms 
extended, for older children and in many cases for adults. 
In order to exclude mental retardation as a possible cause for language impairment, cognitive 
abilities were assessed with the WISC-III test (Wechsler, 1992). This consists of a multi-test battery 
that evaluates both verbal IQ (VIQ) and performance IQ (PIQ). The verbal abilities are examined by 
subtests of vocabulary, similarities, comprehension and abstract reasoning, whereas the 
performance tasks are primarily based on visual and constructional clues (e.g., mazes, block design, 
picture concepts and abstract visual problem solving). WISC Perceptual Organisation Index (POI) 
is a composite score of the non-verbal subtests Picture Completion, Picture Arrangement, Block 
Design and Object Assembly. Verbal IQ and PIQ can be combined in a composite scores to give a 
full-scale IQ. The WISC-III does not include reading or writing tests.  
In some subgroups (Guy’s, Manchester and Cambridge), reading abilities were assessed using 
single-word reading (Read), single-word spelling (Spell) and reading comprehension (Comp) tests 
from the Wechsler Objective Reading Dimensions (WORD) (Rust et al., 1993). 
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In each family, the proband was defined as the individual through whom the family was identified 
and, either currently or in the past, had language skills (ELS and RLS) ≥1.5 SD below the 
normative mean for their chronological age, on the receptive and/or expressive scales of the CELF-
R battery. When considering family segregation patterns, children were classified as affected if they 
were probands or siblings with ELS or RLS scores ≥ 1.5 SD below the normative mean. Children 
with both ELS and RLS scores  0.5 SD below the mean were classified as unaffected. For the 
other family members that did not meet these thresholds, the affection status was considered 
unknown. For many adults, data was unknown, but self-reported problems were taken into account. 
Any proband or sibling found to have WISC POI composite score of <77.5 (1.5 SD below that 
expected for their age) or PIQ <80 was excluded from the CNV genome screen. Additional 
exclusion criteria included: MZ twinning, chronic illness requiring multiple hospital visits or 
admissions, deafness, an ICD-10/DSM-IV diagnosis of childhood autism, English being a second 
language, care provision by local authorities, and known neurological disorders. In the Guy’s 
Hospital sample, those families with chromosome abnormalities, including fragile X, were excluded 
by cytogenetic testing.  
4.2 Samples: ASD cohorts. 
4.2.1 IMGSAC cohort: subjects. 
The International Molecular Genetic Study of Autism Consortium (IMGSAC) (IMGSAC, 1998, 
2001) collected multiplex ASD families from different countries (UK, Netherlands, France, USA, 
Germany, Denmark, Greece). The individuals had predominantly a Caucasian origin (>90%). 
Clinical diagnosis of ASD was made using the Autism Diagnostic Interview-Revised (ADI-R) 
(Lord et al., 1994) and Autism Diagnostic Observation Schedule (ADOS) (Lord et al., 1989) or 
ADOS-Generic (ADOS-G) (Lord et al., 2000), that will be described later.  
A clinical evaluation was undertaken in order to exclude known medical disorders etiologically 
associated with autism. The multiplex families had fragile X testing and were karyotyped whenever 
possible. The following items were used to exclude individuals so as to keep the sample set more 
homogeneous: 
• Any medical condition likely to be aetiological (e.g. tuberous sclerosis, fragile X, focal 
epilepsy, infantile spasms, single gene disorders involving the central nervous system). 
• Any neurological disorder involving pathology above the brain stem, other than 
uncomplicated non-focal epilepsy. 
• Contemporaneous evidence, or unequivocal retrospective evidence, of probable neonatal 
brain damage. 
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• Clinically significant visual or auditory impairment after correction. 
• Rearing in adoptive or foster homes. 
• Institutional rearing during the first 4 years when there is any possibility that this led to an 
autistic-like picture. 
• Any circumstances that might possibly account for the picture of autism (e.g. very severe 
nutritional or psychological deprivation). 
• Birth in a place making it difficult to obtain satisfactory obstetric data (this would ordinarily 
exclude those born in a developing country). 
• Autism secondary to some other psychiatric disorder (e.g., schizophrenia), but not 
psychiatric co-morbidity. 
• Observational data that cast doubt on the diagnosis. 
• In vitro fertilisation as a means of conception.  
• Cases arising from consanguineous marriage. 
A number of features were not used as exclusion criteria these are: epilepsy (unless focal); 
psychiatric co-morbidity; head circumference over 97%; mental illness in a parent and belonging to 
an ethnic minority.   
In a previous study (IMGSAC, 2001), the affection status was classified in a hierarchical fashion:  
 “case type 1” if they had a clinical diagnosis of autism, met ADI-R and ADOS or ADOS-G 
algorithm criteria for autism, had a history of language delay and a PIQ ≥35.  
 “case type 2” if they had a clinical diagnosis of autism, atypical autism, Asperger syndrome, or 
PDD-NOS and met at least ADOS-G criteria for PDD; there was no requirement for a history 
of language delay, and individuals were allowed to fall one point below threshold on one 
behavioral domain of the ADI-R.  
 “case type 3” if they had a clinical diagnosis of autism or another PDD and either met ADI-R 
criteria for autism or fell one point below threshold in one behavioral domain, but failed to 
meet ADOS-G criteria for PDD.  
In this project, all three classes of individuals were included as ASD cases.  
Genomic DNA was extracted from blood using Nucleon® kit (IMGSAC, 1998). In a minority of 
cases in which a blood sample could not be obtained, DNA was extracted from buccal swabs 
(IMGSAC, 1998). In addition, whenever possible, lymphoblastoid cell lines (LCLs) have been 
generated from peripheral blood leukocytes. 
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4.2.2 Italian cohort: subjects. 
The Italian ASD cohort was formed by Italian simplex families, each with one individual affected 
by ASD, collected by the clinical team of Professor Agatino Battaglia and Dr Raffaella Tancredi at 
the Institute Stella Maris (Pisa, Italy) and the group of Professor Luigi Mazzone from the University 
of Catania (Catania, Italy). Phenotypes were assessed using the two diagnostic tools: ADI-R (Lord 
et al., 1994) and ADOS-G (Lord et al., 2000). A clinical evaluation was undertaken in order to 
exclude known medical disorders etiologically associated with autism. Standard karyotyping and 
fragile-X testing were obtained for probands whenever possible. 
DNA was extracted from blood with the QIAGEN DNA Blood extraction kit.  
4.2.3 AGP cohort: subjects. 
The third group of cases was part of the cohort of families collected by the Autism Genome Project 
(AGP), an ongoing international project which gathers more than 50 research groups from different 
countries in North America and Europe (Pinto et al., 2010), including the group headed by Elena 
Maestrini. The affection status was determined using the diagnostic tools ADI-R and ADOS. Three 
categories of affected individuals were established (strict, broad and spectrum ASD), based on 
proband diagnostic measures: 
- the strict class included affected individuals who met criteria for autism on both ADI-R and 
ADOS instruments; 
- the broad class included individuals who met full autism criteria on one diagnostic 
instrument and ASD criteria on the other one; 
- the spectrum class included all individuals who were classified as ASD on both the ADI-R 
and ADOS or who were not evaluated on one of the instruments but were diagnosed with 
autism on the other instrument.  
Given the international and multi-site nature of the project and the range of chronological and 
mental ages of the probands, a range of cognitive tests were used, and standard scores were 
combined across tests to provide consolidated IQ estimates. Subjects from all classes (strict, broad, 
and spectrum) were included in the association analyses performed in this thesis.  
DNA, extracted from blood, buccal-swabs or cell-lines, has been previously genotyped with 
Illumina Human 1M-single and Illumina Human 1M-Duo BeadChip arrays (Anney et al., 2010; 
Pinto et al., 2010). 
298 affected individuals and 592 parents from IMGSAC multiplex families, 27 affected individuals 
and 54 parents from IMGSAC simplex families and 69 Italian trios were included in the AGP 
sample. 
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4.2.4 ASD diagnostic instruments: ADI-R and ADOS-G. 
The ADI-R (Lord et al., 1994) is a standardized interview conducted with caregivers of autistic 
individuals. The questionnaire explores the areas of communication, social interactions, restricted 
and repetitive behaviours and developmental history. An algorithm was generated to make a 
standard diagnosis on the basis of the ADI-R scores obtained in each area and it includes only the 
items that more closely depicted the phenotypic abnormalities described in the Diagnostic and 
Statistical Manual of mental disorders-4th edition (DSM-IV) ([APA], 1994). The algorithm 
specifies a cut-off score for each of three core domains of autism, therefore, only the individuals 
who meet all the cut-offs, meet diagnostic criteria for autism, the most severe form of ASD.  
The ADOS-G (Lord et al., 2000) is an interactive test that aims to assess social interactions, 
communication, play and spontaneous behaviours in a standardized context. ADOS-G is an 
implementation of ADOS (Lord et al., 1989), which was proposed as a complementary instrument 
to ADI. ADOS-G has four possible modules that provide different structured and unstructured 
situations in order to evaluate social-communicative skills of the referred subject. As for ADI-R, 
subsets of items in each module of ADOS-G were selected to generate the diagnostic algorithm. 
Classification is made on the basis of exceeding cut-offs in social behaviour, communication and 
social-communication totals.  
4.3 Identification of CNVs in the SLIC cohort. 
A genome-wide CNV screen of 542 individuals from 170 2-generation families from the SLIC 
cohort (119 individuals from Cambridge collection, 165 from the Edinburgh collection, 210 from 
the Guy’s collection and 48 from the Manchester collection) was performed to investigate copy 
number variation burden in individuals with SLI.  
This study utilized genome-wide SNP data generated on the Illumina Human OmniExpress (v12.1) 
beadchip. CNVs were identified using QuantiSNP (Colella et al., 2007) and PennCNV (Wang et al., 
2007) algorithms. All the data were generated in Build GRCh37/hg19. 
4.3.1 Illumina Human OmniExpress array. 
The Illumina Human OmniExpress beadchip generates genotype calls for more than 700,000 
markers using the Infinium HD technology (Figure 4.1).  
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Figure 4.1. Schematic representation of the Illumina Infinium HD Assay protocol. 
This assay is based on a two-step detection process: 
a) fragments of the DNA of interest selectively hybridize to specific probes (50-mer 
oligonucleotides), designed to be complementary to the loci of interest, but stopping one 
base before the interrogated SNP;  
b) an enzymatic single-base extension incorporates a nucleotide labelled with a fluorescent 
dye, complementary to the base present at the SNP site. 
For each SNP, Cy3 and Cy5 fluorescence signals specify the two alleles (generally referred to as 
allele A and allele B). Dual-colour staining of the labelled nucleotides is followed by an image 
scanning performed by Illumina’s iScan imaging system, which detects both colour and signal 
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intensity. Homozygous genotypes are specified by red/red or green/green signals, heterozygous 
genotypes are indicated by red/green (yellow) signals. 
The data generated by a SNP genotyping array can be analyzed and visualized with GenomeStudio 
Data Analysis software (Illumina). This program can covert the raw image scan into quantitative 
values and calculate the signal intensities for alleles A and B at each SNP, indicated as X and Y, 
respectively. The allele specific intensities are normalized using a proprietary algorithm of the 
Illumina GenomeStudio software: this procedure adjusts for background and makes markers more 
comparable to each other. Normalized allelic intensities are used to calculate the total fluorescent 
intensity signal (R) and the allelic intensity ratio (θ). R is calculated as a combined SNP intensity: 
Robserved = X+Y, while θ is calculated as arctan(Y/X)/(π/2). R and θ values are calibrated to 
canonical genotype clusters generated from a large panel of normal samples, used to determine the 
R and theta values expected for each genotype (AA, AB and BB). R and θ are then converted to two 
important measures: Log R Ratio (LRR) and B Allele Frequency (BAF).  
LRR, which represents a normalized measure of the total signal intensity at each SNP, derives from 
the comparison of the Robserved with the R obtained from a reference sample population (Rexpected) 
and it is calculated as log2(Robserved/Rexpected). In autosomic regions without CNVs (copy number =2 
for autosomes), LRR is ~0: LRR lower than zero may indicate a deletion, LRR higher than zero a 
duplication. 
BAF, which derives from the normalized θ, represents the proportion contributed by allele B to the 
total copy number. BAF represents an estimate of NB/(NA+NB), where NA and NB are the number of 
A and B alleles, respectively, therefore its value range from 0 to 1. BAF close to 1 indicates that all 
alleles for that marker are B alleles (e.g. BB, BBB or B/-), viceversa BAF close to 0 indicates that 
all alleles for that SNP are A alleles (e.g. AA, AAA or A/-), values close to 0.5 indicate a 
heterozygous genotype AB. 
These two transformed parameters, LRR and BAF, are plotted along each chromosome for all SNPs 
on the array and can be then visually inspected (Figure 4.2). The exported values of LRR and BAF 
for each SNP in each individual can be used for the identification of changes in copy number by 
QuantiSNP and PennCNV. 
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Figure 4.2. Examples of LRR and BAF plots for a deleted region (1 copy, genotype B/- or A/-), region with 2 normal 
copies (three possible genotypes for each SNP: AA, AB, BB) and duplicated region (3 copies, four possible genotypes 
for each SNP: AAA, AAB, ABB, BBB). 
4.3.2 QuantiSNP. 
The algorithm QuantiSNP (Colella et al., 2007) was originally developed for Illumina Infinium 
SNP genotyping data. This program incorporates the LRR and the BAF values simultaneously in an 
Objective Bayes Hidden Markov Model (OB-HMM). The HMM provides a statistically powerful 
framework suitable for CNV detection from signal intensity data. This model sets a priori 
probability of observing copy number changes between SNP loci at a certain distance. The hidden 
state represents the unknown copy number at each SNP site. Instead of using only three possible 
states (loss, normal and gain), QuantiSNP adopts a six-state definition for modelling CNV events 
(Table 4.1) and the states are inferred using the LRR and the BAF, and assumed to be independent.  
Copy no. state Copy no. Description CNV genotypes 
1 0 Deletion of 2 copies Null 
2 1 Deletion of 1 copy A, B 
3 2 Normal state AA, AB, BB 
4 2 Copy neutral with LOH AA, BB 
5 3 Single copy duplication AAA, AAB, ABB, BBB 
6 4 Doubles copy duplication AAAA, AAAB, AABB, ABBB, BBBB 
Table 4.1 (Wang et al., 2007). Hidden states and correspondent copy numbers and genotypes. This table is valid for 
autosomes. 
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When a copy number variation is detected, QuantiSNP assigns a Bayes Factor to all of the possible 
copy number states, a measure of likelihood that the region harbours that copy number. Among all 
the possible copy number states, the most probable is indicated with the Maximum Log Bayes 
Factor. Therefore, higher values of Log Bayes Factor indicate a stronger support for the presence of 
CNV in the specified position given by the available SNP data. 
We downloaded QuantiSNP package (version 2, April 2010) from the website 
https://sites.google.com/site/quantisnp/downloads. 
CNV detection performed with QuantiSNP requires:  
- Configuration files (provided with the package), that contain default model parameters. 
These files are levels-hd.dat (list of the copy number states and associated mean levels for 
LRR, suitable for Illumina-Omni arrays and other Illumina Infinium users) and params.dat 
(list of hyperparameter settings involved in the statistical model underlying QuantiSNP).  
- MATLAB Run-Time Libraries; 
- Input signal file, which is a text file with 5 columns for each marker (SNP Name, 
Chromosome, Position, Log R Ratio, B Allele Frequency), as exported from Genome Studio;  
- Emitters (optional), which represents the number of iterations used for the EM algorithm 
during learning. We used the default number 10. 
- lsetting (optional), which indicates the length used to calculate transition probabilities. We 
set the default value (2,000,000). 
- GC file (optional): SNP data can present wave-like artefacts in the Log R Ratio, called 
“genomic waves” (Diskin et al., 2008), that are not platform-specific, but depend on local 
genomic features, in particular the GC content. In order to reduce false CNV calls, 
QuantiSNP can incorporate local GC content information to remove these artefacts. We used 
the local GC content-based correction for Build 37.  
Chromosome X needs a special processing: using --doXcorrect in the command line, the program 
adjusts the LRR for the X chromosome at zero for females or the deletion level for males. 
After CNV calling, QuantiSNP generates two output files for each sample: a list of putative copy 
number alterations and a summary of quality parameters. 
The quality control (QC) output file reports three measures for each chromosome: 
- an estimated probability of outliers (outlier rate); 
- a measure of the standard deviation of LRR values (SD_LRR);  
- a measure of the spread of BAF distribution for heterozygous genotypes (SD_BAF).  
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A high outlier rate and high standard deviations provide a measure of the noise in the data, which 
can also be visually deduced from scatter plots of the two metrics within Genome Viewer 
(Illumina), that indicate bad quality samples. 
For each individual, we calculated the average of LRR_SD and BAF_SD values, taking into 
account all chromosomes, and we filtered out samples with LRR_SD > 0.3 and BAF_SD > 0.15 to 
exclude low quality samples. These thresholds were established based on the quality parameters 
values specified by previous CNV studies (Marenne et al., 2011; Pankratz et al., 2011; Sanders et 
al., 2011). 
The output file with the list of putative CNVs reports a Maximum Bayes Factor for every copy 
number variant identified. Since Log Bayes Factors of less than 10 are frequently associated to false 
positives (>10%), only CNV calls including three or more probes and with a log Bayes Factor ≥10 
were kept in the analysis.  
4.3.3 PennCNV. 
PennCNV (Wang et al., 2007) represents an integrated HMM algorithm, originally developed for 
the Illumina Infinium assay, but then extended to other SNP genotyping platforms. This algorithm 
is based on more realistic models for state transition between different copy number states. Indeed, 
in addition to LRR and BAF, PennCNV also incorporates the distance between adjacent SNPs and 
the population frequency of the B allele for each SNP (PFB). The list of PFB for all SNPs is 
compiled using a large set of control individuals with no clinical phenotypes and, if possible, with 
mixed ethnic backgrounds, and contributes to a more accurate modelling of the likelihood of copy 
number genotypes. All these values (LRR, BAF, PFB and distance) determine the probability of 
having a copy number change at a specific position.  
Chromosome X needs a special treatment: using the --chrx argument, LRR levels are adjusted, so 
that the average LRR is either 0 for females or the values expected for a single copy deletion for 
males. After this procedure, the CNV calling is performed in a similar way as for autosomes. 
The PennCNV package (version of June 2011) was freely downloaded at 
http://www.openbioinformatics.org/penncnv/penncnv_download.html. 
PennCNV individual-based calling. 
PennCNV requires several files for CNV detection: 
 a signal input file for each sample, which is a text file containing the SNP name, LRR and 
BAF values for each marker; 
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 the HMM file (“hhall.hmm” file in our analysis, supplied with the package), which 
specifies the HMM model, that indicates the expected signal intensity values and the 
expected transition probability for different copy number states; 
 the PFB file (Build 37), which is a four column text file containing SNP name, 
chromosome, position, and population of the B allele for each marker; 
 the GC file (Build 37), which specifies the content in G and C base pairs (ranging from 0% 
to 100%) of a 1 Mb genomic region surrounding each marker (500 kb each side) and allows 
an adjustment of LRR to reduce GC-content-caused fluctuation.  
The file was downloaded from http://hgdownload.cse.ucsc.edu/goldenPath/hg19/database 
(gc5Base.txt.gz). 
For each sample, a quality summary is provided, containing mean, median and standard deviation 
for LRR and BAF, BAF_DRIFT, waviness Factor (WF) and GC-waviness factor (GCWF). WF is a 
measure of the total signal fluctuation across the genome in the given individual, while GCWF 
value indicates the signal intensity fluctuation correlating with the GC-content. Since the WF and 
the GCWF are based on the median absolute deviation of signal intensities, they are less sensitive to 
extreme values (such as those within CNVs) than a standard deviation measure. 
After the CNV calling, samples were discarded if the quality control (QC) summary reported 
LRR_SD > 0.35, BAF drift 0.002 and waviness factors (WF value) less than -0.04 or higher than 
0.04. These thresholds were established taking into account the quality parameters values specified 
by previous CNV studies (Marenne et al., 2011; Pankratz et al., 2011; Sanders et al., 2011). 
Only CNV calls including three or more markers and with a confidence score ≥10 were taken 
forward. This confidence score is a log Bayes factor and, as for QuantiSNP, it has been suggested 
that a value of ~10 or larger can be a reliable threshold. 
For recently developed SNP arrays with high-density markers, PennCNV tends to split large CNVs 
(such as those >500kb) in smaller fragments. Therefore, the raw calls were visually inspected and 
adjacent boundaries were joined when appeared close enough to belong to the same rearrangement. 
Trio and quartet base-calling. 
PennCNV offers a Father-Mother-Offspring trio calling algorithm which incorporates information 
from related individuals in a Bayesian approach for a posteriori validation. The principle is that 
pedigree information could be integrated to determine the most likely configuration, improving the 
number of detected CNVs and the accuracy for boundary mapping.  
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The -trio or -quartet argument in the command line specifies to use family-based CNV detection 
algorithm to jointly update CNV status for a father-mother-offspring trio (parents-child) or quartet 
(parents and two children). 
After the individual-based calling step, 92 SLI families with both parents genotyped on the array 
and passing the quality control (including 167 individuals - 87 affected individuals, 28 unaffected 
individuals and 52 of unknown affection status), were also analysed as trios or quartets. PennCNV 
cannot use this approach on families with 3 or more children; therefore, we divided the families into 
trios and quartets, and then combined the CNV calls together. This method was used to identify de 
novo CNVs. 
4.3.4 Generation of a CNV consensus list: BEDTool. 
Only CNVs detected by both algorithms QuantiSNP and PennCNV and meeting the quality criteria 
that we set, were included in subsequent analyses as “high-confidence CNVs”. 
A CNV was considered detected by both algorithms if the two independent calls were found to 
reciprocally overlap for at least 50% of their length. The innermost boundaries of the overlap were 
then used to define the CNV. This was achieved using the BEDTool “intersectBed”, which returns 
overlapping “features” between two BED files. BED (Browser Extensible Data) format, as 
described on the UCSC Genome Browser website, is a tab-limited file which requires at least three 
columns (chromosome, start position, end position), but can have additional columns. It represents a 
simple way to annotate genomic features, such as SNPs or structural variants. As QuantiSNP and 
PennCNV, BEDTools works in a “command line” environment. In cases where one programme 
identified a large CNV and the other one smaller overlapping CNVs, if the total overlapping 
segments intersected 50% or more of the larger CNV then the CNV was called as one CNV using 
the innermost boundaries of the overlapping segments. 
4.3.5 Overlap of the CNV consensus list with DGV. 
To identify rare and novel CNVs, the calls were compared to CNV loci published in the Database of 
Genomic Variants (DGV; http://dgv.tcag.ca/) (Macdonald et al., 2013). We used the version of 
DGV available in January 2012. The list of structural variants present in this catalogue was 
downloaded from the UCSC Genome Browser (hg19, Jan2012). 
Using BEDTool, CNVs were classified as “rare” if they overlapped less than 50% and 5 or less 
times with CNVs in the DGV, as “novel” if no CNVs were reported in the same genomic region, 
otherwise they were classified as “common”. 
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4.3.6 PLINK: CNV burden analyses. 
PLINK is a free whole-genome association analysis tool 
(http://pngu.mgh.harvard.edu/purcell/plink/), running in a command line environment (Purcell et 
al., 2007). A recent application of PLINK allows CNV burden analyses. The program does not 
identify CNVs, but offers functions for downstream analysis of CNV data.  
In PLINK, CNVs are considered as segments and the analyses require: 
-a MAP file, with dummy entries corresponding to the start and stop sites of all “segments”;  
-a FAM file, which contains 6 fields: FID (Family ID), IID (Individual ID), Paternal ID, Maternal 
ID, Sex (1=male; 2=female; other=unknown) and phenotype (1= unaffected, 2 =affected, 0 or -9 
missing); 
-a CNV list, a text file with 8 columns: FID, IID, CHR (Chromosome), BP1 (Start position, bp), 
BP2 (End position, bp), TYPE (number of copies), SCORE (confidence score associated with the 
variant), SITES (number of probes included by the variant). 
By default, a summary of the PLINK analysis is reported in a file named “plink.cnv.summary”, that 
represents a count of CNVs, in cases and controls, assuming that the individuals are unrelated. 
The arguments --cnv-indiv-perm and --mperm 10000 allow a set of global tests of CNV burden in 
cases versus controls to be performed. In this test (1-sided), the number of CNVs (RATE), the 
proportion of samples with one or more segments (PROP), the total kb length spanned per person 
(TOTKB) and the average segment size per person (AVGKB) are the metrics compared between 
cases and controls and evaluated by permutation.  
We also supplied a “gene.list” file (Build 37) to add an extra test, that takes into account the number 
of genes spanned by CNVs (GRATE), the number of CNVs with at least one gene (GPROP) and 
the number of genes per total CNV kb (GRICH). 
4.4 Validation of CNVs by Real-Time PCR. 
The presence of selected microdeletions and microduplications was validated by quantitative PCR 
(qPCR) using iQ SYBR Green Supermix (Bio-Rad). Briefly, SYBR Green is a non-specific dye that 
emits fluorescence when it intercalates with double stranded DNA. In a qPCR experiment, the 
fluorescence is measured after each extension step and this allows the monitoring of the increasing 
amount of DNA produced during the PCR reaction. The analysis of qPCR data is based on the 
threshold Cycle (Ct), which represents the cycle at which the fluorescence passes the threshold 
level, within the exponential phase, and it is a relative measure of the amount of target in the 
reaction. 
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All the primers used for the CNV validation were designed with Primer3 
(http://bioinfo.ut.ee/primer3-0.4.0/primer3/) and are listed in Table 4.2. Oligonucleotide primers 
were designed taking into account an optimal primer length of 20-22 nucleotides, a GC content of 
40–60% and an optimal PCR product size of 90-140 bp. In order to evaluate the PCR efficiency, a 
standard curve was set up for each primer pair, using three replicates of a control DNA and 5 
template concentrations (five DNA template amounts deriving from a 1:4 serial dilution). The 
primers used for the CNV validation were selected to have a PCR efficiency in the range of 90%-
110%. We made sure the concentration of the DNA we would be using occurred within the serial 
dilution range. 
Each reaction was set up in triplicate using the following conditions: 
qPCR Reaction MIX Amount (μl) 
DNA template  5 
iQ SYBR Green Supermix 12.5 
Primer F (5μM) 1 
Primer R (5μM) 1 
H2O 5.5 
Final volume 25 
For the relative quantification, the DNA template was used with a concentration of 5 ng/μl.  
The qPCR program included three main stages: 
 Initial denaturation: incubation at 95°C for 4’ 30”; 
 Amplification: 40 cycles of incubation at 95°C for 30”, at 60°C for 30”, at 72°C for 30”; 
 Melting curve: incubation at 95°C for 1’, followed by an incubation at 55°C for 30”, 
repeated for 81 times with an increase of 0.5°C each cycle. 
The melting curve analysis, also called dissociation curve, consists of a step in which the 
temperature is gradually increased while the fluorescence is constantly monitored. When the 
temperature is high enough, the double strands of DNA fragments are denatured and the SYBR 
Green dye dissociates from the double stranded DNA, causing a decrease in fluorescence. Analysis 
of melting curves allows the detection of primer-dimers or other non-specific PCR products that 
could reduce the PCR efficiency and give spurious fluorescence signals. Primer-dimers usually 
have lower Tm compared to the PCR products, since they have a smaller size. The melting 
temperature (Tm) depends on primer features (such as sequence complementarity and G-C 
composition) and reaction conditions.  
For each sample, the qPCR data were compared against a control gene (ZNF423) and a control 
subject, genotyped on the same SNP array and predicted to have two normal copies of the tested 
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region. The number of copies of each amplified fragment was calculated using the 2
-ΔΔCt
 method
  
(Livak and Schmittgen, 2001): 
∆Ct sampleDNA= Ct fragment of interest - Ct ZNF423 
∆Ct controlDNA= Ct fragment of interest - Ct ZNF423 
∆∆Ct = ∆Ct sampleDNA - ∆Ct controlDNA 
Copy number = 2 x 2
-∆∆Ct 
4.5 Analysis of the candidate gene ZNF277. 
4.5.1 Validation of the ZNF277 microdeletion in the discovery pedigree G4. 
All the members of the discovery family G4 were analyzed for the presence of the ZNF277 
microdeletion (minimum predicted size: 4,153 bp, chr7:111,955,948-111,960,100, hg19) by qPCR, 
except the sister G4_5, for whom insufficient DNA was available. Four primer pairs were used 
(Table 4.2): chr7_fg1, mapping to intron 1 of DOCK4, and chr7_fg4, mapping to intron 8 of 
ZNF277, were used as control probes for the regions predicted to be not deleted, whereas chr7_fg2 
and chr7_fg3, mapping to intron 4 and exon 5 of ZNF277 respectively, were used to confirm the 
predicted deletion. The sister G4_5 was instead tested using a PCR assay, described in the next 
paragraph. 
4.5.2 Breakpoint characterization of the ZNF277 microdeletion in the discovery pedigree. 
To further confirm the qPCR results, two PCR assays were performed in all the members of family 
G4. A primer pair (ZNF_break) spanning the ZNF277 microdeletion breakpoints was used to show 
the presence of the microdeletion, in the heterozygous or homozygous form. A primer pair that 
amplifies exon 5 of ZNF277 (ZNF277_x5) was used instead to detect the presence of at least one 
non-deleted allele.  
These PCR assays were performed using the following conditions: 
PCR mix Amount (μl) Program 
NH4 Buffer (10X) 2.5 Initial Denaturation 95°C x 4 minutes 
MgCl2 (50 mM) 1.25 Amplification (30 cyles) 95°C x 30 seconds 
dNTPs (10 μM) 0.5 55°C x 30 seconds 
Primer F (10 μM) 0.5 72°C x 30 seconds 
Primer R (10μM) 0.5 Final extension 72°C x 7 minutes 
BioTaq:Pfu (9:1)* 0.1 
H2O 14.65 
Template DNA (5 ng/μl) 5 
Final volume 25 
* BioTaq DNA Polymerase 5 u/μl (Bioline), Pfu DNA polymerase 2.5 u/μl (Thermo Scientific). 
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The PCR products were visualized using a UV transilluminator after electrophoresis on a 2% 
agarose gel and SYBR safe staining (Invitrogen). The 1kb Plus DNA ladder (Invitrogen) product 
size was loaded to check the PCR fragment size.  
PCR purification. 
Prior to sequencing, the PCR products were purified with Exonuclease I (ExoI) and Shrimp 
Alcaline Phospatase (SAP). The enzyme ExoI removes single-strand DNA (primers or intermediate 
products), the enzyme SAP removes the unconsumed dNTPs remaining in the PCR mixture. The 
PCR cleanup was performed adding the Exo-SAP reaction mix to the PCR products, followed by a 
two-step incubation:  
EXOSAP mix Amount (μl) Program 
SAP Buffer (10X) 1 Treatment 37°C x 30 minutes 
SAP enzyme 1 Enzymatic inactivation 80°C x 20 minutes 
ExoI enzyme 0.1 
H2O 0.9 
PCR product 7 
Final volume 10 
Sanger Sequencing reaction. 
Sanger sequencing was performed to verify the predicted breakpoints of the ZNF277 microdeletion 
in the G4 family, using primers flanking the predicted deletion boundaries (ZNF_break). The 
reaction was performed using the ABI PRISM BigDye v3.1 Terminator Cycle Sequencing (Life 
Technologies). 
Sequencing mix Amount (μl) Program 
Big Dye terminator buffer (5X) 1.75 Initial Denaturation 95°C x 1 minute 
Big Dye terminator  0.5 Amplification  
(35 cycles) 
95°C x 10 seconds 
Primer (F or R, 10μM) 0.5 50°C x 10 seconds 
H2O 5.25 60°C x 4 minutes 
PCR product 2 
Final volume 10 
 
Ethanol-EDTA Precipitation of Sequencing Reactions. 
The products of sequence reactions were precipitated using the following procedure. 
1) A “precipitation mix” was prepared and added to each sample (volume of the sequence 
reaction: 10 μl). This solution was composed by 50 μl of 100% EtOH, 2 μl of NaAc (sodium 
acetate) 3M pH 5.2, 2 μl of EDTA (ethylenediaminetetraacetic acid) 125 mM. 
2) The samples were spun in a centrifuge for 30 minutes at 3000 g (4°C). 
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3) The surnatant was discarded and the microplate was spun inverted for 10 seconds at 190 g. 
4) The pellet was rinsed with 70 μl of 70% EtOH. 
5) The samples were spun in a centrifuge for 15 minutes at 1650 g (4°C). 
6) The surnatant was discarded and the microplate was spun inverted for 10 seconds at 190 g. 
7) The pellet was dried at room temperature and stored away from direct light. 
The purified sequencing products were sent to the DNA sequencing facility at the Zoology 
Department (Oxford, UK). 
4.5.3 IBD and homozygosity analysis in the discovery pedigree G4. 
In order to test whether G4 was a consanguineous family, we used the Pairwise IBD Estimation tool 
in PLINK (http://pngu.mgh.harvard.edu/~purcell/plink/ibdibs.shtml) to estimate the proportion of 
IBD in each pair of individuals within the same family of the SLIC cohort. The analysis was 
performed using genome-wide SNPs genotyped on the on Illumina Human OmniExpress beadchip. 
Given IBS information, this statistic evaluates the IBD alleles in order to estimate whether two 
individuals look more similar than expected by chance in a random sample. The proportion of IBD 
is calculated as PI_HAT =P(IBD=2)+0.5*P(IBD=1). The expected values for a pair of unrelated 
individuals is zero, for a parent-child pair or a sibling pair it is 0.5 and for a pair of half-siblings it is 
0.25. 
SNP data were used to analyse the haplotypes of a 10 Mb region encompassing the gene ZNF277 
(chr7:106790042-11673037, hg19), in family G4. This analysis was performed using the 
Haplotyping tool of Merlin (http://www.sph.umich.edu/csg/abecasis/merlin/tour/haplotyping.html). 
The command requires a .ped file, that provides pedigree information (a family identifier, an 
individual identifier, a link to each parent and finally an indicator of each individual's sex) and 
various types of genetic data, including genotypes and phenotypes; a .map file, which provides the 
chromosomal locations of the markers used in the analysis; and a .dat file, which describes the .ped 
file structure. The output file lists the two haplotypes for each individual and indicates the location 
of recombination events.  
4.5.4 Screening of Larger Cohorts: SLIC, IMGSAC and controls. 
The same PCR assays used to confirm the presence of the ZNF277 microdeletion in family G4 were 
used in a PCR-based screening for ZNF277 microdeletions of three separate cohorts: a cohort of 
families containing individuals with SLI, a cohort of families containing individuals with ASD and 
a control cohort. Amplification with the primer pair spanning the deletion breakpoints identified 
ZNF277 microdeletion carriers, while the primer pair amplifying exon 5 of ZNF277 was 
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subsequently used to test whether the identified microdeletions were in the heterozygous or 
homozygous form. 
The SLI screening cohort consisted of DNA from 1234 individuals from 322 SLIC families (545 
parents, 318 SLI probands, 371 sibs). This cohort included the 512 individuals who comprised the 
CNV study but included many additional SLI subjects (144 additional probands) and their family 
members (550 individuals).  
The ASD cohort consisted of DNA from 1021 individuals from 252 IMGSAC multiplex families 
(454 parents, 412 affected children, 155 affected and unaffected sibs).  
The control cohort consisted of DNA from 224 non-related UK Caucasian blood donors from the 
ECACC Human Random Control (HRC) panel 
[http://www.hpacultures.org.uk/products/dna/hrcdna/hrcdna.jsp]. In addition, we had access to 
sequence data from 130 unrelated Caucasian samples through an in-house project at the Wellcome 
Trust Centre for Human Genetics–the 500 Whole-Genome Sequences Project [WGS500 
Consortium] (Palles et al., 2013). 
We used the two-tailed Fisher’s exact test (1 degree of freedom) to test whether the allelic 
frequency of ZNF277 microdeletions was significantly different between SLI probands and control 
individuals. 
4.5.5 Gene Expression Evaluation for ZNF277, DOCK4 and IMMP2L. 
RNA samples were not available for the discovery individuals of family G4. We therefore chose to 
examine expression levels of ZNF277, DOCK4 and IMMP2L by qPCR in cDNA derived from 
lymphoblastoid cell lines (LCLs) from ten individuals belonging to 4 ASD families, five of whom 
carried a heterozygous ZNF277 microdeletion, and in cDNA derived from blood from the parents of 
a single Dutch multiplex ASD family (15-0084) previously described (Pagnamenta et al., 2010) 
with a IMMP2L-DOCK4 microdeletion (chr7:110876742-111470446, hg19).  
RNA extraction from LCLs and cDNA synthesis. 
EBV-transformed peripheral LCLs were grown in RPMI 1640 media (Sigma) supplemented with 
10% fetal bovine serum (PAA), L-glutamine (final concentration 2 mM) and penicillin (Sigma) 
(500 U/ml) and streptomycin (Sigma) (5 μg/ml). When the cells reached an amount of 
approximately 1 x 10
7
, RNA was extracted using the RNeasy Mini kit (QIAGEN, Crawley, UK), 
according to the manufacturer's suggested protocol. 
1. After determining the number of cells, the amount correspondent to 1 x 10
7
 cells was spun 
for 5 min at 150 x g, then the supernatant was removed by aspiration.  
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2. 600 μl of lysing Buffer RLT was added to the pelleted cells mixed by vortexing or pipetting, 
ensuring that no cell clumps were visible before proceeding to the next step. Incomplete 
homogenization leads to significantly reduced RNA yields and can cause clogging of the RNeasy 
spin column. 
3. We added 1 volume (600 μl) of 70% Ethanol to the homogenized lysate, and mixed well by 
pipetting.  
4. 700 µl of the sample was transferred to an RNeasy spin column placed in a 2 ml collection 
tube. Each column was spun for 15 s at 8000 x g (10,000 rpm), the flow-through was discarded. 
5. 700 µl Buffer RW1 was added to the RNeasy spin column, that was spun for 15 s at 8000 x 
g (10,000 rpm), to wash the spin column membrane. The flow-through was discarded. 
6. 500 µl Buffer RPE was added to the RNeasy spin column that was spun for 15 s at 8000 x g 
(10,000 rpm), to wash the spin column membrane. The flow-through was discarded. 
7. 500 µl Buffer RPE was added to the RNeasy spin column that was spun for 2 minutes at 
8000 x g (10,000 rpm), to wash the spin column membrane. The long centrifugation dries the 
spin column membrane, ensuring that no ethanol is carried over during RNA elution. Residual 
ethanol may interfere with downstream reactions.   
9. After placing the RNeasy spin column in a new collection tube, the column was spun for 1 
minute at 8000 x g, to dry the membrane. This step was performed to eliminate any possible 
residue of Buffer RPE, or residual flow-through remained on the outside of the RNeasy spin 
column. 
10 The RNeasy spin column was then transferred to a new collection tube, then 30 µl of 
RNAse-free water was added to the column and spun for 1 minute at 8000 x g. The collected 
RNA was conserved at -80°C. 
cDNA was synthesized using the QuantiTect Reverse Transcription kit (QIAGEN, Crawley, UK), 
using approximately 1 μg of RNA as template, according to the manufacturer’s protocol. 
qPCR analyses. 
All the primers were designed with Primer3 (http://bioinfo.ut.ee/primer3-0.4.0/primer3/), as 
described before, and are listed in Table 4.2. Moreover, to ensure the specific amplification of 
cDNA, the forward and the reverse primers of each pair were designed in different adjacent exons 
or across exon-exon boundaries. The qPCR reaction was performed as stated in section 4.4. Two 
primer pairs were designed for each gene, ZNF277 (NM_021994.2), DOCK4 (NM_014705.3), 
IMMP2L (NM_032549.3). Four housekeeping were tested (ACTB, B2M, TFRC and GUSB). Among 
these, the housekeeping gene GUSB (NM_000181.3) had expression levels more similar to our 
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genes of interest and was used as a normalizer. Expression levels were also normalized against a 
control individual. The 2
-ΔΔCt
 method was applied to estimate the difference in the expression of the 
three genes between samples.  
Statistical significance was calculated with the Student T-test, assuming unequal variance between 
the two independent sample groups for the expression analysis. 
4.6 Analysis of the candidate gene DPYD. 
4.6.1 SLI probands. 
A screening for the splicing variant rs3918290 was performed in a group of 166 independent SLI 
cases. The screening was performed by PCR amplification of the fragment containing exon 14 and 
exon-intron boundaries (primers and conditions are described in Table 4.2), followed by Sanger 
sequencing, as previously described (section 4.5.2). 
4.6.2 Autism Cohorts: Italian, IMGSAC and AGP families. 
A screening for the splicing variant rs3918290 was performed in two groups of cases and a group of 
control individuals. 
The first group of cases was formed by 231 Italian simplex families, each with one individual 
affected by ASD (413 parents, 231 probands, 48 unaffected sibling). The second group of cases was 
constituted of 224 multiplex families belonging to the IMGSAC Consortium (365 parents, 224 
probands, 161 affected siblings, 115 unaffected siblings). The third group of cases was part of the 
cohort of families collected by the AGP Consortium. Subjects from all phenotypic classes (strict, 
broad, and spectrum) were included in the analyses for DPYD. These individuals had been 
previously genotyped on the Illumina Human 1M-single and Illumina Human 1M-Duo BeadChip 
arrays, which also include the SNP rs3918290. The association analyses were performed on the 
individuals who have been successfully genotyped for rs3918290 and for another 99 independent 
SNPs of the surrounding region (chr1:97499599-98599144), including DPYD and MIR137. 
The group of controls genotyped for rs3918290 was formed by 449 unrelated and healthy Italian 
individuals. DNA was obtained from blood or buccal-swabs. 
4.6.3 Genotyping by endonuclease restriction analysis. 
We used the bioinformatic program INSIZER (http://zeon.well.ox.ac.uk/git-bin/insizer, not 
available anymore) to find a restriction endonuclease that could specifically discriminate between 
the two allelic variants of the splice donor site at intron 14 of DPYD. We interrogated the sequence 
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of a PCR fragment including exon 14 (413 bp) and we found that the enzyme HpyCH4IV (NEB, 
New England Biolabs) recognizes the site: 
 
In our PCR fragment, these 4 bp can be found only at the junction between exon 14 and intron 14, 
therefore, the target site is unique in our sequence. When the splice donor site is not mutated, the 
enzyme HpyCH4IV cuts the PCR fragment, producing two restriction fragments of different lengths 
(278 bp and 135 bp) that can be easily distinguished on an agarose gel. When the base G is 
substituted by the base A (rs3918290), the enzyme does not recognize the target site and does not 
cut the sequence. Therefore, the distinct gel band patterns produced by the digestion with 
HpyCH4IV allowed the genotyping of the variant rs3918290 in the Italian and IMGSAC ASD 
families and the control samples.  
The PCR fragment containing exon 14 was amplified with the primers DPYD_x14F and 
DPYD_x14R and the conditions are reported in the Table 4.2. Subsequently, the digestion reaction 
was assembled using with the following conditions. 
Digestion mix Amount (μl) Program 
NEB buffer 1  (10X) 1.5 Digestion 37°C for 3 hours 
HpyCH4IV enzyme (10 U/μl)  0.1 Heat inactivation 65°C for 2 minutes 
H2O 10.4 
PCR product 3 
Final volume 15 
The restriction fragments were separated by electrophoresis on a 2% agarose gel, using GelRed 
staining (Biotium). The digestion profiles were visualized with a UV transilluminator. The 100 bp 
DNA ladder (NEB) product size was loaded to check the restriction fragment size.  
4.6.4 Mutation screening of DPYD gene: primers and PCR conditions. 
The 23 coding regions and the flanking intronic regions of the isoform 1 of DPYD (NM_000110.3), 
the coding region of exon 6 of isoform 2 (NM_001160301.1), and regulatory elements at 5’ of the 
gene (chr1:98386616-98386699, hg19) were analysed during a mutation screening. These regions 
were amplified separately using the primers and the conditions listed in Table 4.2. All the primers 
were designed using Primer3 (http://bioinfo.ut.ee/primer3-0.4.0/primer3/). 
The PCR assays were performed using the kit provided with AmpliTaq Gold DNA Polymerase 
(Applied Biosystem). AmpliTaq Gold is a Hot Start polymerase, that is inactive at room temperature 
and is activated during the initial denaturing step at 95°C. The reactions were set up in a final 
volume of 15 μl, with ~30 ng of template DNA (3 μl of 10 ng/μl).  
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The PCR conditions were optimized for each primer pair used in the screening. For some of them, 
we used a traditional PCR program, with one annealing temperature (Ta): 
Program 
Initial Denaturation 95°C for 15 minutes 
Amplification (30 cyles) 
 
95°C for 30 seconds 
Ta°C for 30 seconds 
72°C for 30 seconds 
Final extension 72°C for 7 minutes 
For other fragments, in order to increase the specificity and the yield of the reaction, we used a 
Touch-Down PCR program (TD) (Korbie and Mattick, 2008). In a TD program, the initial Ta (1) is 
higher to ensure a specific annealing of the primers to the template, then it is progressively 
decreased until it reaches a second, lower Ta (2), which is maintained constant for remaining 
amplification cycles. 
TD Program 
Initial Denaturation 95°C for 15 minutes 
Touch-Down 
(Ta decreases 0.5°C at each cycle) 
95°C for 30 seconds 
Ta1°C for 30 seconds 
72°C for 30 seconds 
Amplification (30 cyles) 95°C for 30 seconds 
Ta2°C for 30 seconds 
72°C for 30 seconds 
Final extension 72°C for 7 minutes 
The amplification of the fragment containing exon 1 was particularly problematic, since the region 
has a high GC content. The GC pair has a higher number of hydrogen bonds compared to the AT 
pair, therefore, GC-rich stretches are more stable and require a higher melting temperature. Since 
Dimethyl sulfoxide (DMSO) improves the denaturation of the template DNA, it was added to the 
PCR mix to help the reaction and overcome the problem of non-specific annealing.  
The PCR products were visualized with a UV transilluminator after electrophoresis on a 2% agarose 
gel and GelRed staining (Biotium). The 100 bp DNA ladder (NEB) product size was loaded to 
check the PCR fragment size.  
4.6.5 PCR purification. 
The PCR products were purified with Exonuclease I (ExoI) and Shrimp Alcaline Phosphatase 
(SAP), as described in section 4.5.2.  
For exon 1, the PCR product with the correct size was purified with the GEL/PCR Extraction & 
Purification Kit (Fisher Molecular Biology), using the manufacturer’s instructions. 
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1. PCR products were loaded on a 2% agarose gel and separated by electrophoresis. 
2. The band of the correct size was excised from the gel with a clean scalpel and transferred 
into a microcentrifuge tube (the kit requires a maximum volume of the gel slice of 300 mg). 
3. 500 μl of FSDF Buffer were added to the sample and mixed by vortexing. 
4. The sample was incubated at 55°C for 10-15 minutes and vortexed every 2-3 min until the 
gel slice was completely dissolved. 
5. After cooling down at room temperature, 800 μl of the sample mixture were transferred to a 
FSDF Column, inserted in a collection tube. 
6. The column was spun at full speed in a microcentrifuge for 30 seconds, then the flow-
through was discarded. 
7. 750 μl of Wash Buffer (after addition of ethanol) were added to the FSDF Column.  
8. The column was spun at full speed in a microcentrifuge for 30 seconds, then the flow-
through was discarded. 
9. The FSDF Column was placed to a new microcentrifuge tube. 
10. 40 μl of Elution Buffer were added to the membrane of the FSDF Column and left for 2 
minutes.  
11. DNA was eluted spinning the tube at full speed in a microcentrifuge for 2 minutes. 
4.6.6 Sequencing Reaction. 
Sanger sequencing was performed with the ABI PRISM BigDye Terminator v3.1 Cycle Sequencing 
kit (Life Technologies), using the following conditions. 
Sequencing mix Amount (μl) Program 
Big Dye terminator buffer (5X) 1.75 Initial Denaturation 96°C for 1 minute 
Big Dye terminator  0.5 Amplification (25 cycles) 96°C for 10 seconds 
Primer (F or R, 10μM) 0.16 50°C for 5 seconds 
H2O 6.59 60°C for 4 minutes 
PCR product 2 
Final volume 10 
The primers used for the sequencing reactions were the same used for PCR amplification, except for 
the fragment amplifying exon 1, that needed an internal primer (5’-attaaaggccagtccccaga-3’) and 
the addition of DMSO 5% to the sequencing reaction mix (final reaction volume=10 μl). 
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4.6.7 Ethanol Precipitation of Sequencing Reactions. 
The products of sequence reactions were precipitated using the following procedure. 
1. A “precipitation mix” was prepared and added to each sample (volume of the sequence 
reaction: 10 μl). This solution was composed by 10 ul of H2O, 2.5 volumes of 100% EtOH 
(55 μl), 1/10 of the volume of sodium acetate (NaAc) 3M pH 5.2 (2 μl). 
2. The samples were spun in a centrifuge for 30 minutes at 3000 rpm (4°C). 
3. The surnatant was discarded. 
4. The pellet was rinsed with 70 μl of 70% EtOH. 
5. The samples were spun in a centrifuge for 10 minutes at 3000 rpm (4°C). 
6. The surnatant was discarded. 
7. The microplates were spun upside down for 1 minute at 300 rpm, to remove traces of EtOH 
or NaAc. 
8. The pellet was dried at room temperature and stored away from direct light. 
The purified sequencing products were then resuspended in 15μl of Injection Solution (DNA 
Sequencing Reaction Cleanup kit, Millipore) by pipetting up and down several times and/or using a 
microplate shaker. The sequences products were run on the ABI PRISM 3730 DNA analyser 
(Applied Biosystem). 
4.6.8 Sequence Analyses and Prediction tools. 
The sequences were analysed and compared to the reference sequence using the software 
Sequencher 5.0 (Gene Code Corporation). 
We used two online bioinformatic tools to predict the possible impact of non-synonymous coding 
SNPs on the structure and function of the human protein DPD: PolyPhen-2 (Polymorphism 
Phenotyping v2, http://genetics.bwh.harvard.edu/pph2) (Adzhubei et al., 2010) and SIFT (Sorting 
Tolerant From Intolerant, http://sift.jcvi.org) (Kumar et al., 2009). SIFT is a sequence-based 
algorithm that uses sequence homology to predict the effect of amino-acid replacements, assuming 
that important positions in a protein sequence have been conserved throughout evolution. Polyphen-
2 instead is prediction algorithm, that incorporates sequence conservation information and protein 
structure annotations to predict the impact of the non-synonymous change. For SIFT, the score 
ranges from 0 (damaging) to 1 (neutral); for Polyphen-2, the score ranges from 0 (neutral) to 1 
(damaging). 
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4.6.9 Association Analyses with PLINK. 
In order to test whether there is a preferential transmission of the allele A of the splicing variant 
rs3918290 to individuals with ASD compared to the reference allele G, we performed a 
Transmission Disequilibrium Test (TDT) on 8,363 individuals of the AGP cohort (5200 males and 
3163 females). In this large cohort, rs3918290 was successfully genotyped in 2,681 affected 
individuals and their parents, who were all included in this family-based association analysis. The 
test was performed using PLINK v1.07 (http://pngu.mgh.harvard.edu/~purcell/plink), that required 
a .map file with the SNP rs3918290, a .ped file, which specified the relationships among the 
individuals and a phenotype file, that specified their affection status. This analysis returned a p-
value calculated with a χ2 test with one degree of freedom.  
A TDT test was also performed for the SNPs included in the genomic region chr1:97500000-
98598500 (hg19), that covers the genes DPYD and MIR137. We selected a subset of 99 independent 
SNPs (not in LD) out of 900 SNPs present on the Illumina 1M array in this region, using the 
“indep” command from the PLINK analysis suite (http://pngu.mgh.harvard.edu/~purcell/plink). 
SNPs that had missing genotypes in more that 10% of the samples and SNPs that were not in 
Hardy-Weinberg equilibrium were also excluded.  
4.6.10 Analysis of language items of ADI-R and IQ scores in the AGP cohort. 
Since we hypothesized the involvement of DPYD in SLI, we investigated a possible effect of the 
variant rs3918290 on language development of ASD individuals of the AGP cohort. The ASD 
phenotype of the individuals included in this cohort was assessed using the diagnostic tools ADOS-
G and ADI-R. As previously described, ADI-R is structured interview that includes some questions 
regarding speech development and language abilities. The analysis was performed using available 
information for age of first single words (item M9_12_8), age of first single phrases (item 
M10_13_9) and the overall level of current language (item M30_19_14). Age of first single words 
and age of single phrases were expressed in months. Assuming that the ability of saying and using 
few meaningful words is a milestone that should be achieved within 24 months, we classified the 
children in two categories, depending on the age at which they acquired this skill (if the age of first 
words was <24 months, the child had a “normal” speech onset; if it was ≥ 24 months, then was 
considered “delayed”). We also classified the children in two classes depending on age of first 
phrases. The ability to formulate simple phrases should be acquired within 36 months, therefore we 
classified subjects with age of first phrases ≥ 36 months as “severe language-delayed” and subjects 
with age of first phrases < 36 months as “normal”. A similar item is represented by the overall level 
of current language, which evaluates the spontaneous use of social language. Individuals with the 
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ability of formulating phrases with more than 5 words were reported to have “normal” language 
development, whereas individuals unable of formulating phrases with more than 5 words were 
considered to have a “severe delay” in language development. 
For each sub-phenotype, we compared the number of ASD cases carrying the splicing variant 
rs3918290 with the ASD cases wild-type for that SNP, using a χ2 test. 
We also compared verbal, performance and full scale IQ scores of the AGP cases carrying the 
splicing variant rs3918290 with those of the affected individuals wild-type for the SNP. The 
distributions of these scores were analysed with a Wilcoxon Whitney Mann test.  
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      Table 4.2 PRIMERS 
    
      control gene validation by RealtimePCR 
    
      primer name sequence (5'-3') primer size product size (bp) fragment position (Hg19) 
 ZNF423_RT_F ccaacacagtcacaaacaggaa 22 97 chr16:49529702-49529798 
 
ZNF423_RT_R gcctaagcaacagagaatggag 22     
 
      BP1-BP2 deletion validation by RealtimePCR 
    
      primer name sequence (5'-3') primer size product size (bp) fragment position (Hg19) in the figures 
chr15_del_2F ACAGTACAGGGCTGGAGTTTCA 22 97 chr15:22868848-22868944 TUGCP5_ex20 
chr15_del_2R TCATGGATGGTTGACAGATACC 22     
chr15_del_3F CTGAACAAAGAGCTGCGAAGTA 22 95 chr15:23045509-23045603 NIPA1_ex5 
chr15_del_3R GGAGGAATTTGGTATTCTGGTG 22     
chr15_del_4F ggaaacatccttgccagtgt 20 128 chr15:23,661,907-23,662,034 intergenic-fg 
chr15_del_4R aaagcagcaatacattctctcc 22     
      BP4-BP5 duplication validation by RealtimePCR 
    
      primer name sequence (5'-3') primer size product size (bp) fragment position (Hg19) in the figures 
chr15_dupl_1F aatcaggcagaccttgctctt 21 104 chr15:31,908,496-31,908,599 fg1 
chr15_dupl_1R tccagttaattcctcagcatgt 22     
chr15_dupl_2F gctgattctggcctggtagtaa 22 94 chr15:32,085,461-32,085,554 fg2 
chr15_dupl_2R cttgtgtgatgctcttggacac 22     
chr15_dupl_3F agtagccaaggaagtgaagtgc 22 119 chr15:32,403,945-32,404,063 fg3 
chr15_dupl_3R CATCTGGGAAACGAACAGTC 20     
chr15_dupl_4F TAAGGTTCCCTTGGATGATCTG 22 119 chr15:32,929,848-32,929,966 fg4 
chr15_dupl_4R TTCCTCTTTCTGATGGTCTCCT 22     
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ZNF277 deletion validation by RealtimePCR 
    
      primer name sequence (5'-3') primer size product size (bp) fragment position (Hg19) 
 chr7_Fg1_F cagtgtcagggtatgctttcct 22 95 chr7:111,845,306-111,845,400 
 chr7_Fg1_R tacagggctgctgagtgataaa 22     
 
chr7_Fg2_F cagaaatggttgcacgatagaa 22 136 chr7:111957488-111957623 
 chr7_Fg2_R ctgctctaatcaaggtggttcc 22     
 chr7_Fg3_F agtttcctcccatccagacttt 22 127 chr7:111958153-111958279 
 chr7_Fg3_R TGGTATCATTTCGTTCTTGCTG 22     
 
chr7_Fg4_F cctggtttgggaatgataagaa 22 121 chr7:111977177-111977297 
 chr7_Fg4_R gttaaatctggcggtagacagg 22     
 
      ZNF277 screening PCR 
    
      primer name sequence (5'-3') primer size product size (bp) fragment position (Hg19) PCR conditions 
ZNF277_break_F aattgcccagcatccaatta 20 466 (deleted) chr7:111941453-111963297 2.5 Mg
2+ 
 
95°C-55°C-72°C 
(30",30", 30")  
for 30 cycles 
ZNF277_break_R tgacattttcctggggatct 20     
ZNF277_x5_F tgcaaaaacaggaatggaga 20 434 chr7:111958084-111958517  
ZNF277_x5_R tacccctctgctgcttagag 20     
      expression analyses RealtimePCR 
    
      primer name sequence (5'-3') primer size product size (bp) 
GUSB_x8F cacctagaatctgctggctact 22 93 
GUSB_x9R agagttgctcacaaaggtcaca 22   
IMMP2L_x2F ctgtgtggcaagagtagaagga 22 100 
IMMP2L_x3R cctcactttccagtggttcaaa 22   
IMMP2L_x3F ccactggaaagtgaggaattt 21 136 
IMMP2L_x4-5R tttgtgtcctatggttctgaca 22   
RT_DOCK4_ex47F AGCTGTCAACCGATATTCTTCC 22 128 
RT_DOCK4_ex48R AGCTTGAGGTAGATGGACTTGG 22   
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primer name sequence (5'-3') primer size product size (bp) 
RT_DOCK4_ex17F CATGAAGGCCACAAAGGAGT 20 130 
RT_DOCK4_ex18R AGAGAGACAGCCAGTGATCTTG 22   
ZNF277_x1F GAATGCAGGAAGACCGTGAT 20 102 
ZNF277_x2R GACTTTCTGGCAGGGAAAGC 20   
ZNF277_x3F AATTAATTCCACTGCTCCATTTG 23 129 
ZNF277_x5R TGCTGTTGTTCCAGAATTTCTCT 23   
 
 
DPYD screening 
       
     
PCR conditions  
primer name sequence (5'-3') primer size (bp) product size (bp) exon [ Mg
2+
] PCR Program primer for sequencing 
DPYD_x1_F  gcggactgcttttacctttg 20 679 1 2 mM + TD=65°C-60°C (30",30", 30") 10+30 cycles attaaaggccagtccccaga  
DPYD_x1_R aggcttcctgaaatctcttcc 21     DMSO 5%     DMSO 5% 
DPYD_x2_F ggggcctgtaagaggaaatc 20 641 2 2.5 mM 95°C-55°C-72°C (30",30", 30") for 30 cycles 2F 
DPYD_x2_R aatcacggctgtactttaatacct 24           
DPYD_x3_F ttgataacgaaactccactttga 23 426 3 2.5 mM 95°C-55°C-72°C (30",30", 30") for 30 cycles 3R 
DPYD_x3_R tgaatggtggcaatgaactc 20           
DPYD_x4_F aggagtgccaaagatgaaaca 21 363 4 2.5 mM 95°C-55°C-72°C (30",30", 30") for 30 cycles 4F 
DPYD_x4_R tggatttgctaagacaagctg 21           
DPYD_x5_F tgtttgtcgtaatttggctgt 21 327 5 2.5 mM 95°C-55°C-72°C (30",30", 30") for 30 cycles 5R 
DPYD_x5_R tgggtatcaacagagcacca 20           
DPYD_x6_iso1_F gccataactcctcatctacttgac 24 477 6_isoform 1 2.5 mM 95°C-55°C-72°C (30",30", 30") for 30 cycles 6R 
DPYD_x6_iso1_R ccatctgtgagcctgaagtt 20           
DPYD_x7_F aagattggtcaaagattggtca 22 272 7 2.5 mM 95°C-55°C-72°C (30",30", 30") for 30 cycles 7R 
DPYD_x7_R tgcttctgcctgatgtagctt 21           
DPYD_x8_F cactggcttttcttctgcatt 21 392 8 2.5 mM TD=62°C-55°C (30",30", 30") 14+30 cycles 8F 
DPYD_x8_R ggcagtcattcttctggatattg 23           
DPYD_x9_F ttgatttgcttacagatgttttcc 24 351 9 2.5 mM 95°C-55°C-72°C (30",30", 30") for 30 cycles 9F 
DPYD_x9_R aaggttgggtgtgagagctg 20           
DPYD_x10_F tggaaaactgcaagatgcaa 20 377 10 2.5 mM 95°C-55°C-72°C (30",30", 30") for 30 cycles 10F 
DPYD_x10_R gacaatttcaacattctagcgatt 24           
DPYD_x11_F tggtgaaagaaaaagctgcat 21 427 11 2.5 mM 95°C-55°C-72°C (30",30", 30") for 30 cycles 11F 
DPYD_x11_R tgaaaaacaattccctgaaagc 22           
DPYD_x12_F tgtgaggtgtaaagttaagtcagtg 25 589 12 2.5 mM 95°C-55°C-72°C (30",30", 30") for 30 cycles 12F 
DPYD_x12_R tggcccaatttttaatcaact 21           
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DPYD screening 
       
     
PCR conditions  
primer name sequence (5'-3') primer size (bp) product size (bp) exon [ Mg
2+
] PCR Program primer for sequencing 
DPYD_x13_F actcttcatactgcctttgaaatta 25 612 13 2.5 mM 95°C-55°C-72°C (30",30", 30") for 30 cycles 13F 
DPYD_x13_R tatatgcctgccccttcttc 20           
DPYD_x14_F aaaaatgtgagaagggacctca 22 413 14 2.5 mM 95°C-55°C-72°C (30",30", 30") for 30 cycles 14F 
DPYD_x14_R tgcatcagcaaagcaactg 19           
DPYD_x15_F taattccaaagccccaaatg 20 498 15 2.5 mM 95°C-55°C-72°C (30",30", 30") for 30 cycles 15F 
DPYD_x15_R aggtagtgtgtgaaatccaagg 22           
DPYD_x16_F gctgtgatgcagaaaacagaa 21 342 16 2.5 mM 95°C-55°C-72°C (30",30", 30") for 30 cycles 16F 
DPYD_x16_R aaacaatgcagacctggaagt 21           
DPYD_x17_F tcttgcacgtctccagcttt 20 369 17 2.5 mM TD=62°C-55°C (30",30", 30") 14+30 cycles 17R 
DPYD_x17_R tcctgtgtttgtgggatcaa 20           
DPYD_x18_F  aagagctgcatgaaaatgttg 21 250 18 2.5 mM TD=65°C-60°C (30",30", 30") 10+30 cycles 18R 
DPYD_x18_R gggatcataaagggcacaaa 20           
DPYD_x19_F  aacatccattaacaaattaacatgc 25 394 19 2.5 mM TD=62°C-55°C (30",30", 30") 14+30 cycles 19F 
DPYD_x19_R cattgcatttgtgagatggag 21           
DPYD_x20_F atcatgcctcaaacagtgc 19 461 20 2.5 mM TD=62°C-55°C (30",30", 30") 14+30 cycles 20R 
DPYD_x20_R tggctgtaatcaagtctccttc 22           
DPYD_x21_F catgaaacaatccctagacaca 22 479 21 2.5 mM TD=62°C-55°C (30",30", 30") 14+30 cycles 21R 
DPYD_x21_R catgcttgccagtgttctaaa 21           
DPYD_x22_F aaaaacaggaaaatgctgagtg 22 378 22 2.5 mM TD=62°C-55°C (30",30", 30") 14+30 cycles 22R 
DPYD_x22_R gggtgacaggacagaaagatg 21           
DPYD_x23_F tcatagtgtggctcctctgc 20 366 23 (coding) 2.5 mM TD=62°C-55°C (30",30", 30") 14+30 cycles 23F 
DPYD_x23_R TGGAAAGAGCTGAACACAAGG 21           
DPYD_x6_iso2_F tttcaaaaaccctgaaactaagtaa 25 444 6_isoform2 
(coding)  
2.5 mM 95°C-55°C-72°C (30",30", 30") for 40 cycles 6_iso2_F 
DPYD_x6_iso2_R GGAAGGGTCCCAAAATGAAA 20         
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Chapter 5 
Results 
Screening for Copy Number Variants in a SLI cohort. 
5.1. Detection of CNVs. 
In order to investigate the role of CNVs in the genetic risk for SLI, 542 individuals, belonging to 
170 families recruited by the SLI Consortium, were genotyped using the Illumina Human 
OmniExpress (v12.1) beadchip, which includes more than 700,000 SNPs. This cohort was formed 
by probands, parents, affected and unaffected siblings.  
SNP data were analysed using the CNV detection algorithms PennCNV and QuantiSNP, which 
utilise the Log R ratio and B allele frequency to identify (“call”) CNVs across the genome.  
The quality of the CNVs predicted by each algorithm was examined as described in Materials and 
Methods. Following quality control, the predicted CNVs were taken forward if they were found to 
have been called by both algorithms and the algorithm calls overlapped by 50% or more each way. 
This generated a list of “high-confidence” calls, that included 6,229 CNVs for the entire cohort. As 
a further control, we checked the distribution of CNVs across the cohort and found that the number 
of CNVs per individual, including chromosome X, ranged from 0 to 324 (Figure 5.1), with a mean 
of 11.41 and a median of 11. The majority of the individuals (97%) carried 5-20 CNVs.  
A CNV screen performed on a control population of 1,000 US Caucasian subjects, genotyped with 
the Affymetrix GeneChip Mapping 500K array (Li et al., 2009), found an average of ~9 autosomic 
CNVs/individual, ranging from 1 to 32.  
Since the majority of the SLIC individuals had an average number of CNVs that matched with these 
estimates, while two samples had more than 50 predicted CNVs, we decided to exclude these 
individuals from further analyses, that were performed then on a group of 540 subjects (total 
number of “high-confidence” CNVs =5835). In this sample set, the number of CNVs per person 
ranged from zero to 43, with a mean of 10.72 and a median of 10.5.  
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Figure 5.1. Distribution of the average number of CNVs per each person of the SLIC cohort included in the CNV 
screening (n=542). 
Moreover, we looked at the amount of kilobases globally spanned by CNVs in each individual. We 
found that the mean of kb included by CNVs in each person was 731.6 kb and the median of kb 
included by CNVs was 567.2, ranging from 0 to 14793.6 kb. For the majority of the subjects (96%), 
the burden of CNVs involved a portion of the genome that ranges from 150 kb to 2,500 kb (Figure 
5.2). Nine individuals had a CNV burden of more than 2,500 kb. At the extreme, one sample was 
predicted to have a CNV burden of ~15,060 kb, given by 30 CNVs: 3 of them, falling in intergenic 
regions, had a size >3.5 Mb kb each.  
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Figure 5.2. Distribution of the total number of kilobases (kb) spanned by the CNVs per each person of the SLIC cohort 
included in the CNV screening (n=540). 
73% (n=4247) of the identified CNVs were deletions (Figure 5.3), a number significantly higher 
compared to the duplications (T-test p-value <0.0001). The duplications resulted to be significantly 
larger (142.1 kb vs 45.9 kb, T-test p-value <0.0001). A higher number of deletions and larger 
duplications reflect the trend which is usually observed in the general population (Shaikh et al., 
2009). 
 
Figure 5.3. The graph shows the enrichment of the deletions (n=4247) compared to the duplications (n=1588) identified 
in the CNV screening performed in the SLIC cohort. 
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5.2 CNV burden analyses. 
From the entire cohort, 214 individuals were selected to investigate the burden between cases and 
controls. This analysis included 174 individuals (98 independent individuals and 38 sibling pairs, 
total number of independent individuals =136) classified as language-impaired cases and 40 
siblings (36 independent subjects and two sibling pairs) as unaffected and selected as “super-
controls”. 25 super-controls were related to individuals included in the group of cases. Taking into 
account the overlapping families between the two groups, the total number of cases and super-
controls represented 148 independent families. The remaining children had intermediate language 
ability and were defined to have “unknown” language status. These individuals were removed from 
the following analyses.  
Although the size of this control sample set was very small and included related individuals, we 
decided to perform an exploratory CNV burden analysis using these internal controls, since a larger 
group of unaffected individuals genotyped on the same SNP array (Illumina Human OmniExpress 
v12.1), and therefore with CNVs called with the same genomic coverage and resolution, was not 
available at the time of the analysis. 
When the analysis was restricted to the language-impaired cases and the super-controls, the list of 
CNVs included 2393 calls (Table 5.1). The burden analysis was performed using PLINK to test 
whether the language-impaired cases presented a higher global burden of CNVs compared to 
unaffected siblings. This analysis consists of several tests that examine the number of CNVs per 
person, average size of CNV, total length of CNVs, and the number of genes spanned by CNVs. No 
significant differences in CNV burden were observed between cases and controls, as shown by 
Table 5.1. 
Burden analysis Tests (cases versus controls) TEST AFF UNAFF P-value 
No. of segments (CNVs) N 1963 430  
Average no. of segments (CNVs) RATE 11.28 10.49 0.18 
Proportion of sample with one or more segment PROP 1 1 1 
Total kb length spanned TOTKB 798.5 622.5 0.06 
Average segment size AVGKB 69.81 63.06 0.21 
No. regions/genes spanned by CNVs GRATE 14.17 13.46 0.45 
No. CNVs with at least one gene GPROP 0.95 0.98 0.88 
No. regions/genes per total CNV kb GRICH 0.02 0.02 0.86 
Table 5.1. Results of the PLINK burden analysis performed on the list of CNVs detected in cases and controls.  
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5.3 Detection of rare and novel events. 
Then we focused on the rare and novel CNVs. Common CNVs were classified as those that 
overlapped more than 50% or five or more times with the CNVs reported in the Database of 
Genomic Variants (DGV) database (version of January 2012). After filtering out the common 
CNVs, the remaining CNVs were classified as: 
 Rare CNVs, if they overlapped with a CNV in the DGV by <50% and 5 or less times;  
 Novel CNVs, if they did not appear in the DGV. 
484 rare and novel CNVs were identified within 294 of the initial individuals (Figure 5.4). The 
number of deletions significantly exceeded the number of duplications (T-test p-value<0.0001) in 
the category of novel CNVs and when considering novel and rare CNVs together. Again, in the 
total group of rare and novel CNVs, the average size of duplications resulted to be significantly 
larger than for deletions (74.3 kb vs 38.2 kb, T-test p-value<0.0001). 
 
Figure 5.4. 484 rare and novel CNVs: comparison of the total number of deletions and duplications for each category of 
CNVs (rare, novel or rare and novel CNVs). 
Within the class of rare and novel CNVs, we found 284 CNVs overlapping RefSeq genes. All 
predicted CNVs require a validation (for example by qPCR) before performing in depth analyses 
for CNV burden or pathway enrichment analyses. To prioritize the validation of CNVs, we can 
focus on events that are more likely to have a deleterious effect. For this reason, we compiled a list 
of rare and novel CNVs overlapping exons. The list of rare and novel exonic deletions (Table 5.2) 
and duplications (Table 5.3) detected in the individuals classified as affected is reported. Rare and 
novel exonic events identified in the group of “super-controls” are also reported, in order to 
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evaluate which genes are affected by CNVs that are specific of language impaired cases and are 
absent in unaffected siblings. 
RARE AND NOVEL EXONIC DELETIONS 
Indiv. ID affection Coordinates (hg19) cn score RefSeq Genes 
C94_3 affected chr1:93639101-93651547 1 13.432 CCDC18 TMED5 
E10_4 unaffected chr1:206317334-206329582 1 148.244 CTSE 
E18_3 affected chr1:206317334-206329582 1 134.387 CTSE 
E22_3 affected chr1:206317334-206329582 1 13.991 CTSE 
G69_5 affected chr1:206317334-206329582 1 126.542 CTSE 
C61_4 affected chr1:226018027-226020988 1 181.415 EPHX1 
GCC8_3 unaffected chr2:37241050-37285840 1 19.951 HEATR5B 
G85_3 affected chr2:183244353-183307061 1 514.243 PDE1A 
G25_3 affected chr3:7348129-7391647 1 79.048 GRM7 
E18_5 affected chr6:151865531-151869219 1 128.395 C6orf97 
G65_4 affected chr7:1022728-1052353 1 16.345 CYP2W1 C7orf50  
C26_4 affected chr7:16567628-16576251 1 197.496 LRRC72 
E38_3 affected chr7:81788703-81926808 1 182.705 CACNA2D1 
GCC8_5 unaffected chr7:91588036-91610111 1 15.908 AKAP9 
C4_4 affected chr10:74268031-74362355 1 142.423 MICU1 MIR1256 
G25_3 affected chr11:5255221-5261374 1 236.651 HBD 
G25_4 affected chr11:5255221-5261374 1 29.177 HBD 
G20_5 affected chr11:74771478-74806005 1 17.978 OR2AT4 
G20_6 affected chr11:114163716-114173835 1 184.421 NNMT 
E13_3 affected chr11:118055801-118076069 1 170.047 AMICA1 
E24_4 affected chr12:3859449-3872140 1 154.762 EFCAB4B 
C42_4 affected chr12:54568590-54593953 1 25.449 SMUG1 
C42_4 affected chr12:111946837-111979060 1 14.519 ATXN2 
C88_4 affected chr12:123792848-123825559 1 12.845 SBNO1 
E39_3 affected chr13:92408505-92524032 1 699.837 GPC5 
E39_4 affected chr13:92408505-92524032 1 105.795 GPC5 
E39_6 affected chr13:92408505-92524032 1 92.675 GPC5 
E6_3 affected chr16:55618451-55623080 1 103.719 LPCAT2 
G77_3 unaffected chr17:2227855-2247982 1 16.101 TSR1 SRR SNORD91B SNORD91A SGSM2 
G20_5 affected chr17:19998377-20103560 1 141.521 SPECC1 
GCC8_5 unaffected chr18:29193385-29207155 1 102.765 B4GALT6 
M19_3 affected chr18:77914538-77916015 1 10.565 PARD6G-AS1 PARD6G 
G69_3 unaffected chr22:25315753-25403765 1 34.917 SGSM1 TMEM211 
Table 5.2. The table lists rare and novel exonic deletions found in affected individuals and super-controls. CNVs 
indicated in bold were predicted to be de novo (see Table 5.4). For each CNV, copy number (cn) and confidence score 
of the algorithm prediction (score) are reported. 
One of the interesting deletions that emerge from this list, detected in one affected individual, 
E38_3, is an intragenic copy loss of exon 4 in CACNA2D1, a gene coding for the α2-δ1 subunit of 
Voltage-dependent calcium (Cav) channels. This gene is expressed in several tissues, including the 
CNS (Dolphin, 2013). In particular, in rat brains, its mRNA has been found in areas important for 
learning and memory, such as neocortex, hippocampus cerebellum and baso-lateral amigdala (Cole 
et al., 2005). Moreover, CACNA1C, the gene coding for the α1-C subunit of L-type voltage-gated 
calcium channel, is a widely recognized susceptibility gene for schizophrenia and bipolar disorder 
(Bhat et al., 2012) and it is involved in learning, memory and brain plasticity. Since memory 
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deficits seem to be an important contributing factor for SLI, CACNA2D1 is an interesting functional 
candidate gene for language impairment.  
RARE AND NOVEL EXONIC DUPLICATIONS 
Indiv. ID affection Coordinates (hg19) cn score RefSeq Genes  
G20_5 affected chr1:27930898-27973748 3 14.088 FGR 
G14_5 unaffected chr1:111415841-111422817 3 11.084 CD53 
G62_4 unaffected chr1:153023650-153042554 3 13.979 SPRR2A 
M68_4 affected chr1:185110367-185128250 3 141.907 SWT1 TRMT1L 
G12_3 affected chr1:198574902-198609305 3 10.097 PTPRC 
G14_3 affected chr1:198599301-198660724 3 24.11 PTPRC 
G20_5 affected chr1:198601197-198656407 3 17.784 PTPRC 
C55_3 affected chr2:28846035-28920335 3 768.149 PLB1 
E5_3 affected chr2:37247717-37285840 3 115.403 HEATR5B 
G42_3 affected chr2:98620765-98814054 3 95.129 VWA3B 
G14_5 unaffected chr2:197045077-197123318 3 15.24 HECW2 
E9_3 affected chr2:201766236-201943431 3 25.018 FAM126B NDUFB3 NIF3L1 ORC2 
G12_3 affected chr2:201823460-201943431 3 12.955 FAM126B NDUFB3 ORC2 
C20_5 affected chr4:15791464-15840839 3 142.645 CD38 
E38_4 affected chr4:39426809-39572921 3 100.138 C4orf34 KLB LIAS LOC401127 RPL9 UGDH 
M68_4 affected chr4:76712173-76824078 3 568.956 PPEF2 USO1 
G14_5 unaffected chr5:39172131-39222427 3 16.134 FYB 
E15_3 affected chr5:151273630-151357064 3 568.113 GLRA1 
E45_4 unaffected chr6:74315347-74382213 3 291.513 SLC17A5 
G20_5 affected chr6:109758678-109775436 3 11.941 MICAL1 PPIL6 SMPD2 
M39_3 affected chr7:5133936-5240541 3 36.187 WIPI2 ZNF890P 
E5_3 affected chr7:129709081-129738451 3 107.987 KLHDC10 
E30_4 affected chr9:2718654-2735415 3 269.613 KCNV2 
C17_3 affected chr9:138518114-138555161 3 45.777 GLT6D1 
G16_3 affected chr10:17080633-17211383 3 134.74 CUBN TRDMT1 
G16_4 unaffected chr10:17080633-17211383 3 123.9 CUBN TRDMT1 
G20_5 affected chr10:73500599-73521371 3 151.475 C10orf54 CDH23 
G20_5 affected chr11:63971083-64055905 3 15.331 BAD DNAJC4 FERMT3 FKBP2 GPR137 NUDT22 PLCB3 
PPP1R14B STIP1 TRPT1 VEGFB 
G60_4 affected chr11:122430752-122684597 3 33.445 UBASH3B 
C95_3 affected chr11:122455520-122675454 3 26.886 UBASH3B 
G14_5 unaffected chr12:15089416-15119104 3 12.789 ERP27 ARHGDIB 
M69_4 affected chr12:112219696-112298257 3 407.208 ALDH2 MAPKAP5 
G45_3 affected chr13:46168409-46274638 3 431.298 FAM194B 
G34_4 affected chr14:68026119-68036445 3 18.683 PLEKHH1 
E39_3 affected chr15:71432350-71466241 3 215.547 THSD4 
E39_4 affected chr15:71432350-71466241 3 132.718 THSD4 
M18_3 affected chr15:78907656-78974545 3 15.855 CHRNA3 CHRNB4 
G50_3 unaffected chr16:9288453-9356311 3 177.691 MIR548X 
G14_5 unaffected chr18:2634848-2705700 3 21.106 CBX3P2 SMCHD1 
E37_5 unaffected chr18:9942075-10056733 3 553.227 VAPA 
G87_3 affected chr19:15710360-15732070 3 79.078 CYP4F8 
E1_4 unaffected chr19:58397475-58417426 3 107.728 ZNF814 ZNF417 
M19_3 affected chrX:35827927-36025401 3 52.77 CXorf22 LOC101928564 
E45_5 affected chrX:64346959-64764336 3 21.928 ZC3H12B LAS1L 
GCC13_0 affected chrX:73422412-73564051 3 160.484 FTX MIR421 MIR374B MIR374C ZCCHC13 MIR545 MIR374A 
Table 5.3. The table lists rare and novel exonic duplications found in affected individuals and super-controls. CNVs 
indicated in bold were predicted to be de novo (see Table 5.4). For each CNV, copy number (cn) and confidence score 
of the algorithm prediction (score) are reported. 
A duplication predicted to involve the first two exons of the gene KLHDC10 (kelch domain 
containing 10, OMIM 615152) might be interesting. This gene has been found mainly to be 
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involved in the activation of apoptosis signal-regulating kinase-1 via its kelch repeat domain in 
response to oxidative stress (Sekine et al., 2012). However, a disrupting deletion in a gene of the 
same family, KLHL23, has been found in a ASD family (Holt et al., 2012). Moreover, 3 kelch 
proteins (KLHL17, KLHL22 and LZTR-1) emerged from a functional category enrichment analysis 
of genes hit by de novo CNVs in schizophrenia (Malhotra et al., 2011). De novo mutations with 
large effect are rare, because of purifying selection, therefore the occurrence of de novo mutations 
in the same gene or genes with related functions in multiple unrelated patients might indicate that 
these genes are implicated in the disorder. Therefore, it is possible that rare variants affecting kelch-
proteins might contribute to neuropsychiatric disorders. Further characterization of this CNV will 
be required.  
5.4 Detection of De Novo CNVs. 
167 individuals from 92 families (87 affected individuals, 28 unaffected individuals and 52 of 
unknown affection status) had both parents available for analysis, allowing the identification of 
putative de novo CNVs within the PennCNV trio and quartet-based CNV calling algorithms.  
A total number of 84 de novo CNVs was identified within 60 individuals (28 affected individuals, 
11 unaffected individuals and 21 with affection status unknown) (Figure 5.5). In this total group of 
subjects, we identified more deletions (63.1%, n=53), than duplications (36.9%, n=31), in line with 
that observed for all high-confidence events. However, this difference is not driven by the subset of 
the individuals with a full diagnosis of SLI (affected), as they carry a similar number of putative de 
novo deletions and duplications. 
 
Figure 5.5. Distribution of putative de novo deletions and duplications among affected individuals (n=28), unaffected 
individuals (n=11) and subjects with unknown affection status (n=21). 
Affected  Unaffected  Unknown 
ALL 
samples 
No. Duplications 18 8 5 31 
No. Deletions 22 6 25 53 
0 
10 
20 
30 
40 
50 
60 
to
ta
l 
n
o
. 
o
f 
d
e
 n
o
v
o
 C
N
V
s
 
Results 
 
109 
 
Generally, de novo CNVs are particularly interesting, as deleterious mutations not inherited from 
the parents may account for sporadic cases of a disorder (i.e. affected individuals with no family 
history of the disease) and might be extremely useful for the identification of new candidate genes. 
As for the class of rare and novel CNVs, also for putative de novo CNVs, we filtered the CNVs for 
gene content to prioritize the validation of this group of variants. We identified 43 CNVs 
overlapping RefSeq Genes, 25 of which were deletions (Table 5.4) and 18 were duplications 
(Table 5.5).  
De novo genic deletions 
IID affection Coordinates (hg19) cn score Ref Seq Genes  exonic/intronic 
G38_3 unaffected chr3:189738195-189739056 0 231.736 LEPREL1 intronic 
G72_4 unknown chr3:189738195-189739056 0 24.046 LEPREL1 intronic 
G6_4 affected chr8:51031221-51033517 0 23.929 SNTG1 intronic 
G33_5 affected chr10:54016099-54016782 0 16.498 PRKG1  intronic 
E45_5 affected chr1:25598276-25642596 1 160.905 RHD  exonic 
G45_5 unknown chr1:211447625-211466761 1 137.472 RCOR3 exonic 
E12_3 affected chr2:65486928-66364645 1 690.822 ACTR2 SPRED2  exonic  
E29_3 affected chr4:120289042-120381341 1 17.087 LINC01061 LOC645513 exonic 
G45_5 unknown chr5:142770135-142776684 1 126.311 NR3C1 intronic 
M28_3 affected chr5:148883634-148903068 1 125.178 CSNK1A1 exonic 
G65_3 unknown chr5:152968158-153023165 1 46.367 GRIA1 intronic 
G65_4 affected chr7:1022728-1052353 1 16.345 CYP2W1 C7orf50 exonic 
G45_5 unknown chr8:79622363-79643639 1 17.64 ZC2HC1A LOC101241902 exonic 
G33_5 affected chr11:18949220-18956690 1 166.263 MRGPRX1 exonic 
E20_3 affected chr11:55365761-55427700 1 34.539 OR4C11 OR4P4 OR4S2 exonic 
G16_4 unaffected chr11:55365761-55427700 1 16.6 OR4C11 OR4P4 OR4S2 exonic 
G45_5 unknown chr11:72778457-72800970 1 129.526 FCHSD2 exonic 
E45_4 unaffected chr11:84841573-84918098 1 44.775 DLG2 exonic 
C47_4 unknown chr11:114170465-114173835 1 130.554 NNMT intronic 
M41_4 unknown chr14:50098031-50129548 1 146.715 DNAAF2 POLE2 exonic 
E44_4 unknown chr14:104164522-104169017 1 134.257 KLC1 XRCC3 exonic 
G45_5 unknown chr15:62316035-62340126 1 134.882 VPS13C exonic 
E13_4 unknown chr16:32137965-32392598 1 11.283 LOC390705 TP53TG3D HERC2P4  exonic 
M19_3 affected chr18:77914538-77916015 1 10.565 PARD6G-AS1 PARD6G exonic 
E6_4 affected chr19:53932295-54004939 1 43.974 TPM3P9 ZNF761 ZNF813 exonic 
Table 5.4. List of predicted de novo genic deletions detected in children of the SLIC cohort. CNVs were found in SLI 
cases, unaffected individuals and individuals whose affection status was classified as “unknown”. The overlap with 
exonic or intronic regions of RefSeq Genes (UCSC Genome Browser, hg19) is also indicated. For each CNV, the copy 
number (cn) and the minimum confidence score from QuantiSNP or PennCNV (score) are also reported. Rare/novel de 
novo CNVs are highlighted in bold. 
Among the rare genic de novo deletions, we found an intronic copy loss in the gene GRIA1 (OMIM 
138248), which maps on chromosome 5q31.1 and codes for the subunit GluR1 of the ionotropic 
glutamate receptor AMPA1. Glutamate receptors are the predominant receptors mediating 
excitatory neurotransmission in the mammalian brain. In particular, GRIA1 has been shown to play 
an important role in learning processes and memory (Lee and Kirkwood, 2011; Mead and Stephens, 
2003) and it is one of candidate genes for schizophrenia (Ayalew et al., 2012). Therefore, this gene 
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is an intriguing functional candidate gene for a neurodevelopmental disorder like SLI. Although the 
deletion is predicted to be intronic, in Table 5.4 we report here the minimal predicted coordinates 
by PennCNV and QuantiSNP, therefore it might be possible that the deletion could be larger than 
estimated and might encompass the adjacent exon. Validation will be required to define the CNV 
breakpoints more accurately.  
De novo genic duplications 
IID affection Coordinates (hg19) cn score Ref Seq Genes exonic/intronic 
G12_3 affected chr2:61107207-61171045 3 109.997 LINC01185 REL PUS10 exonic 
G57_5 unaffected chr4:58053743-58098554 3 361.955 IGFBP7-AS1 exonic 
E25_4 unknown chr6:35356143-35356640 3 15.722 PPARD intronic 
E5_3 affected chr7:129709081-129738451 3 107.987 KLHDC10 exonic 
C47_3 unknown chr8:73602555-73635954 3 389.609 KCNB2 intronic 
E49_4 unaffected chr8:144611729-144697653 3 45.583 
ZC3H3 GSDMD MROH6 NAPRT1 EEF1D TIGD5 
TSTA3 PYCRL 
exonic 
E5_3 affected chr8:144974963-145018354 3 17.911 PLEC exonic 
E49_4 unaffected chr9:139693596-139947473 3 50.851 
CCDC183 CCDC183-AS1 RABL6 MIR4292 
C9orf172 PHPT1 MAMDC4 EDF1 TRAF2 
MIR4479 BC034456 FBXW5 C8G LCN12 PTGDS 
LCNL1 C9orf142 CLIC3 ABCA2 C9orf139 FUT7 
NPDC1 ENTPD2 CCDC183 CCDC183-AS1 
C9orf139 C9orf142 C9orf172 
exonic 
E33_3 affected chr11:54794237-55035985 3 20.579 TRIM48 exonic 
E49_4 unaffected chr11:55367889-55427700 3 30.34 OR4C11 OR4P4 OR4S2 exonic 
E12_4 unaffected chr11:64570925-64606177 3 14.197 MEN1 CDC42BPG exonic 
G68_4 unknown chr15:24409977-24714849 3 53.014 PWRN2 exonic  
G35_3 unaffected chr16:1807723-1842209 3 17.301 
MAPK8IP3 NME3 MRPS34 EME2 SPSB3 NUBP2 
IGFALS 
exonic 
G50_3 unaffected chr16:9288453-9356311 3 177.691 MIR548X exonic 
G16_3 affected chr16:34546530-34687052 3 145.404 RP11-488I20.3 exonic 
G33_5 affected chr17:44165803-44350090 3 34.099 KANSL1 KANSL1-AS1 exonic 
G16_3 affected chr17:44238126-44350090 3 15.542 KANSL1 KANSL1-AS1 exonic 
M28_3 affected chr22:21105255-21463730 3 185.271 
PI4KA SERPIND1 SNAP29 CRKL AIFM3 LZTR1 
THAP7 THAP7-AS1 TUBA3FP P2RX6 SLC7A4 
Mir_649 P2RX6P LOC400891 BCRP2 P2RX6P 
exonic 
Table 5.5. List of predicted de novo genic deletions detected in children of the SLIC cohort. CNVs were found in SLI 
cases, unaffected individuals and individuals whose affection status was classified as “unknown”. The overlap with 
exonic or intronic regions of RefSeq Genes (UCSC Genome Browser, hg19) is also indicated. For each CNV, the copy 
number (cn) and the minimum confidence score from QuantiSNP or PennCNV (score) are also reported. Rare/novel de 
novo CNVs are highlighted in bold. 
The 17q21.31 deletion syndrome, a multisystem disorder characterized by ID, hypotonia and 
distinctive facial features, is caused by haploinsufficiency of KANSL1, which encodes an 
evolutionarily conserved regulator of the chromatin modifier KAT8 (Koolen et al., 2012). 
Reciprocal microduplications (~ 500-650 kb) in this region have been also described, generally, in 
association with variable, but milder phenotypes (Grisart et al., 2009; Kitsiou-Tzeli et al., 2012). 
We identified two smaller duplications on chromosome 17q21.31 (Table 5.5), encompassing the 5’ 
end of the gene KANSL1, in two unrelated affected individuals. The region presents frequent 
microduplication in the general population. Looking at the number of gains overlapping the interval 
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chr17:44165803-44350090, we estimated that a duplication in this region (of different length) can 
be found in ~5.4% of healthy individuals. However, the validation and the characterization of these 
de novo events might be interesting and these duplications might reveal other contributing factors to 
SLI. 
5.5 CNVs in candidate genes. 
In addition to genic rare/novel or de novo CNVs, rare homozygous deletions predicted to have a 
deleterious effect on genes can be another interesting source for the identification of new candidate 
genes. As an example, we identified an exonic homozygous copy loss in the ZNF277 gene, on 
chromosome 7q31.1, in the proband G4_4. The minimum predicted size of the deletion included 
only exon 5. The lack of this exon (92 bp) causes a frameshift in the transcript, introducing a 
premature stop codon in the mRNA. Therefore, the complete absence of exon 5, predicted to alter 
the ZNF2777 transcript and possibly causing nonsense mediated decay (NMD), appeared to be an 
interesting finding to follow-up. We decided then to validate and investigate its possible role in SLI 
genetic risk (Chapter 6).   
5.6 CNVs on chromosome 15q11-q13. 
In addition to the previously mentioned classes of rare, novel and de novo CNVs, we identified rare 
CNVs in the region 15q11-q13. CNVs in this locus are rare in the general population, but they are 
recurrently found in a range of neurological conditions, including ID, ASD, schizophrenia, epilepsy 
and language delay (Burnside et al., 2011; Cooper et al., 2011; Moreno-De-Luca et al., 2013; 
Shinawi et al., 2009; Stefansson et al., 2008), as described in chapter 1 (paragraph 1.5), suggesting 
that they might be variants with variable expressivity implicated in different neuropsychiatric 
phenotypes. In the SLIC cohort two interesting types of CNVs on chromosome 15q11-q13 were 
identified and validated: microdeletions between the breakpoints BP1 and BP2 and 
microduplications between BP4 and BP5. 
Microdeletions in the BP1-BP2 region were predicted in two families - family G46, with a size of 
475,950 bp (chr15:22750305-23226254), and family E21, with a size of 522,429 bp 
(chr15:22750305-23272733), as shown by the Figure 5.6. These deletions include four non-
imprinted genes (TUBGCP5, CYFIP1, NIPA1 and NIPA2) and were confirmed by qPCR, using two 
primer pairs, one designed in exon 20 of TUBGCP5 and another one in exon 5 of NIPA1.  
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Figure 5.6. BP1-BP2 region on chromosome 15q and the Refseq genes present in this region (UCSC Genome Browser, 
hg19). The deletions identified in this region are indicated as red bars. The three PCR fragments used for the Realtime 
validation are indicated. 
qPCR confirmed that the deletion in family G46 was present in the proband G46_4, inherited from 
the mother G46_2 (Figure 5.7 a). The event was absent in the sibling G46_3, who also had SLI, 
and the sibling G46_5, who was not severely enough affected to be classified as SLI but had 
expressive language score 1.3 SD below that expected for his age. DNA was not available for the 
father G46_1.  
 
Figure 5.7. Validation of the BP1-BP2 deletion in family G46 by qPCR. A. The graph shows a heterozygous deletion in 
G46_2 and G46_4, that includes the fragments in TUBGCP5_ex20 and in NIPA1_ex5. The third fragment was 
localized in an intergenic region outside the predicted CNV. B. Pedigree of family G46. The children G46_3 and G46_4 
were both affected, while the affection status of G46_5 was classified as unknown as his expressive language 
difficulties were not extreme enough to warrant a diagnosis of SLI.  
 
The two affected children both had low expressive language scores and receptive language scores, 
but the proband G46_4 had lower performance scores for the NWR test compared to the rest of the 
family (Table 5.6). 
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individual  ELS RLS NWR 
G46_1 father    
G46_2 mother   81 
G46_3 Affected brother 59 72 76 
G46_4 proband 54 76 55 
G46_5 Brother (borderline affected) 80 97 96 
Table 5.6. Phenotypic test scores for family G46 (CELF-R Expressive language score ELS; CELF-R Receptive 
language score RLS, Nonword repetition scores NWR) All scores are age-normalised and have a population mean of 
100 and a SD of 15. SLI is diagnosed in our data set as expressive or receptive language abilities at least 1.5 SD below 
that expected for chronological age.  
In family E21, a BP1-BP2 deletion was present in the father E21_1 and inherited by E21_5, whose 
affection status is unknown as CELF data were not available, but who has NWR performance in the 
normal range for her age. The CNV was absent in the proband E21_3 and the sibling E21_4, who 
also has missing CELF data but NWR performance in the normal range (Figure 5.8). 
 
Figure 5.8. A. Validation of the BP1-BP2 deletion in family E21 by qPCR. The graph shows a heterozygous deletion in 
E21_1 and E21_5 (fragments TUBGCP5_ex20 and NIPA1_ex5). The third fragment was localized in an intergenic 
region outside the predicted CNV. B. Pedigree of family E21. Affection status was unknown for the children E21_4 and 
E21_5.   
Phenotypic data for all siblings of family E21 was available only for the NWR test and the scores 
were in the normal range for all the children. Expressive and receptive language scores instead, 
necessary to determine the affection status, were available only for the proband, who did not carry 
the deletion (Table 5.7). 
individual  ELS RLS NWR 
E21_1 father   88 
E21_2 mother   94 
E21_3 proband 86 107 99 
E21_4 sister   93 
E21_5 sister   92 
Table 5.7. Phenotypic test scores for family E21 (Expressive language score ELS; Receptive language score RLS, 
Nonword repetition scores NWR).  
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BP4-BP5 microduplications involving CHRNA7 were detected in three families: G68, G79 and E38 
(Figure 5.9). In the three families, this duplication was predicted to occur together with a deletion 
of the 5’ of LOC100288637 and the 3’ end of an isoform of ARHGAP11B (UCSC isoform 
uc001zeu.3) (chr15: 30936285-30968006, minimum length= 31,721 bp), overlapping with the 
segmental duplications of BP4 and reported to accompany the majority of the microduplications 
involving CHRNA7 (Szafranski et al., 2010).  
Results 
 
115 
 
 
Figure 5.9. BP4-BP5 region on chromosome 15q and the UCSC genes present in this region (UCSC Genome Browser, hg19). The duplications identified in this region are 
indicated as red bars, the deletions as blue bars. The four PCR fragments used for the qPCR validation are indicated as fragments 1-4. 
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Again, all predicted BP4-BP5 events were verified by qPCR across each of the family units. In 
family G68, the CNV (chr15:32018731-32514341, predicted size: 495,611 bp) was predicted to be 
present in the mother G68_2, but not transmitted to the children, two of them with full diagnosis of 
SLI (G68_3 and G68_5) and one with affection status unknown (G68_4), but with expressive and 
receptive language problems (Table 5.8). The presence and the segregation of this duplication was 
checked by qPCR in the entire family, except for the proband G68_5, for whom DNA was not 
sufficient for the experiment (Figure 5.10). The CNV was demonstrated to be absent in the other 
two children, G68_3 and G68_4. Using the available SNP data for all the member of the family, we 
performed a haplotype analysis of this genomic region with the program Merlin and we found that 
all the children share the same maternal haplotype for the BP4-BP5 locus, therefore, we excluded 
the presence of the duplication also in G68_5. 
 
Figure 5.10. A. Validation of the BP4-BP5 deletion in family G68 by qPCR. Fragments 2 and 3 were designed inside 
the region predicted to be duplicated, the fragments 1 and 4 instead in the region outside, as indicated in the previous 
figure 5.9. The graph shows that the duplication was present only in G68_2. G68_5 was not tested. B. Pedigree of 
family G68. G68_3 and G68_5 are affected (black filling), the affection status of G68_4 was classified as unknown, but 
he displayed some expressive and receptive language deficits (grey filling). 
individual  ELS RLS NWR  
G68_1 father   104 
G68_2 mother   64 
G68_3 affected brother 73 105 92 
G68_4 brother 78 80 105 
G68_5 proband 76 80 73 
Table 5.8. Phenotypic test scores for family G68 (Expressive language score ELS; Receptive language score RLS, 
Nonword repetition scores NWR). G68_3 and G68_5 are classified as affected, G68_4 was classified to have unknown 
affection status. 
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In family G79, the BP4-BP5 duplication (chr15:32018731-32514341, predicted size: 495,611 bp) 
was transmitted from the father to three children G79_4, G79_5, G79_6 and the segregation of the 
CNV was confirmed by qPCR (Figure 5.11).  
 
Figure 5.11. A. Validation of the BP4-BP5 deletion in family G79 by qPCR. Fragments 2 and 3 were designed inside 
the region predicted to be duplicated, the fragments 1 and 4 instead in the region outside, as indicated in the previous 
figure 5.9. The graph shows that the duplication was present in G79_1, G79_4, G79_5 and G79_6. B. Pedigree of 
family G79. G79_5and G79_6 are affected (black filling), the affection status of G79_4 was classified as unknown, but 
he displayed some language problems (grey filling). 
The proband G79_5 obtained low scores in all the phenotypic tests. His younger sibling, who also 
inherited the microduplication, appeared to have an expressive language impairment but performed 
in the normal range on the tests of receptive language ability and non-word repetition. The eldest 
brother (G79_3) did not inherit the duplication and performed in the normal range in all tests. The 
remaining child (G79_4) inherited the duplication and showed lower scores than expected in the 
tests of expressive language and nonword repetition but not bad enough to be labelled as “affected” 
(Table 5.9).  
individual  ELS RLS NWR 
G79_1 father    
G79_2 mother    
G79_3 unaffected brother 108 112 98 
G79_4 brother 84 105 76 
G79_5 proband 64 70 72 
G79_6 affected brother 76 101 99 
Table 5.9. Phenotypic test scores for family G79 (Expressive language score ELS; Receptive language score RLS, 
Nonword repetition scores NWR).  
In family E38, the BP4-BP5 duplication occurred in the mother E38_2 (chr15:32176304-32514341, 
hg19, predicted size of 338,038 bp) and was transmitted to the affected sibling, E38_4 
(chr15:32018731-32514341, hg19, predicted size of 495,611 bp) (Figure 5.12). The proband, 
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E38_3 and his sib, E38_4 are half-siblings, on the maternal side, and both with a diagnosis of SLI, 
and similar profiles of severe and widespread language impairment (Table 5.10). The pedigree 
structure of this family may lead to the hypothesis that the children are likely to share strong genetic 
risk factors deriving from the mother. However, the segregation pattern of the chromosome 15q 
CNV indicates that, if the CHRNA7 duplication contributes to SLI susceptibility in the sibling, it is 
separate from other risk factors that may be inherited by the proband.  
 
Figure 5.12. A. Validation of the BP4-BP5 duplication in family E38 by qPCR. The fragments 2 and 3 were designed 
inside the region predicted to be duplicated, the fragments 1 and 4 instead in the region outside. The graph shows that 
duplication was present in E38_2 and E38_4. B. Pedigree of family E38. The two children E38_3 and E38_4 are half-
sibling and are both affected. 
individual  ELS RLS NWR 
E38_9 father of E38_3    
E38_1 father of E38_4    
E38_2 mother   88 
E38_3 proband 73 74 69 
E38_4 Affected half-sib 72 72 79 
Table 5.10. Phenotypic test scores for family E38 (Expressive language score ELS; Receptive language score RLS, 
Nonword repetition scores NWR).  
In conclusion, we identified and validated two types of recurrent CNVs on chromosome 15q in the 
SLI families. We observed an incomplete segregation pattern for both the BP1-BP2 deletion and the 
BP4-BP5 duplication, as they were identified in affected and unaffected individuals and were not 
present in all the affected members of these families. The BP1-BP2 microdeletion, was inherited by 
the proband only in one of the two families in which it was detected. In the other one, it was 
inherited by a sibling with unknown affection status. The BP4-BP5 microduplication was not 
transmitted to the children in family G68, it was inherited by one affected child in family E38 and 
was inherited by all children with language deficits in family G79.  
 
Results 
 
119 
 
5.7 Ongoing analyses. 
Due to the relatedness between the cases and the unaffected siblings used as ‘super-controls’ within 
the CNV burden analysis reported above, further analysis is currently being conducted using 
unrelated samples. A list of high confidence CNVs for 127 independent cases affected with SLI and 
a control population of 269 unrelated individuals, who were unselected in terms of language 
performance, were compared to assess differences in the burden of CNVs for a number of tests. In 
summary, the results so far indicate a general trend that the independent cases have on average 
more CNVs which are of a larger size and span more genes than the control samples. When the 
analysis was extended to include a further 385 individuals from the SLI cohort, who were a mixture 
of parents, affected siblings and unaffected siblings, the trends remained when compared to 
controls. Rare and novel CNVs were interrogated in the same way but there was no overall 
difference between the independent cases and controls. These data suggest that common CNVs play 
a role in the pathogenicity of SLI and that compared to other neurodevelopmental disorders, such as 
autism and ADHD, the increased burden is not driven by rare events. The evidence that the 
extended SLI family sample set remains significant for the trends observed in the independent cases 
indicates shared genetic factors that are inherited and could influence the phenotypic outcomes in 
the wider family, who often present with other language and/or reading difficulties, along with other 
genetic and environmental factors. 
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Chapter 6 
Results 
Validation and follow-up of a homozygous exonic deletion in ZNF277. 
During the CNV screening, an intragenic homozygous deletion involving the gene ZNF277 
(NM_021994, OMIM 605465) was identified.  
ZNF277 maps to chromosome 7q31.1, in a region previously found to be in linkage with ASD 
(AUTS1, OMIM 209850). A fine mapping study of the AUTS1 locus found association of ASD with 
SNPs in two genes that are proximal to ZNF277, DOCK4 (dedicator of cytokinesis 4, OMIM 
607679) and IMMP2L (IMP2 inner mitochondrial membrane protease-like, OMIM 605977) 
(Maestrini et al., 2010). An additional investigation
 
(Pagnamenta et al., 2010) described a rare 
microdeletion involving the 3’ end of DOCK4 (exons 27-52) and the 5’ end of IMMP2L genes 
(exons 1-3), that cosegregated with the presence of dyslexia in an extended family. Therefore, given 
the interesting genomic location of the gene ZNF277 and the potential phenotypic and genetic 
overlap between ASD and SLI, we decided to characterize this homozygous deletion. 
6.1. Identification and validation of a homozygous microdeletion of exon 5 in 
ZNF277. 
The ZNF277 homozygous microdeletion was identified during the CNV screening of the SLI cohort 
in a single child (G4_4) of a Caucasian family (Figure 6.1 b). 
The child G4_4 met full criteria for a clinical diagnosis of SLI and did not develop language skills 
until the age of 4-5 years. She was dependent on being shown what to do with toys and her thinking 
was slightly rigid, but overall she appeared sociable and no other obvious autistic behaviors were 
reported or observed. Her non-verbal intelligence was below average (Performance IQ=75). She 
attended a special unit for speech and language impaired children. 
The proband had two siblings, an older brother (G4_3) and a younger sister (G4_5). All three 
children presented with a similar pattern of speech and language impairment, which primarily 
affected the expressive domain (Table 6.1). They all presented with delayed word and phrase 
speech, unintelligible speech with poor articulation and impaired word retrieval. However, the three 
children differed in terms of the severity of their impairment and their non-verbal attainment. The 
younger sister had a higher non-verbal IQ than the proband (PIQ=94) and also had a diagnosis of 
SLI, although she appeared less severely affected than the proband. The brother had a particularly 
high non-verbal IQ (PIQ=127) and, although he was reported to have had an early speech and 
language delay, he did not have a diagnosis of SLI. He did attend a special educational unit and at 
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age 10 years had a significant verbal performance discrepancy and impaired sentence recall. Both 
parents reported a family history of speech or language problems: the father speech impairment and 
the mother dyslexia. 
 
individual   ELS RLS NWR 
G4_1 father   64 
G4_2 mother   88 
G4_3 brother 99 110 79 
G4_4 proband 50 70 72 
G4_5 sister 54 83 85 
Table 6.1. Phenotypic test scores for family G4 (Expressive language score ELS; Receptive language score RLS, 
Nonword repetition scores NWR).  
The predicted microdeletion included only three SNP probes (rs11769219, rs4727766 and 
rs7802828), had a minimum predicted size of 4,153 bp and overlapped exon 5. The gene is formed 
by 12 coding exons (NM_021994.2), but the absence of exon 5 causes a frame-shift mutation and 
introduces a premature stop codon in exon 7. Given the likelihood of nonsense-mediated mRNA 
decay, this homozygous microdeletion would thus be predicted to result in a complete lack of 
functional protein in the affected individual (Khajavi et al., 2006). 
A qPCR experiment of available family members in this pedigree demonstrated that one copy of the 
microdeletion was transmitted to the proband from each parent, who were both heterozygotes 
(Figure 6.1 a). However, the microdeletion was not transmitted to the proband’s brother, who 
presented with an early expressive speech and language impairment but did not have a diagnosis of 
SLI. Insufficient DNA was available for the qPCR assay in the proband’s sister, who was also 
included in the CNV screening and was predicted to have two normal copies of this genomic 
region. 
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Figure 6.1. A. Results of the qPCR validation of the microdeletion overlapping exon 5 of ZNF277 in family G4. The 
qPCR fragments, designed within the predicted deletion region and used in the qPCR experiment, map in intron 4 and 
exon 5 of ZNF277. The graph shows that the proband G4_4 has copy number of zero in the region encompassing exon 
5, while the father G4_1 and the mother G4_2 carry the microdeletion in the heterozygous state. The CNV is absent in 
the brother G4_3. B. Pedigree of family G4, where black indicates diagnosis of SLI and grey indicates language 
problems. 
A similar microdeletion was observed in an in-house sequencing database at the Wellcome Trust 
Centre for Human Genetics in a heterozygous form (1/130 samples of the 500 Whole-Genome 
Sequences Project [WGS500 Consortium]) (Palles et al., 2013). This deletion, encompassing exon 
5, had a size of 21,379 bp, with breakpoints located within intron 4 and intron 5 of ZNF277. NGS 
technologies offer the advantage of identifying CNVs with a bp resolution, allowing a fine mapping 
of the breakpoints. SNP array instead have a lower resolution and do not detect the precise 
boundaries of a CNV event. Since the size of this deletion was compatible with the maximum and 
minimum predicted size of the microdeletion detected in family G4, we tested whether this CNV 
had arisen from recombination events between the same breakpoints. Primers spanning the 
microdeletion breakpoints were designed: this PCR fragment allowed the specific amplification of 
the allele carrying the deletion. Indeed, this PCR product could be detected only in the proband 
G4_4 (ZNF277 -/-) and the parents (ZNF277 +/-), but not in the siblings G4_3 and G4_5 (ZNF277 
+/+) (Figure 6.2 b). Conversely, the amplification of a fragment including exon 5 of ZNF277 gave 
a PCR product for the parents and the siblings, but not for the proband, who does not have any copy 
of this genomic region (Figure 6.2 a). 
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Figure 6.2. A. Amplification of exon 5 of ZNF277 indicates the presence of at least one allele without the 
microdeletion in the parents and the siblings G4_3 and G4_5, while the PCR product is absent in G4_4, confirming the 
homozygous copy loss of this region. B. The figure shows the results of a PCR amplification across the microdeletion 
breakpoints: only the allele with the microdeletion can be amplified and visualized as a band of 466 bp in the parents 
and in the proband. In both gels, 1kb Plus DNA ladder was loaded at the extremities. 
Sanger sequencing validated the boundaries in the discovery individual G4_4 (chr7:111941769-
111963147, hg19, 21,379 bp) and further confirmed the presence of the microdeletion also in the 
parents (Figure 6.3). This allowed the accurate detection of the breakpoint boundaries, which lie in 
two LINE elements, L2c and L1M4. L2c (chr7:111941666-111941883, hg19, strand +) belongs to 
the L2 LINE family and L1M4 (chr7:111961275-111963848, hg19, strand -) to the L1 LINE 
family, which promote structural variation through NAHR. BLAST alignment of the entire 
sequence of these two elements did not reveal extended homology between them. However, 
sequencing of the breakpoints revealed 2 bp microhomology at the junctions, suggesting that this 
deletion may be generated through a microhomology-mediated repair mechanism (Vissers et al., 
2009). 
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Figure 6.3. Molecular characterization of the ZNF277 microdeletion in the discovery pedigree. Sequence 
electropherograms from the PCR products spanning the microdeletion in ZNF277. The rectangle indicates the genomic 
position of the microdeletion in ZNF277. The 2 bp (TC), common to both ends, are delimited by dotted lines and circled 
in the Reference sequence.  
At the time of detection (January 2012), there were no overlapping deletions described in the DGV 
(Iafrate et al., 2004; Macdonald et al., 2013; Zhang et al., 2006a). The latest version of the DGV 
(January 2014) does report 5 CNVs in ZNF277 (Figure 6.4): 
 Two large duplications, a 1,054,909 bp duplication and a 1,152,320 bp duplication, both 
encompassing the genes C7orf53, C7orf60, DOCK4, IFRD1, TMEM168 and ZNF277 (Itsara 
et al., 2009; Simon-Sanchez et al., 2007).  
 A small insertion (267 bp) within intron 1, identified by the 1000 Genomes Consortium 
Pilot Project; 
 Two deletions: a copy number loss of ~45 kb involving the last 8 exons (5-12) of the gene 
(chr7:111952128-111997265) (Kidd et al., 2008) and a 21 kb copy number loss 
(chr7:111941766-111963145), involving exon 5 and described by the 1000 Genomes 
Consortium Pilot Project (Abecasis et al., 2012). 
The recently reported microdeletion encompassing exon 5 (indicated in Figure 6.4 as esv2656841) 
corresponds to the microdeletion that we detected in family G4 and was identified in 8 samples out 
of 1151. Assuming that these samples carry the deletion in the heterozygous state, the allelic 
frequency would be of 0.35%.  
In the SLI sample set, no duplications were identified for ZNF277. 
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Figure 6.4. Structural variants reported in the last version of DGV (January 2014) within the gene ZNF277. The 
deletion identified in G4_4 is indicated in black. DGV shows also single supporting deletions (red) and duplications 
(blue) for each CNV reported in this region. 
6.2 Homozygosity analysis in family G4. 
The presence of a rare homozygous deletion in proband G4_4 led us to hypothesize that the parents 
might be distantly related. The clinical reports for this family did not contain any information 
suggesting a possible consanguinity between the parents. Therefore, in order to test this hypothesis, 
we estimated the proportion of pairwise IBD using genome-wide SNPs in each pair of individuals 
within the family unit, using PLINK. The proportion of IBD is calculated as PI_HAT 
=P(IBD=2)+0.5*P(IBD=1). This statistic evaluates the IBD alleles in order to estimate whether two 
individuals look more similar than expected by chance in a random sample. The expected values for 
a pair of unrelated individuals is zero, for a parent-child pair or a sibling pair it is 0.5 and for a pair 
of half-siblings it is 0.25. As shown in Figure 6.5, the pairwise IBDs in family G4 were in 
agreement with the expected values, indicating that there is no evidence of consanguinity in this 
family. Accordingly, the inbreeding coefficient estimated from genome-wide SNP data for family 
G4 was ~ 0.  
Screening for runs of homozygous genotypes in proband G4_4 did not reveal the presence of 
homozygous segments longer than 1 Mb throughout the genome, suggesting lack of consanguinity. 
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Figure 6.5. Genome-wide pairwise IBD analysis performed on the SLIC cohort, using PLINK. The PI_HAT values 
obtained for family G4 are indicated in red. The parents pair had an estimated IBD of zero, the other pairs (parent-child 
or sibling pairs) had an estimated IBD of ~0.5. 
Inspection of the haplotypes of the G4 family in a 10 Mb region encompassing the gene ZNF277, 
on chromosome 7q31.1, demonstrated that the proband G4_4 carries a region of homozygosity 
which spans about 800 kb (chr7:111616692-112460775, hg19) and includes the 5’ of DOCK4, 
ZNF277, IFRD1 (OMIM 603502), LSMEM1, TMEM168 and three uncharacterized transcripts 
(LOC100996249, AC002463.3 and C7orf60). For this region, both siblings G4_3 and G4_5 
inherited the other parental haplotypes, confirming the experimental results obtained during the 
validation of the ZNF277 microdeletion. 
6.3. Screening for ZNF277 microdeletions in the SLIC and IMGSAC cohorts. 
In addition to the discovery family G4, another 1229 individuals from the SLI cohort were 
screened, giving a total cohort size of 322 families (1234 individuals - 545 parents, 318 probands 
and 371 siblings). The screening led to the identification of 16 additional individuals with the 
ZNF277 microdeletion. All individuals carried the deletion in a heterozygous form, five of whom 
were probands (allelic frequency 0.8%), 6 parents (allelic frequency 0.6%) and 5 siblings (allelic 
frequency 0.7%) (Figure 6.6), giving an allelic frequency of 0.8% in the entire cohort (20/2468 
chromosomes). Across all SLI probands (i.e. independent cases including the discovery proband), 
the allelic frequency of microdeletions was therefore 1.1% (7/636 chromosomes). 
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Figure 6.6. Pedigree of the SLIC families carrying the ZNF277 microdeletion. Black filling means full diagnosis of 
SLI. 
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In contrast, the microdeletion was observed in the heterozygous form in 1 of 130 unrelated samples 
in our in-house sequencing cohort (allelic frequency 0.4%) and 2 of 224 ECACC control 
individuals (allelic frequency 0.4%) giving a control population allelic frequency of 0.4% (3/708 
chromosomes). The frequency in our control group is in agreement with the estimated frequency of 
the “esv2656841” variant in DGV (0.35% assuming that all the individuals carry the deletion in the 
heterozygous state), identified by the 1000 Genome Consortium. 
Moreover, since the gene ZNF277 maps to AUTS1, a locus previously implicated in autism, we 
investigated whether the ZNF277 microdeletion could represent a risk factor also for ASDs. 
Screening of 252 multiplex ASD families (1021 individuals- 454 parents, 412 affected children, 155 
sibs) from the IMGSAC cohort identified heterozygous ZNF277 microdeletions in 4 ASD families 
(Figure 6.7). Four mothers carried the microdeletion (allelic frequency 0.4%) and it was inherited 
by 3 affected children (allelic frequency 0.4%) giving a frequency of 0.3% (7/2042 chromosomes) 
across the entire cohort. All of the ASD families were ascertained as multiplex pedigrees and thus 
included more than one affected child. Unlike the SLI families, in many cases, there was no single 
designated proband within the family units. All three ASD cases who inherited the microdeletion 
had affected siblings who did not inherit the microdeletion rendering the derivation of an objective 
proband frequency problematic.  
 
Figure 6.7. Pedigree of the IMGSAC families carrying the ZNF277 microdeletion. Black filling means full diagnosis of 
autism, grey filling indicates a diagnosis of PDD. 
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6.4 Expression analyses of ZNF277, DOCK4 and IMMP2L. 
In a previous study (Pagnamenta et al., 2010), a microdeletion involving the 5’ end of IMMP2L 
(exons 1-3) and the 3’ end of DOCK4 (exons 27-52) was identified and characterized in a Dutch 
family (15-0084) with ASD and dyslexia. The microdeletion (chr7:110876742-111470446, hg19), 
leading to a fusion transcript between IMMP2L and DOCK4, was maternally inherited by all three 
children: two of them presented with ASD and one presented with reading impairment. 
Interestingly, the simultaneous presence of the IMMP2L-DOCK4 microdeletion and of a CNTNAP5 
microdeletion of paternal origin, on chromosome 2q14.3, was found to segregate with autism, 
whereas the IMMP2L-DOCK4 deletion segregated with dyslexia in the maternal extended family 
(Figure 6.8).  
 
Figure 6.8 (Pagnamenta et al., 2010). Inheritance pattern of the IMMP2L-DOCK4 deletion within the extended family. 
Long-range PCR products of 3087 bp are visible only where this deletion is present. Gel lanes are aligned with the 
pedigree, with the proband indicated by an arrow. Dark shading indicates ADI-defined autism, lighter shading indicates 
Asperger syndrome or autistic features, and diagonal stripes indicate dyslexic diagnosis or reading impaired. Asterisk 
indicates presence of CNTNAP5 deletion.  
Since numerous deletions in IMMP2L are reported in the DGV, while copy number losses in 
DOCK4 are rare and generally small, the haploinsufficiency of DOCK4 was proposed to be a risk 
factor for dyslexia susceptibility, and in addition with other variants, for autism susceptibility. 
Moreover, DOCK4 encodes for a guanine nucleotide exchange factor (GEF) for Rac1 and Rap1 and 
positively regulates the dendritic spine formation (Ueda et al., 2013), and thus represents an 
interesting functional candidate for neurodevelopmental disorders. 
Interestingly, ZNF277 and its adjacent gene DOCK4 are separated only by 180 bp and are 
transcribed in opposite directions (Figure 6.9). Since the transcription start sites of DOCK4 and 
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ZNF277 are so close, it might be possible that regulatory elements for ZNF277 might lie within 
DOCK4 and vice versa. 
 
Figure 6.9. Schematic representation showing ZNF277, DOCK4, IMMP2L loci with respect to chromosome 7. The blue 
bars underneath show the chromosomal position of the two types of deletions that were analyzed in this study: the 
IMMP2L-DOCK4 deletion includes exons 27-52 of DOCK4 and exons 1-3 of IMMP2L. ZNF277 deletion includes exon 
5. The red arrows indicate the direction of transcription of each gene.  
We assessed the effects of the ZNF277 microdeletion on the expression of ZNF277, DOCK4 and 
IMMP2L by qPCR. Conversely, we also assessed the effect of the IMMP2L-DOCK4 deletion on the 
expression of ZNF277. 
In the SLIC cohort we did not identify any CNV overlapping DOCK4, whereas 5 deletions and 1 
duplication, all common, were predicted for IMMP2L in 6 families. RNA from lymphoblastoid cell 
lines or blood was not available for these SLI families or for the pedigree G4 carrying the ZNF277 
microdeletion. However, lymphoblastoid cell lines were available for four ASD families in which 
the ZNF277 microdeletion was detected in the heterozygous state and RNA from blood was 
available for the parents of the ASD/dyslexia family 15-0084, in which the mother carried the 
IMMP2L-DOCK4 deletion. 
Two qPCR fragments were tested to analyse the ZNF277 transcript levels: one within the region 
encompassed by exons 1-2 (which lies outside of the microdeletion) and another one within the 
region encompassed by exons 3-5 (included by the microdeletion). The expression pattern for the 
fragments was decreased in both cases when compared to individuals without the CNV (Figure 
6.10) whilst that in exon 5 was significantly lower (p=0.035), indicating that the microdeletion 
causes a decreased expression of the entire ZNF277 transcript and supporting the hypothesis of 
nonsense mediated decay. However, in its heterozygous form, the ZNF277 microdeletion did not 
significantly alter the expression of the genes DOCK4 or IMMP2L (Figure 6.10). 
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Figure 6.10. The graph shows the ratio of IMMP2L, DOCK4 and ZNF277 transcript levels, normalized using GUSB as 
a reference. The ratio has been calculated as an average of 5 samples for each group of individuals, belonging to 4 ASD 
families: “not-del” indicates the group of individuals with two wild-type copies of ZNF277, “del” the group of 
individuals with the heterozygous ZNF277 microdeletion. Bars indicate the standard errors. 
Similarly, when we tested the effect of the deletion within DOCK4 and IMMP2L, we did not 
observe a difference in ZNF277 levels between the individual carrying the deletion (mother) and the 
individual carrying normal copies of IMMP2L and DOCK4 (father) (Figure 6.11). Note that this 
deletion has previously been shown to decrease the expression level of DOCK4
 
(Pagnamenta et al., 
2010). 
 
Figure 6.11. Ratio of ZNF277 transcription levels in an individual with IMMP2L-DOCK4 microdeletion (the mother 
15-0084-002), compared to an individual with two normal copies of IMMP2L and DOCK4 (the father 15-0084-001). 
The ratio has been normalized on GUSB expression levels. Standard error bars are indicated. 
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In conclusion, we validated an interesting homozygous exonic microdeletion in the gene ZNF277 in 
a child with severe language impairment. This microdeletion was found in the heterozygous state in 
other individuals of the SLIC cohort, in which the probands showed an increased allelic frequency 
(1.1% in independent SLI probands) compared to both ASD family members (0.3%) and 
independent controls (0.4%). Moreover, although ZNF277 falls within the ASD linkage locus 
AUTS1 and its neighbouring genes are IMMP2L and DOCK4, previously implicated in dyslexia and 
autism, we observed that microdeletions encompassing exon 5 of ZNF277 reduce the expression of 
ZNF277, but do not alter the levels of DOCK4 or IMMP2L transcripts. Conversely, the 594 kb 
IMMP2L-DOCK4 deletion described in the ASD/dyslexia family 15-0084 does not affect the 
expression levels of ZNF277. Taken together, these results suggest that ZNF277 microdeletions 
may contribute to the risk of language impairments in a complex manner that is independent of the 
autism risk loci previously described in this region. 
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Chapter 7 
Results 
Analysis of the candidate gene DPYD 
7.1 Analysis of the candidate gene DPYD in SLI cases. 
7.1.1 DPYD in family G4. 
The interesting findings in family G4 led us to re-analyse the clinical reports of these individuals in 
detail. We found that, after a hospitalization, the younger sister G4_5, who was also diagnosed with 
SLI, had received a diagnosis of dihydropyrimidine dehydrogenase (DPD) deficiency. This 
autosomic recessive disorder, caused by homozygous or heterozygous compound mutations in the 
gene DPYD, can be recognized by increased levels of thymine and uracil in blood and urine. As 
discussed in the introduction, DPYD also represents a candidate gene for neurological dysfunctions, 
since rare CNVs and sequence variants in this gene have been described in individuals with ASD, 
ID, schizophrenia and other neurological abnormalities. Therefore, we hypothesized that DPYD 
mutations in the sister G4_5 could have contributed to her language deficits. 
First, in order to identify the causal mutations of the DPD deficiency in G4_5, we carried out a 
mutational screening of all the coding parts of the two isoforms of DPYD. We detected two 
potentially causing mutations: a splice site mutation in intron 14 (rs3918290, also known as 
IVS14+1G>A or DPYD*2A) and a missense change in exon 6 of the isoform 1 (rs72549308, 
AGT⇒CGT, pS201R).  
The splice site mutation rs3918290 is well-known to be implicated in DPD deficiency: the 
disruption of the donor splice site in intron 14 determines the absence of exon 14 (165 bp) in the 
mRNA, resulting in a shortened protein which lacks the corresponding 55 amino acids and has no 
residual activity.  
The missense variant rs72549308 is not reported in the database of the NHLBI Exome Sequencing 
Project (ESP, http://evs.gs.washington.edu/EVS/), that collects the exome sequence data of more 
than 200,000 individuals from the Unites States, and no allelic frequency is reported in dbSNP138, 
suggesting that rs72549308 is rare in the population. We used the bioinformatics tools Polyphen2 
and SIFT to predict the impact of the substitution of the amino acid serine 201 with arginine and 
both predicted a deleterious effect for this change (PolyPhen2 score of 1.00, SIFT score 0). This is 
in agreement with a reported association of this missense change with decreased DPD activity 
(Ezzeldin and Diasio, 2004).  
Results 
 
134 
 
Analysis of the segregation pattern of the two coding variants detected in G4_5 revealed that she 
had inherited the missense change from the mother and the splice site mutation from the father 
(Figure 7.1). The proband in this family, G4_4 did not inherit either of the DPYD mutations, 
whereas the older brother G4_3 inherited just the splice site variant. Therefore, the DPD deficiency 
reported in G4_5 resulted from a compound heterozygous of two damaging mutations, whereas the 
parents and the brother carried only one deleterious variant in the heterozygous state and were also 
unlikely to be affected by DPD deficiency. 
 
Figure 7.1. Pedigree structure of family G4 with the variants detected in this study: the deletion of exon 5 in ZNF277 
(on chromosome 7) and the sequence variants identified during the mutational screening of the gene DPYD (on 
chromosome 1). The two copies of chromosome 1 are indicated with different colours for each parental allele: in the 
children, the maternal and paternal copies of chromosome 1 are deduced from the segregation pattern of the two 
mutations detected in exon 6 and intron 14. 
In this family, then, the complete loss of DPD activity was found only in one out of two affected 
children. However, since SLI is a complex disorder in which multiple risk factors are likely to be 
implicated, it remains possible that this heterogeneity could be observed also within families and 
that damaging mutations in DPYD might still contribute to SLI in a complex manner.  
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7.1.2 Screening for the splicing variant rs3918290 in SLI probands. 
Considering that DPYD represents a good candidate gene for a range of neurological deficits, 
including language and speech delay, and that we identified two deleterious mutations in this gene 
in a child with language impairment, we decided to investigate whether DPYD could contribute to 
SLI susceptibility. Over the years, several variants have been reported in this gene, however their 
functional impact on DPD activity is often uncertain. Although the SNP rs3918290 is rare in the 
general population, it is the most frequent mutation found in individuals with DPD deficiency and it 
is widely recognised as a damaging mutation. Therefore, we decided to carry out a preliminary 
analysis for a possible role of the gene DPYD in SLI focusing on this splice site variant 
(rs3918290).  
A group of 166 language-impaired independent cases from the SLIC cohort was screened for the 
presence of the variant rs3918290. Sequencing of a PCR fragment including rs3918290 was 
performed and the variant was found in 3 cases, giving an allelic frequency of 0.9% (A=3/G=329). 
Including also G4_5 in this analysis, the allelic frequency raises to 1.2% (A=4/G=330). 
We compared the observed frequency of the rs3918290 minor allele in the SLI samples with that 
reported by several databases: the 1000 Genome Project (http://www.1000genomes.org/), The 
HapMap Project (http://hapmap.ncbi.nlm.nih.gov/) and the ESP database 
(http://evs.gs.washington.edu/EVS/). In Table 7.1 the allelic frequencies of rs3918290 are reported 
for different populations.  
Controls Allele G Allele A Genotype 
G|G 
Genotype 
G|A 
Allele count Genotype count 
1000Genomes_ALL 0.997 0.003 0.995 0.005 2178 (G)/6(A) 1086 (G|G)/6 (G|A) 
1000Genomes_EUR 0.993 0.007 0.987 0.013 753 (G)/5(A) 374 (G|G)/5 (G|A) 
1000Genomes_CEU 0.994 0.006 0.988 0.012 169 (G)/1(A) 84 (G|G)/1 (G|A) 
1000Genomes_TSI 0.995 0.005 0.990 0.010 195 (G)/1(A) 97 (G|G)/1 (G|A) 
1000Genomes_GBR 1.000 
 
1.000 
 
178 (G) 89 (G|G) 
HAPMAP-CEU 0.996 0.004 0.991 0.009 225 (G)/1(A) 112 (G|G)/1(G|A) 
HAPMAP-TSI 0.994 0.006 0.989 0.011 175 (G)/1(A) 87 (G|G)/1 (G|A) 
ESP6500: 
European-American 
0.994 0.006 0.988 0.012 8550 (G)/50(A) 4250(G|G)/50(G|A) 
SLI cases 0.988 0.012 0.976 0.024 330 (G)/4 (A) 163 (G|G)/ 4 (G|A) 
Table 7.1. Allelic and genotypic frequencies for rs3918290 reported in three databases for populations of European 
origin: 1000 Genome Project, HapMap, ESP database, compared with those found in the SLI cases. In the 1000 
Genome Project, 26 populations have been analysed (ALL), but then they have been divided in five super-populations, 
one of those is represented by the Europeans (EUR). EUR includes CEU (Utah Residents (CEPH) with Northern and 
Western European ancestry), TSI (Tuscans in Italy), and GBR (British in England and Scotland). 
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For individuals with European ancestry, the frequency of the minor allele is lower (~0.6%) than that 
observed in our SLI cases (1.2%). However, the difference between these controls and the SLI cases 
is not statistically significant (one-tailed Fisher’s exact test, p-value= 0.1423 against the ESP-EA 
controls, p-value= 0.4524 against CEU controls of the 1000 Genome Project, p-value= 0.4319 
against EUR controls-1000 Genome Project). 
7.1.3 Mutation screening of DPYD in SLI cases carrying the variant rs3918290. 
In order to check whether the three additional SLI cases carrying the splice variant rs3918290, also 
had a second functional sequence mutation in DPYD, we screened the coding regions and the two 
known regulatory regions in the 5’ flanking region of both isoforms in these probands and their 
family members. We identified several known variants, all common in the population, except for a 
novel variant in the promoter region found in one family and detailed below (Figure 7.2 c, Table 
7.3).  
In family E6 (Figure 7.2 a), we identified four changes: 
1. the splice variant rs3918290, inherited by the proband E6_3 from his mother E6_2; 
2. a missense mutation in exon 2 (rs1801265, also referred to as DPYD*9A, TGT⇒CGT, 
pC29R), inherited from the father by the affected sibling E6_4; 
3. a missense change in exon 6 of isoform 1 (rs2297595, ATG⇒GTG, p.M166V), carried by 
all family members; 
4. a missense mutation in exon 13 (rs1801158, AGT⇒AAT, p.S534N), inherited from the 
mother by the affected sibling E6_4. 
In family M18 (Figure 7.2 b), we identified two changes: 
1. the splice mutation rs3918290, inherited by the proband M18_3 and the unaffected child 
M18_4, from the mother M18_2.  
2. a common missense mutation in exon 2 (rs1801265, TGT⇒CGT, pC29R), carried by both 
parents and the unaffected sibling M18_4. 
In family E30 (Figure 7.2 c), we identified five changes: 
1. the splice variant rs3918290, inherited from the father E30_1 by the proband E30_3 and her 
affected sibling E30_4; 
2. a novel C/T change in the promoter region (chr1:98,386,652, hg19), inherited by the 
affected sibling E30_4, from the mother E30_2; 
3. a common missense mutation in exon 2 (rs1801265, TGT⇒CGT, pC29R), identified only in 
the father E30_1; 
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4. a common missense mutation in exon 13 (rs1801159, ATA ⇒ GTA, p.I543V), found only 
in the father E30_1; 
5. a common missense change in exon 18 (rs1801160, GTT⇒ATT, pV732I) inherited by the 
proband E30_3 from the mother E30_2. 
 
 
Figure 7.2. Pedigree of the three SLI families in which the mutation screening of DPYD has been performed. Paternal 
and maternal haplotypes for DPYD are represented with rectangles of different colours. The haplotypes of the children 
have been deduced from the inheritance pattern of all the variants identified during the screening. Electropherogram is 
shown for the variant C/T (strand -) identified in the regulatory region flanking the 5’ of the gene. 
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All the variants identified are summarized in Table 7.3. For each change, the expected 
frequencies observed in the general population are reported in Table 7.4, in which the functional 
effect for the protein DPD predicted by Polyphen and SIFT is also indicated. 
 
Phenotypic scores of ELS, RLS and NWR language tests are reported in Table 7.2. 
Indiv.  ELS RLS NWR AFF 
E6_1 father   94 0 
E6_2 mother    0 
E6_3 proband 76 87 92 2 
E6_4 brother 67 89 67 2 
M18_1 father   111 0 
M18_2 mother   104 0 
M18_3 proband 95 131 115 2 
M18_4 brother 112 117 113 1 
E30_1 father    0 
E30_2 mother   81 0 
E30_3 proband 70 59 55 2 
E30_4 brother 72 85 91 2 
Table 7.2. Phenotypic scores for ELS, RLS and NWR tests available for the three families carrying the splicing 
variant in intron 14. Individuals were classified as affected (AFF=2) if they were probands or siblings with ELS or 
RLS scores ≥ 1.5 SD below the normative mean. Individuals with both ELS and RLS scores  0.5 SD below the 
mean were classified as unaffected (AFF=1). For the other family members that did not meet these threshold, the 
affection status was considered unknown (AFF=0). 
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DPYD E30_1 E30_2 E30_3 E30_4 E6_1 E6_2 E6_3 E6_4 M18_1 M18_2 M18_3 M18_4 
promoter - SNP (C/T) - SNP (C/T) - - - - - - - - 
exon 2 
rs1801265 
(C/T, C29R)  
- - - 
rs1801265 
(C/T, C29R) 
- - 
rs1801265 
(C/T, C29R) 
rs1801265 
(C/T, C29R) 
rs1801265 
(C/T, C29R) 
- 
rs1801265 
(C/T, C29R) 
exon 6 
isoform1 
- - - - 
rs2297595 
(A/G, M166V) 
rs2297595 
(A/G, M166V) 
rs2297595 
(A/G, M166V) 
rs2297595 
(A/G, M166V) 
- - - - 
exon 13 
rs1801159 
(A/G, I543V) 
- - - - 
rs1801158 
(G/A, S534N) 
- 
rs1801158 
(G/A, S534N) 
- - - - 
ex/intr 14 
rs3918290 
(G/A, splicing) 
- 
rs3918290 
(G/A, splicing) 
rs3918290 
(G/A, splicing) 
- 
rs3918290 
(G/A, splicing) 
rs3918290 
(G/A, splicing) 
- - 
rs3918290 
(G/A, splicing) 
rs3918290 
(G/A, splicing) 
rs3918290 
(G/A, splicing) 
exon 18 - 
rs1801160 
(G/A, V732I) 
rs1801160 
(G/A, V732I) 
- - - - - - - - - 
 
Table 7.3 . Variants identified in the mutation screening of DPYD (Gene accession number: NM_000110.3), carried out in the 3 SLI families with the variant rs3918290. 
 
chr position 
(hg19) 
rsID Position 
AA 
Change 
cDNA Ref 
Base 
NCBI 
37 
dbSNP ESP (EA)  ConservationScore Prediction 
Pos. Strand - MAF (%) Allele 
Count 
MAF % Phast 
Cons 
GERP Grantham 
Score 
Polyphen (score) SIFT (score) 
1:98386652 unknown promoter - 
 
C NA NA NA       NA NA 
1:98348885 rs1801265 Exon 2 C29R 85 C 
C= 26.30 
T= 73.69 
T=6666 
C=1934 
22.488 0.997 5.84 180 benign (0.00) Tolerared (0.18) 
1:98165091 rs2297595 Exon 6 M166V 496 A 
G= 6.562 
A= 93.438 
G=852 
A=7748 
9.907 0.999 5.26 21 
probably-damaging 
(1.00) 
damaging (0.05) 
1:97981421 rs1801158 Exon 13 S534N 1601 G 
A= 1.458 
G= 98.542 
A=174 
G=8422 
2.0242 0.95 5.2 46 
probably-damaging 
(0.996) 
damaging (0.00) 
1:97981395 rs1801159 Exon 13 I543V 1627 A 
A= 80.182 
G= 19.818 
G=1704 
A=6896 
19.814 0.026 -3.13 29 benign (0.00) tolerated (1.00) 
1:97915614 rs3918290 
Splice donor 
site intron14 
- 
  
G 
A= 0.358 
G= 99.642 
A=50 
G=8550 
0.5814 0.997 5.31 NA NA NA 
1:97770920 rs1801160 Exon 18 V732I 2194 G 
A= 4.543 
G= 95.457 
A=402 
G=8198 
4.6744 0.918 5.55 29 
probably-damaging 
(0.998) 
damaging (0.00) 
 
Table 7.4. Variants in DPYD (Gene accession number: NM_000110.3) identified in the mutational screening. For each variant, position and allelic frequencies reported in dbSNP 
and ESP (only for European-American individuals) databases are indicated. Functional effects of aminoacid substitutions were predicted using Polyphen2 and SIFT. Residue 
conservation was estimated by three tools. PhastCons describes the degree of sequence conservation among 17 vertebrate species, expressed with values ranging from a 
minimum of 0 to a maximum of 1 (Siepel et al., 2005). The Genomic Evolutionary Rate Profiling (GERP) score ranges from -12.3 to 6.17, with 6.17 being the most conserved 
(Cooper et al., 2005). Grantham Scale ranks amino acid substitutions in classes of increasing chemical dissimilarity (Grantham, 1974), based on chemical properties, including 
polarity and molecular volume. The changes can be considered conservative (0-50), moderately conservative (51-100), moderately radical (101-150), or radical (≥151). 
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Interestingly, the variant C/T (chr1:98,386,652, hg19) in the 5’ flanking region of DPYD (identified 
in family E30) is not described in dbSNP 138, in the ESP database or the 1000 Genome Project. 
This nucleotide falls within a CpG island and represents the first nucleotide of a positive regulatory 
region (element II, that includes the nucleotides from -72 to -51, considering the transcription start 
site as the position +1), previously described by Shestopal et al. (2000). A subsequent study (Zhang 
et al., 2006b) demonstrated that the ubiquitously expressed transcription factors Sp1 and Sp3 bind 
to the DPYD promoter. They found 3 Sp-binding sites, designated as SpA (from -148 to -140), SpB 
(from -68 to -60) and SpC (from -37 to -19), with the major promoter activity detected for SpB, 
suggesting that, when bound by Sp1, it may function as an upstream enhancer.  
Moreover, we consulted the UCSC Genome Browser (hg19) to find which transcription factor 
target sites are reported for the region flanking the 5’ of DPYD by the ENCODE Project. Using the 
track that shows the sequences bound by Transcription Factors identified by ChIP-seq, we saw that 
the region overlapping element II has several predicted target sites (Figure 7.3). In particular, the 
C/T variant falls within 11 putative target sites, with the highest cluster scores (in black) for the 
components of RNA Polymerase II and Egr-1 (early growth response, known also as Zif268). 
Zif268/Egr-1 belongs to the family of Egr C2H2-type zinc-finger proteins and binds to the DNA 
sequence 5'-CGCCCCCGC-3' (EGR-site), activating the transcription of target genes required for 
mitogenesis and differentiation. In brain, Zif268/Egr-1 has a key role in different types of synaptic 
plasticity, memory consolidation and reconsolidation processes (Veyrac et al., 2014). Other 
potential binding sites have been predicted for E2F, ZNF263, GATA-1, AP-2gamma. 
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Figure 7.3. The figure shows the transcription factors reported in UCSC Genome Browser by the track provided by the 
ENCODE Project. These transcription factor binding sites have been identified by ChIP-seq (chromatin 
immunoprecipitation with antibodies specific to the transcription factor followed by DNA sequencing of the 
precipitated fragments), and the grey scale indicates the cluster scores, with black being the highest scores. 
7.1.4 DPYD variants from exome sequences. 
Exome data for 45 independent probands of the SLIC cohort were also available. In these 
individuals, the splicing variant in intron 14 of DPYD was not identified, but 4 missense coding 
variants were detected in 24 individuals and confirmed by Sanger sequencing: p.M166V (11/45 
individuals, allelic frequency 12.2%), p.S534N (3/45 individuals, allelic frequency 3.3%), p.I543V 
(13/45 individuals, one of whom was homozygous for the variant, allelic frequency 14.4%), 
p.V732I (6/45 individuals, allelic frequency 6.7%). Some of the probands (7 individuals) carried 
more than one of these changes.  
Since p.M166V (rs2297595), p.I543V (rs1801159) and p.V732I (rs1801160) do not affect the 
enzymatic activity of DPD (Ezzeldin and Diasio, 2004; Offer et al., 2013), whereas p.S534N 
(rs1801158, exon 13) seems to have an effect on DPD activity, we decided to check the segregation 
of this variant in the three families in which it was identified: E35, E53, G67 (Figure 7.4).  
In family E53 (Figure 7.4 a), the missense variant p.S534N was maternally inherited from the 
proband E53_3 and and the sibling E53_4, who also had full diagnosis of SLI (Table 7.5). 
In family G67 (Figure 7.4 b), p.S534N was present in the proband G67_4 and absent in the sister 
G67_3, whose affection status was classified as unknown (Table 7.5). Both children carried another 
missense change in the same exon, p.I543V. We could not assess the inheritance of these mutations, 
because DNA for the parents was not available. 
Results 
 
142 
 
In family E35 (Figure 7.4 c), the variant p.S534N was maternally inherited by the proband E35_3 
and his sister E35_5, while it was absent in the brother E35_4. For both siblings E35_4 and E35_5, 
the affection status was classified as unknown (Table 7.5). The father instead carried the missense 
change p.I543V, on exon 13, inherited by all children (Figure 7.4).  
From the segregation pattern of p.S534N and p.I543V then, we deduced that, in both families,  
these variants were carried by different parental alleles.  
The probands of these three families did not carry the splicing mutation rs3918290 and the exome 
sequencing did not detect other variants in the coding region of DPYD. 
 
Figure 7.4. Pedigree of the three families carrying the p.S534N variant. 
individuals gender proband ELS RLS NWR AFF S534N  
(minor allele: A) 
I543V 
(minor allele: G) 
E53_1 male Father   91 0 G/G A/A 
E53_2 female Mother   55 0 G/A A/A 
E53_3 male Proband 64 65  2 G/A A/A 
E53_4 female Sister 73 85 77 2 G/A A/A 
G67_1 male Father    0 no DNA no DNA 
G67_2 female Mother   108 0 no DNA no DNA 
G67_3 female Sister   106 0 G/G A/G 
G67_4 male Proband 62 74 66 2 G/A A/G 
E35_1 male Father   104 0 G/G A/G 
E35_2 female Mother   91 0 G/A A/A 
E35_3 male Proband 72 72 92 2 G/A A/G 
E35_4 male Brother 86 93 103 0 G/G A/G 
E35_5 female Sister   116 0 G/A A/G 
Table 7.5. Phenotypic scores for ELS, RLS and NWR tests available for the three families carrying the p.S534N 
variant. AFF=2 means a full diagnosis of SLI, AFF=0 means affection status unknown. 
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7.2 Analysis of the candidate gene DPYD in ASD cases. 
7.2.1 Screening for the splicing variant rs3918290 in ASD cases and controls.  
Since rare variants in DPYD have been reported for autism and autistic features have been observed 
in patients with DPD deficiency, we decided to investigate also the frequency of the splice variant 
rs3918290 in ASD cohorts. The analysis was carried out in two stages. In the first one, the SNP 
rs3918290 was genotyped in 231 Italian simplex families, 224 IMGSAC multiplex families and 449 
Italian unrelated controls, with a restriction endonuclease analysis. Subsequently, we extended the 
analysis to the entire cohort of families of the AGP Consortium, which have been genotyped with 
the Illumina Infinium 1M-single and 1M-duo SNP array, that include the variant of interest 
rs3918290.  
Given the size of the ASD cohorts in the first stage, we developed a restriction enzyme assay to 
allow the genotyping of the SNP rs3918290. The assay used the restriction endonuclease 
HpyCH4IV which specifically recognizes the site 5’...A|CGT...3’, which also corresponds to the 
sequence that includes the splice donor site of intron 14. Therefore, HpyCH4IV is able to cut a PCR 
fragment containing the splice site with the reference allele G. In our case, the PCR fragment used 
to amplify the exon 14 and the surrounding intronic regions had a size of 413 bp and a unique target 
site for HpyCH4IV (Figure 7.5). In the presence of the wild-type donor splice site, the PCR 
fragment was cut in two fragments of 278 bp and 135 bp. In the presence of the variant rs3918290 
or another mutation altering the target sequence, the restriction site was not recognized by the 
enzyme HpyCH4IV and the PCR fragment was not cut.  
 
Figure 7.5. The figure shows the PCR fragment used to amplify exon 14 and the surrounding intronic regions. This 
fragment contains only one restriction site for the enzyme HpyCH4IV and the position of the SNP rs3918290 is 
indicated in red: it is represented by the base G in the reference sequence, by the base A in the variant sequence. 
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Visualization of the restriction products on a 2% agarose gel allowed the discrimination of 
homozygous individuals of the reference allele at the splice donor site (G/G), who presented two 
bands (278 bp and 135 bp), and heterozygotes individuals (G/A), who displayed three bands (the 
278 bp and 135 bp fragments derived from the reference allele G and the 413 bp fragment from the 
mutated allele A at the splice donor site) – Figure 7.6. Homozygous individuals for the mutated 
allele (A/A), would have shown only a band of 413 bp, but were not identified in this screening. 
Since a mutation of any of the four bases of the target site could prevent the recognition by the 
enzyme, the presence of the splicing variant in all identified heterozygotes individuals was then 
confirmed by Sanger sequencing. 
 
Figure 7.6. Example of genotyping of the SNP rs3918290 using the restriction endonuclease HpyCH4IV. The arrows 
indicate two of the individuals identified during the screening, carrying the variant rs3918290 (G/A) in the heterozygous 
state. The ladder 100 bp was loaded in the first and the last lane. 
In the IMGSAC cohort, which is formed by multiplex families, the screening was performed on one 
affected case per family. In cases where mutations were identified, all family members were 
screened in order to check the inheritance of the variant, the segregation pattern and detect possible 
de novo mutations. 
From restriction endonuclease analysis in the sample of 224 IMGSAC cases, rs3918290 was 
identified in two families: 203 and 171. In family 203, the variant was transmitted from the father 
203.1 to the affected son 203.3, but not to the other affected child 203.4. In family 171, the variant 
was transmitted from the mother 171.5 to the affected son 171.6 and to the unaffected child 171.7. 
The presence of the variant and its segregation were confirmed in both families with Sanger 
sequencing (Figure 7.7). 
In the Italian ASD cohort, including 231 cases, restriction endonuclease analysis was performed on 
all available family members and identified 9 families in which one or more individuals showed a 3 
bands digestion profile. Sanger sequencing confirmed the presence of the SNP rs3918290 in 8 out 
of 9 families (Figure 7.7). In 5 of them (SM2, SM38, SM161, C19 e C22), the variant was present 
in the proband, inherited from one of the parents, whereas in three families (SM23, SM77 e C38) it 
was carried by one parent but not transmitted to the children. In the ninth family, the mother 
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SM81.2 and the unaffected child SM81.4 showed the presence of a different variant that altered the 
target site of the enzyme HpyCH4IV (5’…ACGT…3’ →5’…ATGT…3’), corresponding to a rare 
synonymous SNP (rs3918289, aminoacid N635) of the last base of the exon 14 (Figure 7.7). 
 
Figure 7.7. The figure shows the electropherograms of the individuals in which the Sanger sequencing confirmed the 
presence of the variant rs3918290 (G/A, indicated by the red rectangle): the Italian probands SM38.3, C22.3, SM161.3, 
SM2.3 and C19.3; the IMGSAC cases 203.3 and 171.6; and the parents SM23.1 (father), SM77.2 (mother) e C38.2 
(mother). In family SM81 instead, the Sanger sequencing revealed the presence of the SNP rs3918289 (C/T, indicated 
by the blue rectangle), that corresponds to the last base of exon 14 and to the second base of the HpyCH4IV target site 
(5’…ACGT…3’ →5’…ATGT…3’). 
The analysis of 449 unrelated controls identified 4 subjects carrying the splice site mutation 
rs3918290 in the heterozygous state, all confirmed by Sanger sequencing. 
7.2.2 Statistical analysis of the rs3918290 frequency in the Italian and IMGSAC cohorts. 
The SNP rs3918290 was identified in 7 individuals with ASD (171.6, 203.3, SM2.3, SM38.3, 
SM161.3, C22.3, C19.3) and 4 unaffected controls. Thus, the splicing variant is present in 5/231 
Italian independent probands, with an allelic frequency of 1.08% versus an allelic frequency in 
Italian controls of 0.45% (4/898). Although the frequency in affected individuals is higher than in 
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controls, as observed in the SLI cohort, the difference is not statistically significant (p-value = 
0.1541, one-tailed Fisher’s exact test). 
The allelic frequency observed in our control group is similar to the one observed in the sample of 
Tuscan controls in the database of 1000 Genome Project, with a Minor Allele Frequency (MAF) for 
rs3918290 in these individuals of 0.5% (A=1/G=195) (Table 7.6). 
In the IMGSAC sample, in which the families were all Caucasian but recruited from different 
Countries (UK, Netherlands, France, USA, Germany, Denmark, Greece), the splicing variant was 
identified in 2 out of 224 families. Since these families included multiple affected individuals, in 
order to calculate the allelic frequency of the variant in independent individuals we selected a priori 
one affected member in each family and we obtained an estimated allelic frequency of 0.45% 
(2/448). We compared this frequency with the data reported in public databases for samples of 
European origin, already shown earlier in Table 7.1 The frequency of the minor allele A in the 
CEU samples of the HapMap project is 0.4% (A=1/G=225), in the CEU samples of the 1000 
Genome Project is 0.6% (A=1/G=169) and in European-American (EA) individuals of the ESP 
database is 0.6% (A=50/G=8550) (Table 7.6). Therefore, the allelic frequency in the IMGSAC 
cases was similar to the MAF reported in ethnicity-matched controls, showing no difference 
between the cases and controls. Therefore, the findings obtained from the multiplex families of the 
IMGSAC cohort did not replicate the trend observed for the Italian ASD simplex families and the 
SLIC families.  
7.2.3 Frequency and association analysis of rs3918290 in the AGP ASD cohort. 
To further investigate this discrepancy and analyse this variant in a larger number of ASD 
individuals, we extended the analysis to the entire AGP cohort. The genotyping of more than 1M 
SNPs distributed across the whole genome has been recently performed in 2,705 families, simplex 
and multiplex, collected by the AGP Consortium (Anney et al., 2012). Since the SNP rs3918290 
was included among the markers interrogated by the SNP arrays used for the genotyping (Infinium 
1M and 1M-Duo), we calculated the frequency of the splicing variant in this larger cohort of ASD 
subjects. The SNP rs3918290 was successfully genotyped in 2,681 independent cases and the allele 
A was detected in the heterozygous state in 25 of them, giving an allelic frequency of 0.47% 
(25/2681 probands), again not significantly different from the frequency reported in European 
populations (Table 7.6) and supporting that observed in the IMGSAC samples. When we compared 
this frequency with the one reported in the ESP database (EA: 0.58%), we did not find a significant 
difference (one-tailed χ2 test, p-value= 0.1826).  
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heterozygotes tot individuals tot alleles Allelic freq. % 
Italian ASD probands 5 231 462 1.08 
Italian Controls 4 449 898 0.45 
1000 Genomes Tuscans 1 98 196 0.51 
IMGSAC cases 2 224 448 0.45 
AGP cases 25 2681 5362 0.47 
HapMap CEU controls 1 113 226 0.44 
1000 Genomes CEU controls 1 85 170 0.59 
ESP EA controls 50 4300 8600 0.58 
Table 7.6. Summary of the allelic frequencies of rs3918290 used in the statistical analyses. 
Given the availability of genotype information for the parents of the affected individuals of the 
AGP cohort, we also performed a Transmission Disequilibrium Test (TDT) on these AGP samples, 
using the program PLINK. However, as shown by the Table 7.7, we did not observe a preferential 
transmission of allele A to individuals with ASD, therefore, the splicing variant did not result to be 
associated with the ASD phenotype in the AGP families.  
SNP allele % in cases T NT O.R. CHISQ P 
rs3918290 
A 0.5% 25 25 
1 0 1 
G 99.5% 25 25 
Table 7.7. Output of the TDT analysis in the AGP cohort: this table shows that there is not a preferential transmission 
of allele A to the affected children, compared to allele G (T= parents transmitting allele A to the affected child; NT: 
parents NOT transmitting allele A to the affected child). We found 25 parents transmitting allele A versus 25 parent 
who did not transmitted allele A to the affected children, p-value =1.  
7.2.4 TDT analysis for DPYD and MIR137 in the AGP cohort. 
Rare structural variants involving DPYD and its adjacent gene MIR137 have been found in ASD 
cases (Carter et al., 2011; Prasad et al., 2012) and in individuals with ID (Willemsen et al., 2011). In 
schizophrenia, rare sequence mutations have been identified in DPYD (Xu et al., 2012), while 
common variant association has been detected for the region surrounding MIR137 (Ripke et al., 
2013; Schizophrenia_Psychiatric_GWAS_Consortium, 2011) (Figure 7.8). 
 
Results 
 
148 
 
 
Figure 7.8. The figure shows the genomic location of DPYD and MIR137 (UCSC Genome Browser, hg18). LD plots 
SNPs genotyped in the HapMap CEPH (CEU) population are shown. In addition, the position of SNPs found in 
association with schizophrenia, rs1625579 (Schizophrenia_Psychiatric_GWAS_Consortium, 2011) and rs1198588 
(Bergen et al., 2012), is indicated.  
Since MIR137 and DPYD are both interesting candidates for neurological phenotypes, it has been 
suggested that both genes could be implicated in neurodevelopmental disorders. Therefore, in order 
to investigate whether variants in the two genes were in association with the ASD phenotype in our 
sample, we decided to extend the TDT analysis to the SNPs of the genomic region including DPYD 
and MIR137 (chr1:97499599-98599144, hg19), that have been genotyped in the AGP cohort. The 
analysis was performed on ninety-nine independent markers (i.e. not in LD), including the SNP 
rs1625579 previously found in association with schizophrenia. Few SNPs reached a p-value <0.05 
(minimum p-value= 0.01494, Table 7.8), all within DPYD. However, the signals for the SNPs that 
showed a preferential transmission of the minor allele to the affected individuals did not survive 
multiple testing correction. 
coordinates position  SNP A1 A2 T U OR CHISQ P-value 
chr1:98336940 intron 2 rs17117281 A G 0 4 0 4 0.0455 
chr1:98296425 intron 2 rs11802430 G A 15 6 2.5 3.857 0.04953 
chr1:98226950 intron 3 rs6604874 A C 5 0 NA 5 0.02535 
chr1:98198206 intron 4 rs4554755 A G 1097 1214 0.9036 5.923 0.01494 
chr1:98079228 intron 8 rs7533902 A G 959 856 1.12 5.845 0.01562 
chr1:98075118 intron 8 rs12068454 A G 21 10 2.1 3.903 0.04819 
chr1:98073410 intron 8 rs12144462 A G 392 331 1.184 5.147 0.02329 
chr1:98036219 intron 11 rs2811216 A G 6 16 0.375 4.545 0.03301 
chr1:98014940 intron 12 rs2786525 A C 6 16 0.375 4.545 0.03301 
chr1:98003908 intron 12 rs4950041 G A 1006 911 1.104 4.708 0.03002 
chr1:98001389 intron 12 rs12063030 A C 1001 911 1.099 4.236 0.03957 
chr1:98000861 intron 12 rs2786519 G A 1016 918 1.107 4.966 0.02585 
chr1:97578236 intron 20 rs12076846 G A 3 11 0.2727 4.571 0.03251 
Table 7.8. The SNPs that obtained a p-value< 0.05 in the TDT analysis for the region chr1:97499599-98599144, 
performed on the AGP cohort, are listed in this table. For each SNP, the position in the gene DPYD (NM_000110.3) is 
indicated. A1 indicates the minor allele, A2 the major allele. The numbers of transmitted minor allele count (T) and 
untrasmitted allele count (U) are reported. Odds ratio (OR) and p-value calculated for each SNP are also reported. 
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Among the SNPs examined in this TDT analysis, three of the missense variants identified during 
the mutation screening of DPYD carried out in the SLI families (p.C29R, p.M166V and p.I543V) 
were included. However, we did not detect a statistically different transmission of the minor allele 
to the affected individuals for any of these coding variants (Table 7.9). 
coordinates position SNP A1 A2 T U OR CHISQ P-value aa 
change 
chr1:98348885 exon 2 rs1801265 G A 881 872 1.01 0.046 0.8298 C29R 
chr1:98165091 exon 6 rs2297595 G A 449 421 1.067 0.901 0.3425 M166V 
chr1:97981395 exon 13 rs1801159 G A 842 819 1.028 0.319 0.5725 I543V 
Table 7.9. Results of the TDT association analysis for 3 common missense changes identified during the mutation 
screening of the gene DPYD.  
7.2.5 Mutation screening of DPYD in ASD probands carrying the variant rs3918290. 
In order to identify other possible variants in DPYD in the 7 ASD probands from the Italian and 
IMGSAC cohorts carrying the variant rs3918290, we completed a mutation screen of the gene in 
these individuals. The coding regions of both isoforms, the splice sites and the two regulatory 
regions at 5’ flanking region of the gene (Shestopal et al., 2000) were examined by Sanger 
sequencing. This screening identified 2 missense variants in four families: one in exon 2 
(rs1801265) and another one in exon 13 (rs1801158), identified also in the SLI samples (Table 
7.3). 
The SNP rs1801265 (p.C29R), a common variant predicted to have neutral effect for the protein, 
was identified in 3 families: 171, SM2 and C22.  
In the IMGSAC family 171 (Figure 7.9 a): 
 the splicing variant rs3918290 was inherited from the mother 171.5 by the proband 171.6, 
and by the unaffected brother 171.7;  
 the missense change p.C29R was present in the heterozygous state in the proband 171.6, the 
mother 171.5 and the unaffected brother 171.7, whereas the father 171.5 carried the minor 
allele C in the homozygous state. This segregation pattern indicated that the children had the 
two variants on different chromosomes, the rs1801265 on the paternal chromosome and the 
rs3918290 on the maternal one.  
In family SM2 (Figure 7.9 b): 
 the splicing variant rs3918290 was inherited from the father by the proband SM2.3, and not 
by the unaffected brother SM2.4;  
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 the missense change p.C29R was inherited by the proband SM2.3 from the father and was 
absent in the unaffected brother SM2.4, therefore we deduced that this variant lies on the 
same paternal haplotype that carries the splicing variant.  
In family C22 (Figure 7.9 c): 
 the splicing variant rs3918290 was inherited from the mother C22.2 by the proband C22.3; 
 both parents carried the missense variant p.C29R in the heterozygous state and the proband 
C22.3 was found to be heterozygote as well, therefore it was not possible to establish 
whether the two variants identified in the proband were on the same parental haplotype. 
 
Figure 7.9. Pedigree of six families included in the mutational screening of DPYD. The SNP G/A in the splice donor 
site of intron 14 (rs3918290) is indicated in red, the SNP rs1801265 (T/C, p.C29R) in exon 2 is indicated in green. For 
the pedigrees 171 (a) and SM2 (b), the haplotypes for DPYD were deduced from the segregation of these two variants. 
Families C19 (d), SM38 (e) and SM161 (f) carried only the splicing variant rs3918290. 
In the IMGSAC multiplex family 203, we identified the splicing variant and the missense change 
p.S534N (rs1801158) (Figure 7.10): 
 the splicing variant rs3918290 was inherited from the father by the affected child 203.3, and 
not by the affected sibling 203.4;  
 the missense change p.S534N was identified again in the proband 203.3, inherited from the 
father, but not in the affected brother 203.4. From this segregation pattern, we deduced that 
the two mutations are likely to lie on the same paternal haplotype, which is not shared by the 
affected siblings.  
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Figure 7.10. Pedigree of family 203. The electropherograms of the two SNPs identified in DPYD are shown for each 
family member. Based on these variants we could discriminate between the paternal haplotypes, but not between the 
maternal haplotypes (and for this reason they are indicated in grey). As represented in the figure, the siblings inherited 
different paternal haplotypes for DPYD. 
7.2.6 IQ analysis of ASD individuals carrying the variant rs3918290. 
In order to evaluate whether the splicing variant rs3918290, and therefore the partial loss of DPD, 
could have an effect on cognitive functioning in ASD individuals carrying this variant, we decided 
to analyse the IQ scores of these subjects in comparison with the entire AGP cohort.  
From this large group, Full scale IQ (FIQ) measures were available for 1246 affected individuals. 
37% of the subjects had normal cognitive functioning (FIQ≥86). The mean FIQ was 76 with a 
standard deviation of 25. Verbal IQ (VIQ) and performance IQ (PIQ) scores were also available for 
the majority of ASD cases genotyped for the SNP rs3918290. The VIQ, PIQ and FIQ scores were 
analysed separately and compared between ASD patients carrying the splicing variant in DPYD and 
those who were wild-type for the SNP, using a non parametric test, the Wilcoxon-Mann-Whitney 
test. Figure 7.11 shows that the distribution of the FIQ scores in ASD cases with the variant 
r3918290 did not significantly differ from the distribution of values measured in individuals without 
the variant. In contrast, non-verbal (PIQ) scores were significantly higher in individuals with the 
splicing mutation (p-value=0.02962). Although the median VIQ value for individuals carrying the 
splicing variant (median VIQ=59) was lower than that of wild-type individuals, the distribution of 
VIQ scores in the two groups did not show significant differences (p-value=0.5628). 
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Figure 7.11. The graph shows verbal, performance and full-scale IQ score analyses in ASD cases of the AGP cohort, 
genotyped for the SNP rs3918290. For each IQ measure, the distribution of the scores in individuals with the splicing 
variant (rs3918290) and individuals wild-type for the SNP (wt) is represented with a box plot. P-values were obtained 
from the Wilcoxon-Mann-Whitney test. 
7.2.7 Analysis of language phenotypes in ASD individuals carrying the variant rs3918290. 
The autism affection status of the individuals of the AGP cohort was derived from two diagnostic 
tools: Autism Diagnostic Interview-revised (ADI-R) (Lord et al., 1994) and Autism Diagnostic 
Observation Schedule-Generic (ADOS-G) (Lord et al., 2000). The ADOS-G schedule consists of a 
series of interacting tasks that aim to examine communication and behaviours in a standardized 
context. ADI-R instead is a structured interview conducted with the parents of individuals referred 
for a possible ASD condition. The questionnaire spans the three main domains that are impaired in 
autism: language and communication skills, social interactions and patterns of behaviour. Since we 
hypothesized the involvement of DPYD in SLI, we investigated a possible influence of the variant 
rs3918290 on language development of ASD individuals of the AGP cohort. We examined ADI-R 
items relative to language development and abilities (the overall level of current language, the age 
of first single words and the age of first phrases) in individuals for whom the rs3918290 has been 
successfully genotyped. 
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The ADI-R item regarding the overall level of current language evaluates the spontaneous use of 
social language, based on the formulation of sentences of at least three words. We performed a 
qualitative analysis dividing the children into two categories: “normal” language development 
(ability of formulating phrases with more than 5 words) and “delayed” language development 
(inability of formulating phrases with more than 5 words). For each category, the number of 
affected children carrying the splice variant rs3918290 was compared to affected children who are 
wild-type for rs3918290, using a χ2 test. However, no statistical difference between the two 
categories was detected (Table 7.10). 
Overall level of language normal delay total χ2 P-value 
with rs3918290 (G/A) 21 5 26 
1.4011 0.2365 
without rs3918290 (G/G) 1831 781 2612 
total 1852 786 
 
  
Table 7.10. Overall level of language abilities in ASD cases of the AGP cohort, genotyped for rs3918290. For each 
category (“normal” or “severe delay”), the number of individuals (with or without the variant rs3918290) is reported. 
The p-value, calculated with a χ2 test, does not indicate a statistical significant difference between the two groups. 
The same qualitative analysis was performed for “age of first words” and “age of first phrase” 
items. Generally, most babies say meaningful first words by age of 18 months. When this milestone 
is not achieved within 24 months, language abilities are considered abnormal. We performed a 
qualitative analysis subdividing the children in two categories: “normal” (age of first words < 24 
months) and “delayed” onset of speech (age of first words ≥ 24 months). The results of the χ2 test 
are shown in Table 7.11. No statistical difference between the two categories was detected. 
Age of first words Normal Delayed total χ2 P-value 
with rs3918290 (G/A) 12 12 24 
0.563617261 0.452806 
without rs3918290 (G/G) 1075 1461 2536 
total 1087 1473 
   
Table 7.11. Comparison of ASD cases of the AGP cohort, for whom age of first words and rs3918290 genotypes were 
available. The p-value, calculated with a χ2 test, does not indicate a statistical significant difference between the two 
groups. 
Within 36 months, children should be able to formulate simple phrases, formed by at least two or 
three words. Children who do not develop this ability within 3 years are referred for language delay. 
The results of the qualitative analysis performed comparing the number of affected children 
carrying splice variant rs3918290 with the number of ASD children without the variant, taking into 
account “normal” (age of first phrases < 36 months) and phrase speech “delay” (age of first phrases 
≥ 36 months), are shown in Table 7.12. As for the two previous tests, no statistical difference 
between the two categories was identified. 
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Age of first phrases Normal Delayed total χ2 P-value 
with rs3918290 (G/A) 5 19 24 
0.1698095 0.68028 
without rs3918290 (G/G) 617 1905 2522 
total 622 1924 
 
  
Table 7.12. Comparison of ASD cases of the AGP cohort, for whom age of first phrases and rs3918290 genotypes were 
available. The p-value, calculated with a χ2 test, does not indicate a statistical significant difference between the two 
groups. 
In conclusion, we investigated the role of DPYD in SLI and ASD, focusing on the most commonly 
implicated variant in DPD deficiency, rs3918290. In the SLI cohort and the Italian ASD cohort, we 
observed a slightly increased frequency of this SNP, compared to controls. However, this trend was 
not replicated in the IMGSAC cohort of multiplex families or the large number of cases belonging 
to the AGP cohort. Furthermore, in the AGP cohort, we did not observe a preferential allelic 
transmission of the minor allele of rs3918290 or other missense changes identified during mutation 
screening of the gene (p.C29R, p.M166V, p.I543V).  
In order to test whether the presence of the damaging splicing variant could have an effect on 
phenotypic features rather than ASD diagnosis per se, we analysed IQ scores of ASD cases carrying 
the rs3918290, but we found that they did not significantly diverge from the cognitive abilities of 
the rest of the cases, except for PIQ, that was reported to be slightly higher in the rs3918290-
carriers. When we stratified the AGP samples for language endophenotypes (age at first words, age 
at first phrases, overall level of language), again, we did not observe a significant difference in 
language delay between individuals with the splicing variant and individuals without it. However, it 
is worth noting that we examined a variant which is rare in the population, therefore our analyses 
included only a very small number of cases carrying the variant rs3918290, even in the large AGP 
cohort. The mutation screening of DPYD in the ASD probands with the splicing mutation identified 
two common missense changes, p.C29R and p.S534N, and their putative effect on DPD activity 
will be later discussed. 
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Chapter 8 
Discussion 
8.1 CNV screening in the SLIC cohort. 
Specific language impairment (SLI) is a common neurodevelopmental disorder diagnosed in 
children with an unexpected failure in the acquisition of language abilities, given adequate 
educational opportunities and in the absence of other medical conditions that could have an 
influence on language, such as hearing deficits or intellectual disability (Tomblin et al., 1996).  
Twin and family studies have provided evidence for the role of a strong genetic background in SLI, 
but the inheritance pattern suggests that several loci and environmental factors contribute to the 
overall risk in a complex manner (Stromswold, 1998). 
So far, the genetic bases of SLI have been investigated by genome-wide linkage studies, which 
yielded borderline significant p-values for few susceptibility loci: SLI1 on chromosome 16q, SLI2 
on chromosome 19q (SLIC, 2002, 2004), SLI3 on chromosome 13q (Bartlett et al., 2004; Bartlett et 
al., 2002) and a region on chromosome 7q (Villanueva et al., 2011). Further investigations on the 
SLI1 region with a targeted association study led to the identification of two candidate genes, 
ATP2C2 and CMIP (Newbury et al., 2009). Association with SLI has been detected also for variants 
in CNTNAP2, a gene on chromosome 7q35-q36.1 implicated in a broad spectrum of 
neurodevelopmental disorders. Moreover, two recent GWAs (Eicher et al., 2013; Luciano et al., 
2013) have reported association of language skills and related traits with variants in the genes 
ABCC13, DAZAP1, ZNF385D, COL4A2 and NDST4. 
A large portion of the genetic risk factors contributing to SLI, however, remains to be unravelled. 
Recent studies have shown that CNVs can be an important source of susceptibility to complex 
psychiatric disorders, such as ASD, ADHD and schizophrenia (Coe et al., 2012). Therefore, in order 
to investigate whether CNVs play a role also in the genetic architecture of SLI, we performed a 
genome-wide CNV screen in 540 individuals of the SLIC cohort, formed by families with one or 
multiple individuals with SLI. To our knowledge, this is the first study of CNVs within a SLI 
cohort.  
A high-confidence list of CNVs was generated using QuantiSNP (Colella et al., 2007) and 
PennCNV (Wang et al., 2007) algorithms. Moreover, using the annotations in DGV, a database that 
collects structural variants observed in the general population, we compiled a list of rare and novel 
CNVs.  
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A role for rare de novo CNVs has been proposed for neuropsychiatric disorders such as ASD (Levy 
et al., 2011; Sebat et al., 2007), schizophrenia (Xu et al., 2008) and bipolar disorder (Malhotra et al., 
2011). Rare de novo events are an extremely important source for the discovery of risk variants with 
a strong penetrance on the phenotype. Therefore, we also generated a list of predicted de novo 
CNVs for the families in which SNP data from both parents were available for the analysis.  
In order to investigate whether there are differences in CNV burden between language impaired 
individuals and subjects with normal language abilities, we carried out preliminary CNV burden 
analyses comparing the children with a formal diagnosis of SLI (174 individuals from 136 
independent families) with unaffected siblings (40 subjects from 38 independent families). These 
individuals could be considered ideal “super-controls”, as they share the same ethnic background of 
the affected siblings and their language abilities were assessed with the same tests used for the 
cases, that excluded the presence of language impairment. Moreover, cases and controls were 
genotyped on the same SNP array and this allows a comparison between two homogeneous sets of 
CNV calls. The use of different array types could introduce a bias in the analysis, due to different 
genomic coverage and resolution and possible array-specific artefacts (Pinto et al., 2011). On the 
other hand, a major disadvantage of using unaffected siblings as controls is that they are not 
independent. Hence, further analysis is currently being carried out by the SLI research group in 
Oxford, using a set of unrelated controls which have been genotyped using the same array (Illumina 
Human OmniExpress beadchip). 
The comparison of several classes of CNVs (the global list of CNVs, only deletions, only 
duplications, rare and novel CNVs and de novo CNVs) did not detect any significant difference 
between cases and controls. This could be due to the small sample size of the controls and to the 
fact that the burden analysis did not take into account their non-independent nature. For this reason, 
these results should be only considered as preliminary, and warrant further investigations using a 
larger set of independent controls (and this stage is being carried out by the SLI research group in 
Oxford).  
In contrast to CNV screenings for autism, schizophrenia and ID, that found an increased burden of 
rare/de novo CNVs in cases, the exploratory analyses that were performed for SLI yielded a result 
more similar to that obtained for dyslexia, bipolar disorder and Tourette Syndrome (Coe et al., 
2012). As previously discussed (chapter 1, paragraph 1.4), the comparison of CNV findings in 
different neurodevelopmental disorders with a certain degree of co-morbidity (ID, schizophrenia, 
autism, bipolar disorder and dyslexia) has shown that the difference in burden of large rare/de novo 
CNV between cases and controls increases with the severity of the phenotype (Coe et al., 2012). In 
particular, since the highest CNV burden has been observed in Developmental Delay and ID and the 
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lowest in bipolar disorder and dyslexia, it has been suggested that large rare/de novo CNVs might 
correlate with the level of cognitive impairment. This model then postulates that this range of 
disorders might be considered a part of a continuum and the overall level of disruptive mutations 
increases with the phenotypic severity (Coe et al., 2012). SLI is a neurodevelopmental condition in 
which the language domain is specifically impaired, while non-verbal IQ performances are in the 
normal range. Therefore, according to this model, it is conceivable that a high difference in rare/de 
novo CNV burden might not be observed in cases compared to controls.   
Although the class of rare/de novo CNVs did not show an overall increased burden, some CNVs 
might be of interest. The validation of the predicted CNVs will prioritize the events occurring in 
interesting functional candidates. For example, among the genic CNVs including exonic regions, 
we identified a rare de novo duplication predicted to involve the first two exons of the gene 
KLHDC10 (kelch domain containing 10, OMIM 615152). It has been implicated in response to 
oxidative stress, but the presence of a kelch domain, which is generally involved in protein-protein 
interactions, suggests that this protein might have various functions. A disrupting inherited deletion 
in a gene of the same family, KLHL23, has been previously identified in an ASD family (Holt et al., 
2012). Proteins containing the kelch domain have been also detected as one of the functional 
categories enriched among de novo genic CNVs in schizophrenia (Malhotra et al., 2011). The 
occurrence of de novo mutations in the same gene or genes with related functions in multiple 
unrelated patients with the same neuropsychiatric disorder or co-morbid conditions might indicate 
that these genes are implicated in important neurological processes. Therefore, validation of this 
CNV will be required in order to investigate whether rare variants in KLHDC10 might be possible 
contributing factors also for SLI.  
Another example of an interesting candidate is given by CACNA2D1. Widespread expression of this 
gene, encoding the α2-δ1 subunit of Voltage-dependent calcium (Cav) channels, has been detected 
in rat brain with an enrichment in regions involved in learning and memory (Cole et al., 2005). 
Another gene, coding for the subunit α1-C of voltage calcium channel, CACNA1C, has been 
implicated in schizophrenia and other neuropsychiatric conditions (Bhat et al., 2012) and its 
inactivation in mouse hippocampus and neocortex has been shown to impair memory formation 
(White et al., 2008). Weak verbal short term memory, as evidenced by tasks requiring repetition of 
words or sentences (such as the NWR test), is an important feature of SLI and association with the 
NWR trait has been found for ATP2C2, which codes for a calcium ATPase (Newbury et al., 2009). 
Calcium is an important ion in the regulation of many neuronal cell functions (Zheng and Poo, 
2007), therefore it is plausible that calcium homeostasis might be important also for neuronal 
processes required for verbal memory and language acquisition.  
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We also identified a homozygous deletion involving the gene ZNF277, predicted to cause the 
complete lack of exon 5. The absence of this exon is predicted to cause a frameshift that would 
introduce a premature stop codon in exon 7. Little is known about this gene, but it is conserved 
throughout evolution and it is expressed in brain (Liang et al., 2000), in particular in neocortex and 
hippocampus. We therefore validated this exonic homozygous deletion. The characterization and 
the follow-up of this CNV will be discussed in the paragraph 8.3.  
CNVs at loci implicated in microdeletion/microduplication syndromes can be found also in multiple 
neuropsychiatric disorders, such as ASD, ADHD, epilepsy and ID. For example, during our CNV 
screening, we identified common duplications in the region 17q21.31. The 17q21.31 locus is 
associated with KANSL1-related ID syndrome, which can be caused by a 500-650 kb heterozygous 
deletion at chromosome 17q21.31 that includes the gene KANSL1 (Koolen et al., 2012; Zollino et 
al., 2012). The KANSL1 protein plays a role in chromatin modification regulating KAT8, which 
influences gene expression through histone H4 lysine 16 (H4K16) acetylation (Koolen et al., 2012). 
Reciprocal microduplications have been described, generally, in association with variable, but 
milder phenotypes (Grisart et al., 2009; Kitsiou-Tzeli et al., 2012). In the SLIC cohort, two smaller 
de novo duplications (one of ~184 kb and the other one of ~112 kb) on chromosome 17q21.31, 
encompassing the 5’ end of the gene, were predicted in two unrelated affected individuals. 
Although duplications overlapping this region are commonly reported in the DGV, the validation 
and characterization of the breakpoint positions will be needed to clarify the effect of these CNVs 
and the potential implication of KANSL1 gene in SLI.  
8.2 CNVs on chromosome 15q11-q13. 
A chromosomal region in which CNVs are recurrently observed across multiple neuropsychiatric 
conditions is the 15q11-q13 locus (Coe et al., 2012; Cooper et al., 2011; Moreno-De-Luca et al., 
2013). The presence of complex patterns of highly homologous LCRs makes this locus one of the 
most unstable regions in the human genome and can lead to a number of different rearrangements 
(Szafranski et al., 2010). Deletions and duplications are likely to be caused by NAHR between the 
LCRs, which are organized in clusters, that have been designated BP1-BP6. 
Microduplications and microdeletions between BP1 and BP2 include four non-imprinted genes, 
TUBGCP5, CYFIP1, NIPA1 and NIPA2, all possible candidates for neuronal alterations (Burnside 
et al., 2011), while microduplications and microdeletions between the breakpoints BP4 and BP5 
include the candidate gene CHRNA7, coding for the α7 subunit of the neuronal nicotinic 
acetylcholine receptor (Shinawi et al., 2009). Both types of CNVs have been associated with a wide 
spectrum of phenotypes, primarily represented by neurological and developmental problems. CNVs 
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at the BP1-BP2 region have been observed in individuals with language delay and developmental 
delay (Burnside et al., 2011; Doornbos et al., 2009), ID (Cooper et al., 2011), ASD (Doornbos et al., 
2009; Sanders et al., 2011; van der Zwaag et al., 2010), schizophrenia (Kirov et al., 2009; 
Stefansson et al., 2008) and epilepsy (de Kovel et al., 2010). Interestingly, a retrospective analysis 
of individuals carrying BP1-BP2 CNVs found that speech delay was one of the most frequent 
features of microdeletion carriers (Burnside et al., 2011). 
CNVs at the BP4-BP5 region have been described in individuals with intellectual disability with 
seizures (Sharp et al., 2008), autism (Miller et al., 2009; Pagnamenta et al., 2009), schizophrenia 
(International_Schizophrenia_Consortium, 2008; Stefansson et al., 2008), bipolar disorder (Ben-
Shachar et al., 2009), epilepsy (Helbig et al., 2009; Masurel-Paulet et al., 2010) and language delay 
(Ben-Shachar et al., 2009). 
In the CNV screening performed on the SLIC cohort, we identified and validated microdeletions 
(~500 kb) between the breakpoints BP1 and BP2 in two families, and microduplications (~495 kb) 
between the breakpoints BP4 and BP5 in another three families.  
In family G46, the BP1-BP2 microdeletion was inherited by the proband, but not by the affected 
sibling. In family E21 instead, the paternal BP1-BP2 deletion was not inherited by the proband, but 
was inherited by his sister E21_5, whose language status was classified as unknown. The frequency 
of this deletion in SLI probands was then 0.76% (1 out of 132 independent probands). 
In family G68, the BP4-BP5 microduplication, identified in the mother, was not transmitted to the 
affected children. In family E38, we found that the microduplication in the 15q11-q13 region was 
not inherited by the proband E38_3, but was inherited by the affected half-sibling E38_4. In family 
G79 instead, the paternal BP4-BP5 microduplication was inherited by all children with language 
deficits and was absent in the unaffected child G79_3. As for the BP1-BP2 microdeletion, the 
frequency of the BP4-BP5 microduplication in SLI probands was 0.76% (1 out of 132 independent 
probands). 
Therefore, both the BP1-BP2 microdeletion and the BP4-BP5 microduplication were identified in 
affected and unaffected individuals and were not present in all the affected members of these 
families. This incomplete segregation suggests that these CNVs, if implicated in SLI, might be 
contributing risk variants with an incomplete penetrance and variable expressivity, as has 
previously been suggested. 
These findings are not surprising, as these types of CNVs can be found also in healthy controls 
(Cooper et al., 2011; Leblond et al., 2012; Moreno-De-Luca et al., 2013; Shaikh et al., 2009). 
Although the study carried out by Leblond et al. (2012) did not find a different frequency for BP1-
BP2 microdeletions between ASD cases (0.32%) and controls (0.25%), the study conducted by 
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Cooper et al. on a large cohort of 15,767 cases with ID, developmental delay and/or other 
abnormalities and 8,329 healthy controls, found that microdeletions at 15q11.2 were significantly 
enriched in cases (p-value=2.5 x 10
-5
).  
A similar situation has been described for BP4-BP5 microduplications. Although the phenotypes 
observed in microduplication carriers are similar to those of microdeletion carriers (developmental 
delay, intellectual disability, ADHD, ASD) (Szafranski et al., 2010), the microduplications do not 
show an increased frequency in cases of ASD or epilepsy compared to controls (Helbig et al., 2009; 
Leblond et al., 2012). Therefore, it has been hypothesized that haploinsufficiency of CHRNA7 
might have a stronger effect on the phenotype compared to the microduplication, but this does not 
exclude that the microduplication could also predispose to neurodevelopmental or neuropsychiatric 
disorders.  
In conclusion, our findings support the hypothesis that these CNVs are not sufficient to cause a 
pathological phenotype, but may represent modifiers in a range of neurodevelopmental conditions, 
including SLI, acting in concert with other factors (genetic, epigenetic or environmental), that 
determine then a variable phenotypic outcome (Leblond et al., 2012; van Bon et al., 2009).  
8.3 Identification of a homozygous exonic deletion in ZNF277. 
During the CNV screening in the SLIC cohort, we identified a novel homozygous microdeletion of 
exon 5 of the ZNF277 gene in a proband with severe receptive and expressive language impairment. 
The characterization of this microdeletion, predicted to result in a frameshift of the transcript and in 
the introduction of a premature stop codon, allowed the fine mapping of the deletion breakpoints. 
This 21,379 bp microdeletion was not found in the proband's affected sister or her brother, who had 
mild language impairment. However, it was inherited from both parents, each of whom carries a 
heterozygous microdeletion and have a history of language problems. IBD analyses demonstrated 
that the parents were not consanguineous. 
Screening of an additional 321 SLI families indicated that the allelic frequency of ZNF277 
microdeletions was more than twice that observed in control cohorts (1.1% vs 0.4%), although the 
rarity of the microdeletion meant that this difference did not reach significance when examined with 
a two-tailed Fisher’s exact test (p-value =0.206). 
Although a diagnosis of SLI excludes the presence of other clinical conditions that affect language, 
SLI presents co-morbidity with other neurodevelopmental disorders, such as ASD (as discussed in 
paragraph 2.6.2). Recent studies investigated whether the phenotypic similarities of the language 
deficits may reflect potentially shared causes. An example of a functional link between SLI and 
ASD, in addition to other neurodevelopmental disorders, is given by CNTNAP2 (contactin 
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associated protein-like 2): variants in and disruptions of this gene are reported to be associated with 
language endophenotypes in both SLI and ASD (Peñagarikano and Geschwind, 2012), suggesting 
that CNTNAP2 might harbour susceptibility risk factors that could impair language skills in distinct 
language-related disorders.  
The ZNF277 microdeletion falls in the AUTS1 region of linkage to ASD (7q21-q32, OMIM 
209850). In this region, association with ASD was found for two genes that are proximal to 
ZNF277, DOCK4 (dedicator of cytokinesis 4) and IMMP2L (IMP2 inner mitochondrial membrane 
protease-like) (Maestrini et al., 2010). A rare microdeletion involving these two genes was 
described in a family with autism and dyslexia: deletions of DOCK4 were suggested to be a risk 
factor for reading impairment, and, in conjunction with other variants, for ASD (Pagnamenta et al., 
2010).  
Therefore, given the genomic position of the ZNF277 gene within a known ASD risk locus, as well 
as the prior observations of phenotypic and genetic overlaps between SLI and autism, we postulated 
that disruption of this gene may be relevant for both disorders. However, screening of a cohort of 
ASD multiplex families found that the frequency of ZNF277 microdeletions in individuals with 
autism was similar to that observed in controls. At the time of the discovery, the ZNF277 
microdeletion that we describe was not documented in the Database of Genomic Variants, possibly 
because of the small number of standard array SNPs contained within the deleted segment. We 
specifically searched supplementary data from CNV studies of ASD and found that the 
microdeletion had been previously characterized during a CNV screen of the Simons Simplex 
Collection (Sanders et al., 2011) and occurred at a frequency of 0.3% (6/2248 chromosomes). This 
figure matches the one observed in our ASD cohort, reinforcing our conclusion that the ZNF277 
microdeletion does not contribute to ASD susceptibility.  
Since DOCK4 lies head-to-head with the ZNF277 gene, we investigated whether there is a 
reciprocal position effect for deletions. We found that the heterozygous microdeletion of exon 5 in 
ZNF277 does not affect the expression of autism candidate genes IMMP2L and DOCK4. Similarly, 
a microdeletion involving the 3’ end of DOCK4 (exons 27-52) and the first three exons of IMMP2L, 
decreases the expression level of DOCK4 but not ZNF277 (Pagnamenta et al., 2010). Taken 
together, these data suggest that ZNF277 microdeletions may play a role in SLI susceptibility that is 
distinct from the autism risk loci described in the AUTS1 region.  
In the SLI families where DNA of both parents was available, we observed that none of the 
observed heterozygous ZNF277 microdeletions was de novo and that, in many cases, the 
segregation with language impairment was incomplete. In three families, the microdeletion was not 
inherited by the proband, while in another three families, the microdeletion was inherited by 
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unaffected siblings. These data suggest that the heterozygous copy loss of exon 5 of ZNF277 may 
represent a low penetrant risk factor rather than a highly penetrant variant, while the homozygous 
copy loss may be expected to have a greater impact on the SLI susceptibility.  
In neurodevelopmental disorders, it is hypothesised that multiple common and rare variants act in 
concert to determine the phenotype in a complex manner. Under this hypothesis, it is perhaps not 
surprising to find risk variants in both affected and unaffected family members, or to observe 
transmission to only a subset of affected individuals of the family. Such findings are consistent with 
a multigenic threshold model (Cook and Scherer, 2008). Some variants may be highly penetrant, 
while others may be individually insufficient to cause the disorder, but they may combine with 
other risk loci and/or environmental factors to cross the risk threshold. Even well-established risk 
loci for autism, ID, schizophrenia and other neurodevelopmental syndromes provide examples of 
imperfect segregation, as shown by exonic CNVs in NRXN1 (Bucan et al., 2009), missense 
mutations in SHANK2
 
(Berkel et al., 2010), rare sequence and structural variants in CNTNAP2 
(Bakkaloglu et al., 2008; Gregor et al., 2011) and microdeletions and microduplications at 16p11.2
 
(McCarthy et al., 2009; Weiss et al., 2008). Interestingly, single case reports and network analyses 
indicate that the pathways implicated in different diseases may converge on common genes, such as 
CNTNAP2 and NRXN1, suggesting that there are some key genes important for several aspects of 
brain development and, if mutated, they can contribute to a range of disorders, depending on the 
genetic background. This supports the hypothesis of shared biological pathways among different 
neuropsychiatric conditions. 
Given these data, some researchers proposed a “dual-hit” model (Girirajan et al., 2010). Under such 
a hypothesis, the phenotypic effects of copy number events, even those of high penetrance, may be 
modulated by a second independent genetic “insult” which may take the form of an additional CNV 
or a rare coding mutation. Support for this model comes from studies of single language-impaired 
cases (Newbury et al., 2013) and larger cohorts of individuals with ASD (Girirajan et al., 2013; 
O'Roak et al., 2011) or particular
 
microdeletion/duplication syndromes (Girirajan et al., 2012; 
Girirajan et al., 2010; Leblond et al., 2012). In the current discovery family with ZNF277 
microdeletion, there were no obviously co-segregating second hits. A rare duplication of 72 Kb was 
observed to occur only in the proband (chr2:41263841-41336618, hg19) and a novel 9 Kb deletion 
was observed in the mother and sister (chr2:125099924-125109738, hg19). However, neither of 
these events affect any coding sequence. Larger or more in-depth studies would therefore be 
required to further investigate possible genetic modulators of ZNF277 microdeletions. It is 
conceivable that the phenotypic variability associated with heterozygous ZNF277 microdeletions 
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might be modulated by a combination of pathogenic single nucleotide variants in other genomic 
locations, small changes in regulatory regions or other factors.  
ZNF277 is an evolutionary conserved zinc finger gene with 12 exons (Liang et al., 2000). It is 
expressed in several tissues, including the brain, particularly in the neocortex and hippocampus in 
early mid-fetal development. Although the function of ZNF277 has not been studied in humans, the 
mouse Zfp277 gene, which shows more than 80% homology to the human gene at the amino acid 
level, has been implicated in the epigenetic regulation of cellular memory (Negishi et al., 2010). 
Zfp277
-/-
 mice were born healthy and fertile, indicating that the knockout is not lethal
 
(Negishi et al., 
2010), consistent with our finding of viability for humans with no functional ZNF277. Interestingly, 
the Zfp277 protein directly interacts with Bmi-1, a key component of the Polycomb Repressor 
Complex (PRC1). This complex has an important role in the maintenance of adult stem cells from 
numerous tissues, including the central nervous system (Molofsky et al., 2005; Molofsky et al., 
2003). 
In conclusion, we propose that the disruption of ZNF277 may contribute to SLI in a complex 
genetic model. We further hypothesize that this risk is distinct from the autism risk loci previously 
described in this region. Further studies will be required to replicate these findings and characterize 
the function of the human protein ZNF277, clarifying its potential implication in language 
development. 
8.4 Analysis of the candidate gene DPYD in SLI. 
After the identification of the ZNF277 microdeletion in the proband G4_4, we consulted the 
clinicians who recruited the family, in order to obtain additional phenotypic information. From the 
clinical reports, we found that the affected sister G4_5, who did not carry the ZNF277 deletion but 
was affected with SLI, had a metabolic disorder known as dihydropyrimidine dehydrogenase (DPD) 
deficiency. This autosomic recessive disease is caused by mutations in the gene encoding the DPD 
enzyme, DPYD. Partial or complete loss of the activity of DPD, which is the initial and rate-limiting 
enzyme of the catabolism of pyrimidines, causes an accumulation of uracil and thymine and reduces 
the amount of the neurotransmitter β-alanine produced by this pathway (Figure 8.1).  
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Figure 8.1 (Van Kuilenburg et al., 1999). Catabolic pathway of pyrimidines. 
The clinical presentation of children affected by DPD deficiency can be highly heterogeneous, 
however neurological dysfunctions have been frequently observed and, interestingly, in some cases 
language impairment and speech delay have been reported (Henderson et al., 1995; van Gennip et 
al., 1981; Van Kuilenburg et al., 1999). Other disorders in which pyrimidine or purine homeostasis 
is altered, also present a spectrum of neurological abnormalities, indicating that the fine-regulation 
of nucleotide metabolism is important for CNS development (Micheli et al., 2011). Moreover, rare 
variants in DPYD have been found in a range of neurodevelopmental conditions, such as ASD, 
schizophrenia and ID (Carter et al., 2011; Willemsen et al., 2011; Xu et al., 2012). Therefore, 
several lines of evidence indicate that DPYD is an interesting functional candidate gene for 
neurological phenotypes. Thus, we decided to investigate whether DPYD could have a contributing 
role in SLI, both in this family and across the larger SLIC cohort. 
In the discovery pedigree G4, we found that the affected child G4_5 was heterozygous compound 
for two deleterious mutations in DPYD: a paternally inherited splice site mutation in intron 14 
(rs3918290, known also as DPYD*2A), and a maternally inherited missense change in exon 6 
(rs72549308, p.S201R). G4_4 did not show any variant in DPYD, whereas the older brother G4_3 
carried only the paternal splice site variant.  
The splicing variant rs3918290 is one of the few mutations with a well-established role in DPD 
deficiency: the disruption of the donor splice site in intron 14 causes the skipping of exon 14 in the 
mRNA, that would result in a protein lacking the correspondent 55 amino acids with no residual 
activity.  
The missense variant p.S201R is also predicted to have a deleterious effect on DPD activity and it is 
rare in the general population. Analysis of the crystal structure of the pig DPD protein indicates that 
the substitution of serine at position 201 with an arginine, which is an amino-acid with large side 
chain, could interfere with the electron flow, as this residue participates in a domain interface close 
to FAD and cluster Fe-S (van Kuilenburg et al., 2002). A compound heterozygosity for rs3918290 
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and S201R has been previously reported in a Scottish patient with motor impairment, intellectual 
disability and history of regression (van Kuilenburg et al., 2002). In this individual, no DPD activity 
was detected in peripheral blood mononuclear cells (PBM). Therefore, the compound 
heterozygosity rs3918290/S201R genetically confirmed the diagnosis of DPD deficiency in G4_5. 
In this family, the complete loss of DPD activity was found only in one out of two affected children, 
since we did not identify any variant in DPYD in the proband G4_4, who carries the homozygous 
copy loss in ZNF277. Therefore these findings suggest that, if the complete losses of ZNF277 and 
DPD activity represent risk factor for SLI, they contribute independently to language impairment in 
the affected members of family G4. SLI is a complex disorder in which multiple risk factors are 
likely to be implicated, therefore it remains possible that this heterogeneity could be observed also 
within families and that damaging mutations in DPYD might contribute to SLI in a complex 
manner.  
Since rs3918290 is one of the most common mutations in DPD deficiency, we analysed the 
frequency of this splicing variant in a group of 166 SLIC cases. We identified the variant rs3918290 
in 3 SLI cases in addition to G4_5, thus resulting in a minor allelic frequency (MAF) of 1.2% (A=4; 
G=330). This frequency was twice the reported frequency in controls with European ancestry 
(~0.6% in 1000 Genomes CEU samples and ESP EA controls). Although the frequency is double 
the expected, it does not reach statistical significance, perhaps due to the rarity of the splice site 
mutation.  
To check whether the three affected children, carrying the splice variant rs3918290, also had a 
compound heterozygosity that could determine the complete loss of DPD activity, a mutation 
screening of the coding regions and the regulatory regions at 5’ of DPYD was performed in the 
three SLI cases and their family members. Across the three families (Figure 8.2), we identified a 
novel variant in the region flanking the 5’ of the gene (chr1:98386652, hg19), not reported in public 
databases, and five known coding variants (p.C29R (rs1801265), p.M166V (rs2297595), p.S534N 
(rs1801158), p.I543V (rs1801159) and p.V732I (rs1801160)), all common in the population (allelic 
frequency >1%).  
The non-coding change maps at -72 nucleotides from the transcription start site and was found in a 
single family (E30) from the three studied. In this 5’ flanking region, two GC boxes, essential for 
the promoter activity, have been found to be target sites for the ubiquitous transcription factors Sp1 
and Sp3: SpB (from -68 to -60) and SpC (from -37 to -19) (Shestopal et al., 2000; Zhang et al., 
2006b). This novel change might interfere with the transcription of the gene, therefore further 
investigations would be required to establish the consequences of this variant on DPYD expression.  
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The impact the five known common missense changes on DPD activity is controversially debated in 
the literature.  
 The p.C29R substitution is predicted to have a benign effect on the DPD protein by 
bioinformatic tools. Although DPD-deficient patients heterozygous compound 
rs3918290/pC29R have been described (Vreken et al., 1997b) and the recombinant 
expressed DPD protein carrying the C29R substitution in E.coli was reported to have no 
residual activity (Vreken et al., 1997a), homozygosity for this mutation has been reported in 
individuals with normal DPD activity (Collie-Duguid et al., 2000; Seck et al., 2005). 
Moreover, in a recent study (Offer et al., 2013) DPYD variants were expressed in a 
mammalian cellular model, and the enzymatic activity of the expressed DPD protein was 
determined. In this study, the change p.C29R showed higher enzymatic activity compared 
with wild-type DPD, leading the researcher to hypothesize that it might be a “protective” 
allele.  
 The p.S534N is predicted to have a damaging effect on the protein by bioinformatic tools, 
and the residue Ser534 is highly conserved throughout evolution. This variant was 
previously associated with toxicity reactions to 5-FU (Loganayagam et al., 2013) and 
decreased DPD activity in a control population (Seck et al., 2005); however in the study 
performed by Offer et al. (2013) the expression of the protein carrying this variant in a 
cellular model was associated with a significantly increased DPD activity (Offer et al., 
2013) and this is supported by studies showing a lack of correlation between p.S534N and 
5-FU sensitivity (Amstutz et al., 2009; Schwab et al., 2008). Offer et al. suggested that the 
S534N substitution may alter the protein structure of the conserved loop structure that 
covers the active site and that this might increase the substrate turnover. 
 The change p.V732I is predicted deleterious for the protein, but it has been associated with 
normal DPD activity (Ezzeldin and Diasio, 2004; Offer et al., 2013; Seck et al., 2005) and it 
has been shown not to significantly alter the enzymatic activity in the human cellular model 
(Offer et al., 2013).  
 p.M166V is also predicted damaging for the protein activity and has been found in 
association with 5-FU toxicity (Gross et al., 2008), however the majority of the studies agree 
on the fact that p.M166V is a common polymorphism with no effect on the protein activity 
(Ezzeldin and Diasio, 2004; Seck et al., 2005).  
 The change p.I543V is also reported as a common change with neutral effect on the protein. 
Four of the common changes (p.M166V, p.S534N, p.I543V, p.V732I) identified in these three SLI 
families were found also in the exome sequences of a group of 45 independent probands of the 
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SLIC cohort. Their allelic frequencies were not significantly different from those found in the 
general population. As for the previously investigated SLI families, 7 individuals carried multiple 
variants in DPYD, while 17 individuals were found to have only one of these missense mutations. 
Since none of these variants was consistently reported to have a damaging effect on the protein 
activity, we do not predict that any of the individuals of the SLI families that we analysed have a 
complete loss of DPD activity. The only exception is for E30_4, (Figure 8.2 c), who is compound 
heterozygote for the splicing variant rs3918290, paternally inherited, and for a novel promoter 
variant, maternally inherited, which could possibly affect the gene expression level, thereby 
reducing or abolishing DPD residual activity.  
For the other individuals, we can tentatively formulate a hypothesis for the combined effect of 
DPYD variants, given the well-established damaging effect of rs3918290, the possible higher 
activity for p.C29R and p.S534N (Offer et al., 2013), and a neutral effect for p.M166V, p.I543V 
and p.V732I (Ezzeldin and Diasio, 2004) (Figure 8.2): 
 the three probands E6_3 (rs3918290/+), M18_3 (rs3918290/+), E30_3 (rs3918290/p.V732I) 
are likely to have a partial loss of DPD activity; 
 compound heterozygosity of the two protective alleles p.C29R/p.S534N may determine an 
increased DPD activity in the affected sibling E6_4.  
 The compound heterozygosity of a damaging and a protective allele, such as 
rs3918290/p.C29R (in E30_1, M18_2 and M18_4) or rs3918290/p.S534N (in E6_2), might 
lead to a balanced effect on DPD activity.  
Interestingly, all probands in these 3 families would manifest an altered level of DPD activity, 
meaning that any level of dysregulation might be harmful. 
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Figure 8.2. Hypotheses of DPD activity levels in three SLI families carrying the splicing mutation rs3918290, based on 
the mutation screening results. Alleles A and B indicate the paternal alleles for DPYD, alleles C and D the maternal 
alleles. *M166V was identified in all family members of E6, therefore it was not possible to determine the haplotype 
segregation for this change. Increased (), decreased () and balanced effects (=) on DPD activity are indicated. 
Taken together, the genetic profile of DPYD in the families of rs3918290 carriers revealed complex 
patterns of mutations and the simultaneous presence of multiple coding variants complicate the 
prediction of their effect on DPD activity, since the effect of damaging mutations might be 
compensated by potentially “protective” alleles. Therefore, the genotype-phenotype correlation is 
usually not straightforward and our hypotheses should be verified measuring the effective levels of 
DPD activity. However, it is possible that damaging mutations in DPYD, like rs3918290, or an 
accumulation of multiple mutations could lead to functional effects and that they could be 
contributing factors for neurological abnormalities in at least some language-impaired individuals. 
Moreover, variants in intronic and non-coding regions of the gene, not examined in this study, could 
also influence the transcription levels of this enzyme.  
In conclusion, these results indicate that DPYD is an interesting candidate gene for SLI. In addition 
to a case of complete DPD deficiency, we observed an increased allelic frequency of the splicing 
variant rs3918290 in SLI probands compared to controls, although this difference was not 
significant. The rarity of the variant makes it difficult to provide statistical evidence for its 
involvement in SLI, as very large sample sizes would be needed even if there was a real effect, and 
it cannot be excluded that the reported frequency difference is a chance finding. To further 
investigate the influence of DPYD in language development, we are planning to extend the analysis 
of rs3918290 to a population-based sample, the “Avon Longitudinal Study of Parents and Children” 
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(ALSPAC) cohort (previously described in paragraph 2.4.7), with the aim to test whether this 
mutation in DPYD is associated with low language performance. 
8.5 Analysis of the candidate gene DPYD in ASD. 
Autism Spectrum Disorders (ASD) are a heterogeneous group of neurodevelopmental conditions 
characterized by impairment in social interactions and repetitive and restricted patterns of 
behaviours. Autism, which is the most severe form of ASD, presents deficits also in the language 
and communication domain. The clinical manifestations of autistic features are variable, ranging 
from mild to severe abnormalities. In the past thirty years, epidemiological studies have shown that 
ASD are highly heritable, highlighting the importance of genetic factors in ASD. However, the 
genetic causes underlying this group of disorders have been determined only for a minority of cases 
(Devlin and Scherer, 2012; Schaaf and Zoghbi, 2011). In about 10% of cases, classified as 
“syndromic”, ASD features can be observed together with genetic syndromes or known Mendelian 
conditions, such as Fragile X syndrome, Rett syndrome, PTEN macrocephaly syndrome or 
Neurofibromatosis. Rare chromosomal abnormalities (e.g. 45 X0 Turner syndrome and trisomy 21) 
and CNVs at loci associated with known syndromes (e.g. the maternal duplication in the Prader-
Willi/Angelman syndrome region at chromosome 15q11-q13) can account for 7-20% of ASD cases. 
Known metabolic disorders, such as phenylketonuria and creatine deficiency, have been estimated 
to contribute to ~5% of cases of ASD. The genetic causes of the rest of non-syndromic or idiopathic 
autism have yet to be identified.  
Rare, but penetrant mutations have been identified in genes, such as NLGN3, NLGN4, SHANK1, 
SHANK2, SHANK3, NRXN1, NRXN3, CNTNAP2 (Betancur, 2011; Devlin and Scherer, 2012), 
important for the formation, maturation and regulation of neuronal circuits (Peñagarikano and 
Geschwind, 2012; Südhof, 2008). Moreover, the NGS technologies, which allow the examination of 
the whole exomes without selecting candidate genes a priori, have identified rare sequence variants 
in genes, such as AMT and PEX7, involved in neurometabolic disorders (Yu et al., 2013), but not 
directly implicated in synaptic activity. Highly penetrant mutations in AMT (coding for an enzyme 
essential for glycine degradation) classically cause nonketotic hyperglycinemia and mutations in 
PEX7 (coding for a receptor required for import of proteins into the peroxisomes) classically cause 
rhizomelic chondrodysplasia punctata: interestingly, Yu et al. (2013) demonstrated that 
hypomorphic mutations in these genes, in homozygous state or in compound heterozygosity, could 
result in atypical milder forms of these diseases, associated with a ASD phenotype. This study then 
suggested that unexpected pathways may be involved in ASD aetiology. 
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Since neurological abnormalities and autistic features have been observed in patients with DPD 
deficiency (Van Kuilenburg et al., 1999) and rare CNVs and sequence variants in DPYD have been 
reported for autism (Carter et al., 2011), DPYD represents an interesting non-synaptic candidate 
gene for ASD. Therefore, we decided to investigate its role also in this neurodevelopmental 
disorder. As for the SLIC cohort, our initial analysis evaluated the frequency of the splice variant 
rs3918290 in affected individuals. The analysis was carried out in two stages. In the first one, the 
SNP rs3918290 was genotyped in 231 Italian simplex families, 224 IMGSAC multiplex families 
and 449 Italian unrelated controls, by restriction endonuclease analysis. Subsequently, we extended 
the analysis to the entire cohort of ASD families of the AGP Consortium, which have been 
genotyped with the Illumina Infinium 1M-single and 1M-Duo SNP array (Anney et al., 2012), that 
include also the variant of interest rs3918290.  
In the first stage, we identified the polymorphism rs3918290 in 2/224 IMGSAC multiplex families 
(203 and 171), 8/231 Italian simplex ASD families (5/231 probands) and 4/449 unrelated Italian 
controls. Segregation analyses showed that the variant did not completely segregate with the 
phenotype. The Minor Allele Frequency (MAF) for rs3918290 in the Italian trio sample was 1.08% 
compared to 0.45% in Italian controls (4/898), which is similar to the MAF reported for Tuscan 
controls in the database of 1000 Genomes Project (0.5%). Although the frequency in affected 
individuals is higher than in controls, this difference is not statistically significant (p-value= 
0.1541). 
In the IMGSAC sample, we obtained an estimated allelic frequency of 0.45% (2/448), selecting a 
priori one affected member in each family. In this case, the MAF for rs3918290 did not deviate 
from the frequencies reported in public databases for samples of European origin (0.4% - 0.6%). 
Therefore, the findings obtained from the multiplex families of the IMGSAC cohort did not 
replicate the trend observed for the Italian ASD simplex families.  
To further investigate this variant in a larger number of affected individuals, we extended the 
analysis to the entire AGP cohort. The SNP rs3918290 was successfully genotyped in 2,681 
independent cases and the allele A was detected in 25 of them, giving an allelic frequency of 0.47% 
(25/2681 probands), again not significantly different from the MAF reported in European 
populations (0.4%-0.6%). 
Given the availability of genotype information for rs3918290 for the parents of the affected 
individuals, we also performed a Transmission Disequilibrium Test (TDT) on these AGP samples, 
to test whether the minor allele A was preferentially transmitted to individuals with ASD. However, 
we did not observe a preferential transmission, suggesting that the splicing variant is not associated 
with the ASD phenotype in the whole group of AGP families. To test whether other variants in 
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DPYD and the region encompassing its adjacent gene MIR137, another good candidate gene for 
neurodevelopmental disorders (Willemsen et al., 2011), were associated with ASD in the AGP 
group, we extended the TDT analysis to a set of 99 independent SNPs in the genomic region 
including DPYD and MIR137 (chr1:97499599-98599144). After Bonferroni correction for multiple 
testing, no SNPs reached a p-value <0.05, indicating that common variants do not contribute to the 
ASD phenotype in these families. 
Although rs3918290 showed no effect on the ASD categorical phenotype, it could have an effect on 
specific phenotypic features of ASD, such as cognitive functioning or language abilities. For this 
reason, we decided to investigate if the presence of the mutation rs3918290 could determine lower 
performances on Verbal IQ (VIQ), non-verbal IQ (PIQ) and Full scale-IQ tests (FIQ). We analysed 
the AGP IQ scores for the cases genotyped for the SNP rs3918290, comparing the individuals 
carrying the variants with those without it. We found that the distribution of the VIQ and FIQ scores 
did not significantly differ between the two groups and PIQ scores appeared instead slightly higher 
in individuals with the splicing variant (P-value= 0.03). Therefore, we did not observe an effect of 
the variant rs3918290 on cognitive abilities in the ASD phenotype. 
Qualitative analyses were also performed for language endophenotypes. Information regarding 
language development in the autistic individuals of the AGP cohort were provided by three Autism 
Diagnostic Interview-revised (ADI-R) (Lord et al., 1994) items: the overall level of current 
language, the age of first single words and the age of first phrases. For each test, we subdivided the 
individuals into two categories: subjects with “normal” development and subjects with “delayed” 
language development, according to commonly used thresholds. We did not find a significant 
difference for any of these endophenotypes. It should be noted that given the rarity of the splicing 
variant, these endophenotype analysis were based on a very small number of cases carrying the 
variant, compared to the cohort size.  
In order to check whether the ASD probands carried other variants in the coding or 5’ regulatory 
regions of DPYD, that could potentially cause a complete loss of DPD activity in conjunction with 
rs3928190, we performed a mutation screening of the gene in the IMGSAC and Italian probands 
carrying the splicing variant, as we did for the SLI families. This screening identified 2 common 
missense variants, identified also in the SLI samples and described above: one in exon 2 
(rs1801265, p.C29R) and another one in exon 13 (rs1801158, p.S534N). 
As previously discussed, both p.C29R and p.S534N have been suggested to be protective alleles 
that determine an above-average activity of the protein DPD (Offer et al., 2013). However, this 
effect could be “neutralized” in the presence of the disrupting mutation rs3928190 on the same 
allele. Based on this assumption, a partial loss of DPD activity could be hypothesized at least for the 
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probands 203.3 (with p.S534N and rs3918290 on the paternal allele) (Figure 8.3 d) and SM2.3 
(with p.C29R and rs3918290 on the paternal allele) (Figure 8.3 e), and for C19.3, SM38.3 and 
SM161.3 (all rs3918290/+) (Figure 8.3 a, b, c). In family 171 (Figure 8.3 f), the compound 
heterozygosity p.C29R/rs3918290 in the proband 171.6, the unaffected sibling and the mother, may 
instead determine a balance between the effects of the two variants. For family C22 (Figure 8.3 g), 
the outcome is more uncertain, because the haplotype pattern of the two mutations p.C29R and 
rs3918290 in the proband is unknown.  
Therefore, we did not detect any complete loss of DPD activity in any of the ASD probands 
carrying the splicing mutation, but in at least 5 of them we can hypothesize a partial DPD 
deficiency. Again, as we observed also for SLI families, the interpretation of the genotypic profile 
of DPYD variants in terms of DPD activity is often complex and should be confirmed by an 
enzymatic assay.   
 
Figure 8.3. Hypotheses of DPD activity levels in ASD families carrying the splicing mutation rs3918290, based on the 
mutation screening results. Increased (), decreased () and balanced effects (=) on DPD activity are indicated. 
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From the result of the mutation screening then, it is not excluded that the splice site variant could 
have a role, at least in a subgroup of individuals with ASD, with incomplete penetrance and variable 
expressivity. In addition, its effect may depend also on the interactions with other mutations in the 
same gene or in other genomic locations. We cannot exclude the hypothesis that the ASD probands 
carrying the splicing site mutation in DPYD could have other variants (CNVs or sequence 
mutations), that could contribute to the ASD susceptibility, together with DPYD. According to a 
“multiple hit hypothesis”, some rare variants could manifest a pathogenic role only in the 
simultaneous presence of other variants, rare or common, located in different genomic loci. 
An exome study for schizophrenia (Xu et al., 2012) identified two rare de novo mutations in DPYD 
in two independent cases, suggesting that rare and penetrant point mutations in this gene could 
contribute to this disorder. To date, exome studies of ASD have not identified rare de novo 
mutations in DPYD (Neale et al., 2012; O'Roak et al., 2011; Sanders et al., 2012). However, it is not 
excluded that future studies, not focused only on de novo events and including larger number of 
individuals, will identify new variants in DPYD and/or that they will clarify its contribution to ASD 
aetiology.  
In conclusion, although rare mutations in DPYD have implicated this interesting candidate gene in 
several neurodevelopmental conditions, including ASD, in this study we did not find striking 
evidence for a possible involvement of DPYD in ASD. Our analysis was mainly focused on the 
variant which is the most commonly reported in individuals with DPD deficiency, but further 
investigations would be required, for example, to characterize the genetic background of rs3918290 
carriers. Therefore, it remains possible that different mutations in DPYD, with variable penetrance, 
could act as risk factors for ASD susceptibility and that their contribution may depend also on the 
genetic background of the individual or other non-genetic factors. 
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